<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>373</serviceExecutionTime><Trial id="100826"><TitleDisplay>CP-690550 Thorough QTc Study</TitleDisplay><TitleOfficial>A Phase I, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690550 On QTc Interval In Healthy Volunteers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">A3921028</Identifier><Identifier type="NCT">NCT01743677</Identifier></Identifiers><Indications></Indications><BiomarkerNames><BiomarkerName id="2272" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytochrome P450 2C19</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tofacitinib citrate (oral, inflammation), Pfizer</Name><Drug id="45499">tofacitinib citrate (oral, inflammation), Pfizer</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>moxifloxacin</Name><Drug id="12978">moxifloxacin</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45499">tofacitinib citrate (oral, inflammation), Pfizer</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="45499" type="Drug"><TargetEntity id="306518" type="siDrug">Tofacitinib citrate</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="3560" type="Action"><TargetEntity id="1389" type="Mechanism">Janus Kinase (Jak) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3566" type="Action"><TargetEntity id="1390" type="Mechanism">Jak3 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3560">JAK tyrosine kinase inhibitor</Action><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3566">Jak3 tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2007-11-30T00:00:00Z</DateStart><DateEnd type="actual">2008-02-29T00:00:00Z</DateEnd><DateChangeLast>2019-02-15T10:18:29Z</DateChangeLast><DateAdded>2012-12-07T07:55:26Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pfizer</Affiliation><Name>Pfizer CT.gov Call Center</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy male and/or female subjects between ages of 18 and 55 years, inclusive&lt;/li&gt;&lt;li&gt;Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight&amp;gt; 50 kg
             (110 lb)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Use of tobacco- or nicotine-containing products in excess of equivalent of five
             cigarettes per day&lt;/li&gt;&lt;li&gt;A 12-lead ECG demonstrating QTc&amp;gt; 450 ms or other clinically significant abnormalities
             at screening&lt;/li&gt;&lt;li&gt;History of risk factors for QT prolongation or torsades de pointes&lt;/li&gt;&lt;li&gt;Pregnant or nursing women; women of childbearing potential unwilling or unable to use
             an acceptable method of nonhormonal contraception from at least 14 days prior to
             first dose until completion of follow-up&lt;/li&gt;&lt;li&gt;Use of prescription or non-prescription drugs, vitamins and dietary supplements within
             7 days or five half-lives (whichever is longer) prior to first dose of trial medication&lt;/li&gt;&lt;li&gt;Any clinically significant infections within past 3 months or evidence of infection
             in past 7 days&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>0.25 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>0.5 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>1 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>2 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>4 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>8 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>12 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>16 h postdose</Timeframe></Measure><Measure><Description>Time-matched mean differences in QTcF intervals between CP-690550 and placebo (baseline-adjusted) at each postdose time</Description><Timeframe>24 h postdose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean time-matched difference in QTcF intervals between moxifloxacin compared to placebo</Description><Timeframe>-1, -0.5, and 0 h predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Mean time-matched difference in QTcB intervals between CP-690550 compared to placebo</Description><Timeframe>-1, -0.5, and 0 h predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Area under the curve from time zero to extrapolated infinite time (AUC[0 to infinity])</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Area under the curve from time zero to extrapolated infinite time (AUClast)</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Maximum observed plasma concentration (Cmax)</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Time to reach maximum observed plasma concentration (Tmax)</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Plasma decay half-Life (t1/2)</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Area under the curve from time zero to extrapolated infinite time (AUC[0 to infinity]) by CYP2C19 genotype</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Area under the curve from time zero to last quantifiable concentration (AUClast) by CYP2C19 genotype</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Maximum Observed Plasma Concentration (Cmax) by CYP2C19 genotype</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Time to reach maximum observed plasma concentration (Tmax) by CYP2C19 genotype</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure><Measure><Description>Plasma decay half-life (t1/2) by CYP2C19 genotype</Description><Timeframe>predose, 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 h postdose</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The current study was designed to ascertain whether &lt;ulink linkType="Drug" linkID="45499"&gt;CP-690550&lt;/ulink&gt;
      is associated with QTc prolongation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study, patients will receive either placebo (five tablets) or &lt;ulink linkType="Drug" linkID="45499"&gt;CP-690550&lt;/ulink&gt; (100 mg, 5 x 20 mg tablets) or &lt;ulink linkType="Drug" linkID="12978"&gt;moxifloxacin hydrochloride&lt;/ulink&gt; (400 mg).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Bruxelles</Address1><Address3>1070</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Singapore"><Sites><Site><Name>Pfizer Investigational Site</Name><Address1>Singapore</Address1><Address3>188770</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ankylosing spondylitis</Disease><PatientSegments><PatientSegment><PatientSegment id="416">Others</PatientSegment><SubSegments><SubSegment id="18862">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Systemic lupus erythematosus</Disease><PatientSegments><PatientSegment><PatientSegment id="7583">Others</PatientSegment><SubSegments><SubSegment id="7584">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Psoriatic arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="447">Others</PatientSegment><SubSegments><SubSegment id="3606">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="3740">Others</PatientSegment><SubSegments><SubSegment id="535">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Scleroderma</Disease><PatientSegments><PatientSegment><PatientSegment id="15315">Others</PatientSegment><SubSegments><SubSegment id="17780">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Ulcerative colitis</Disease><PatientSegments><PatientSegment><PatientSegment id="8794">Others</PatientSegment><SubSegments><SubSegment id="8796">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01743677</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ankylosing spondylitis" id="3278"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="4112"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14585"><Endpoint>Assessment of Cardio-Pulmonary System</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Ulcerative colitis" id="15950"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Scleroderma" id="43582"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Psoriatic arthritis" id="44997"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Ankylosing spondylitis" id="3278"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriatic arthritis" id="3535"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4112"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="43206">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Rheumatoid arthritis" id="43207">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14585"><Endpoint>Assessment of Cardio-Pulmonary System</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14607"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15950"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15967"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ankylosing spondylitis" id="43159"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Ankylosing spondylitis" id="43160">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Ankylosing spondylitis" id="43161">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Scleroderma" id="43582"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriatic arthritis" id="44997"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="46577"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ankylosing spondylitis" id="46926"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="47215"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="48186"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriatic arthritis" id="50242"><Endpoint>Gene variants involved in outcome measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Ankylosing spondylitis" id="3295"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Psoriatic arthritis" id="3586"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Psoriatic arthritis" id="3602"><Endpoint>Assessment of Cardiovascular Events</Endpoint></OtherEndpoint><OtherEndpoint disease="Rheumatoid arthritis" id="4139"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Systemic lupus erythematosus" id="14608"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Ulcerative colitis" id="15935"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Scleroderma" id="43317"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Systemic lupus erythematosus" id="45565"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Ulcerative colitis" id="45567"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ankylosing spondylitis" id="1547"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Psoriatic arthritis" id="1670"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1969"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Ulcerative colitis" id="15831"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15842">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15841"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Scleroderma" id="33044"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="34532"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1968">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="34551"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="15395">Subjects with protocol specified weight/BMI values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="34653"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="13797">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Psoriatic arthritis" id="34700"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Psoriatic arthritis" id="3836">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ankylosing spondylitis" id="34705"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="1545">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ankylosing spondylitis" id="2320"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2327"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="2353"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Psoriatic arthritis" id="2396"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriatic arthritis" id="2438"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Psoriatic arthritis" id="2464"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2906"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2922"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2931"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2936"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2877">History of ECG abnormalities</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriatic arthritis" id="3012"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="5644"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12632"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12642">Subjects with infectious disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12634"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12648"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12649">Subjects with abnormal cardiac function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12658"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12668"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="13308">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13128"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13142"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13154"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13166"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13170">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Scleroderma" id="24290"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Scleroderma" id="24518"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Scleroderma" id="24519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Scleroderma" id="24526"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Scleroderma" id="24968"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Scleroderma" id="24517">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="25118"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2953">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="25124"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13179">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="25734"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2354">Pregnant/lactating women</SubCriterion><SubCriterion disease="Ankylosing spondylitis" id="2357">Women of child bearing potential without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriatic arthritis" id="25763"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Psoriatic arthritis" id="2486">Pregnant/lactating women</SubCriterion><SubCriterion disease="Psoriatic arthritis" id="2488">Women of child bearing potential without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ankylosing spondylitis" id="25840"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ankylosing spondylitis" id="2288">Nutrient supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="26004"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2965">Pregnant/lactating women</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2969">Women of child bearing potential without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="26490"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="27016"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13174">Subjects excluded based on prespecified body weight/BMI</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriatic arthritis" id="27457"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="27468"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Scleroderma" id="27470"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="27482"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="27493"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="27510"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Scleroderma" id="27757"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="28354"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="28359"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Ankylosing spondylitis" id="28388"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Psoriatic arthritis" id="28533"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="28539"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2966">Pre-specified exclusion criteria based on body weight/height</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Scleroderma" id="28541"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-02-29T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-10-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-07T07:55:26Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="107881"><TitleDisplay>A Retrospective Trial to Study the Efficacy of Megestrol Acetate in the Treatment of Hormone Refractory Prostate Cancer</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>megestrol acetate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20659" type="Company"><TargetEntity id="5035893896" type="organizationId">University of Pittsburgh- of the Commonwealth System of Higher Education</TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20659">University of Pittsburgh</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>14</PatientCountEnrollment><PatientCountEvaluable>14</PatientCountEvaluable><DateStart>1997-06-30T00:00:00Z</DateStart><DateChangeLast>2013-02-07T11:19:39Z</DateChangeLast><DateAdded>2013-02-07T11:19:39Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with hormone-refractory prostate cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this  retrospective trial was to study the efficacy of megestrol acetate in the treatment of hormone refractory prostate cancer  [&lt;ulink linkType="Reference" linkID="1359484"&gt;1359484&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 1997, results showed that megestrol acetate showed minimal therapeutic efficacy as a second-line hormonal therapy in patients with prostate cancer [&lt;ulink linkType="Reference" linkID="1359484"&gt;1359484&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received megestrol acetate (160 mg/day) (n =  11) or  megestrol acetate (320 mg/day) (n = 3)  [&lt;ulink linkType="Reference" linkID="1359484"&gt;1359484&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-07T11:19:39Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="109550"><TitleDisplay>A Placebo-controlled, Double-blind, Randomized Study To Evaluate Efficacy Of Cholesterol-lowering Therapy On Coronary Endothelial Vasomotor Function In Patients With Coronary Artery Disease</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Disease marker" type="Biochemical">Total cholesterol</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>simvastatin</Name><Drug id="44313">simvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44313">simvastatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1078271">Boston University School of Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44313" type="Drug"><TargetEntity id="122234" type="siDrug">Simvastatin</TargetEntity></SourceEntity><SourceEntity id="1078271" type="Company"><TargetEntity id="5038058790" type="organizationId">Boston University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1078271">Boston University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="71">Antihypercholesterolemic agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>83</PatientCountEnrollment><PatientCountEvaluable>83</PatientCountEvaluable><DateStart>2000-08-22T00:00:00Z</DateStart><DateChangeLast>2013-02-13T10:18:11Z</DateChangeLast><DateAdded>2013-02-13T10:18:11Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with coronary artery disease and mildly elevated cholesterol levels&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this placebo-controlled, double-blind, randomized study was to evaluate efficacy of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease [&lt;ulink linkType="Reference" linkID="1361522"&gt;1361522&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2000, results showed that  &lt;ulink linkType="Drug" linkID="44313"&gt;simvastatin&lt;/ulink&gt; did not produce significant effects on coronary endothelial vasomotor function in patients with coronary artery disease and mildly elevated cholesterol levels [&lt;ulink linkType="Reference" linkID="1361522"&gt;1361522&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received either &lt;ulink linkType="Drug" linkID="44313"&gt;simvastatin&lt;/ulink&gt;, 40 mg/d p.o. + diet x 6 mo  or placebo + diet [&lt;ulink linkType="Reference" linkID="1361522"&gt;1361522&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-13T10:18:11Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="120426"><TitleDisplay>A Study on The Effects on Plasma Insulin And Glucose After a Single Meal Replacement in Patients With Type 2 Diabetes Mellitus</TitleDisplay><TitleOfficial>A study on the effects on plasma insulin and glucose after a single meal replacement in patients with T2DM</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN48222371</Identifier><Identifier type="Secondary Organisational">NTR942</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>amino acid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1081550" type="Company"><TargetEntity id="5036857902" type="organizationId">DSM Japan KK</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1081550">Dutch State Mines</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2007-04-01T00:00:00Z</DateStart><DateEnd type="actual">2007-09-01T00:00:00Z</DateEnd><DateChangeLast>2016-08-29T07:53:17Z</DateChangeLast><DateAdded>2013-04-12T07:50:53Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Center for Human Drug ResearchZernikedreef 10, Leiden, Netherlands, 2333 CL</Affiliation><Name>J Burggraaf</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult&lt;/li&gt;&lt;li&gt;Type 2 diabetes mellitus (T2DM) patients&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Insulin use&lt;/li&gt;&lt;li&gt;Significant clinical abnormalities&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Insulin and glucose response</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Hormones involved in glucose homeostasis</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess the effects on plasma insulin and glucose after a single meal replacement in patients with type 2 diabetes mellitus [&lt;ulink linkType="Reference" linkID="1402842"&gt;1402842&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1402832"&gt;1402832&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Potential patients would be recruited using the CHDR database, contacts with department of Endocrinology of LUMC (&lt;ulink linkType="Company" linkID="27406"&gt;Leiden University Medical Center&lt;/ulink&gt;) and general practioners and advertisements. After an information session and upon providing informed consents, patients would be medically screened. When no objections against participation in the study could be identified during the screening, the patients would be invited to visit CHDR three times, with each visit separated by at least 7 days [&lt;ulink linkType="Reference" linkID="1402842"&gt;1402842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At each visit, patients would be given single meals with different composition of amino acids or placebo and blood sampling for glucose metabolism would take place for a period of 4 h   [&lt;ulink linkType="Reference" linkID="1402832"&gt;1402832&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1402842"&gt;1402842&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN48222371</Identifier></Identifiers></Registry><Registry><Name id="1015">Netherlands Trial Registry (NTR)</Name><Identifiers><Identifier type="Secondary Organisational">NTR942</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-12T07:50:53Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="125369"><TitleDisplay>A prospective, cross-sectional and longitudinal study to examine the  role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio (SEVR) in patients with rheumatoid arthritis (RA)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="781" role="Therapeutic effect marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1082502" type="Company"><TargetEntity id="5039676477" type="organizationId">Dudley Group NHS Foundation Trust Charity</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1082502">The Dudley Group NHS Foundation Trust</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>347</PatientCountEnrollment><PatientCountEvaluable>347</PatientCountEvaluable><DateChangeLast>2015-12-02T16:00:36Z</DateChangeLast><DateAdded>2013-04-29T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with rheumatoid arthritis (RA)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Systemic markers of disease activity</Description></Measure><Measure><Description>Classical CVD risk factors</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was  a prospective, cross-sectional and longitudinal study  to examine specific predictors of subendocardial viability ratio (SEVR), the  role of inflammation,   and classical cardiovascular disease (CVD) risk factors on SEVR in patients with rheumatoid arthritis (RA) [&lt;ulink linkType="Reference" linkID="1411313"&gt;1411313&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in November 2012. In the primary  and validation cohorts, SEVR (mean +/- standard deviation) for RA was148 +/- 27 and 142 +/-    25, respectively. Regression analyses showed  that all parameters of RA disease activity were associated with SEVR, along with gender, blood pressure and heart rate.    Similar results were seen in the validation cohort.  Longitudinal data analysis demonstrated  that C-reactive protein (P &amp;lt; 0.001), erythrocyte sedimentation rate (P &amp;lt; 0.005), Disease Activity Score in 28 joints (P &amp;lt; 0.001), mean blood pressure (P &amp;lt; 0.005) and augmentation index (P &amp;lt; 0.001) were significantly reduced after commencing anti-TNFalpha treatment.  Increasing C-reactive protein was  associated with a reduction in SEVR (P = 0.02) and an increase in augmentation index (P = 0.001)   [&lt;ulink linkType="Reference" linkID="1411313"&gt;1411313&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;This study included two patient cohorts: a primary cohort consisted of 220 RA patients and a validation cohort consisted of 127 RA patients. Using pulse wave analysis, all patients underwent SEVR assessment. Patients (n = 31)  from the primary cohort who were about to start anti-inflammatory treatment were prospectively examined for SEVR at pretreatment baseline and 2 weeks, 3 months and one  year following treatment  [&lt;ulink linkType="Reference" linkID="1411313"&gt;1411313&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="128176"><TitleDisplay>Phase III, Randomized, Open-label Study of Lopinavir/ritonavir Tablets Once-Daily Versus Twice-Daily in Antiretroviral-experienced, HIV-1 Infected Subjects</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="159">HIV-1 infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lopinavir + ritonavir</Name><Drug id="14681">lopinavir + ritonavir</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14681">lopinavir + ritonavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="14681" type="Drug"><TargetEntity id="291602" type="siDrug">Lopinavir/ritonavir</TargetEntity></SourceEntity><SourceEntity id="204" type="Action"><TargetEntity id="436" type="Mechanism">HIV Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="204">HIV protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="742">Pellet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><DateStart>2006-11-01T00:00:00Z</DateStart><DateEnd type="actual">2009-06-02T00:00:00Z</DateEnd><DateChangeLast>2014-03-21T04:32:49Z</DateChangeLast><DateAdded>2013-05-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Name>Rachelle Branford</Name><Phone>011 858 2163/ 011 858 2037</Phone></Contact><Contact type="Public contact"><Name>Bhadrish Vallabh</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Currently receiving an antiretroviral regimen which has not changed for at least 12 weeks&lt;/li&gt;&lt;li&gt;Currently failing antiretroviral regimen&lt;/li&gt;&lt;li&gt;HIV-1 infected subjects&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Received&lt;ulink linkType="Drug" linkID="14681"&gt; lopinavir + ritonavir&lt;/ulink&gt; before&lt;/li&gt;&lt;li&gt;History of allergic reactions to lopinavir or ritonavir&lt;/li&gt;&lt;li&gt;Significant history of cardiac, renal, neurological, psychiatric, oncological, metabolic or hepatic disease&lt;/li&gt;&lt;li&gt;Screening analyses showing abnormal laboratory results for hemoglobin, Abs neutrophil count, platelet count, ALT or AST&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to study effect of &lt;ulink linkType="Drug" linkID="14681"&gt;lopinavir + ritonavir&lt;/ulink&gt; tablets given once-daily versus twice-daily in antiretroviral (ARV) experienced HIV-1 infected patients [&lt;ulink linkType="Reference" linkID="1416698"&gt;1416698&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="14681"&gt;lopinavir + ritonavir&lt;/ulink&gt; tablets once-daily or twice-daily  [&lt;ulink linkType="Reference" linkID="1416698"&gt;1416698&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Africa"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7108">Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7116">Subjects Refractory/Intolerant to Anti Retroviral Therapy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment><SubSegments><SubSegment id="7126">Subjects with HIV-1 Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5418">Subjects with HIV-1 infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5344"><Criterion>Subjects on Prior/Concurrent Antiretroviral Therapy</Criterion></Inclusion><Inclusion disease="HIV infection" id="5375"><Criterion>Subjects Refractory/Intolerant to Anti Retroviral Therapy</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6824"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="HIV infection" id="6829"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="HIV infection" id="6834"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6843"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6845">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6848"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6850"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="HIV infection" id="6860"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6861">Abnormal/unacceptable hematology</SubCriterion><SubCriterion disease="HIV infection" id="6863">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6941">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6944"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><ChangeHistory><Change type="added"><Date>2013-05-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="149896"><TitleDisplay>A phase III, randomized trial to evaluate the safety and efficacy of IPI-145 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="203">Lymphoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>duvelisib</Name><Drug id="62418">duvelisib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>ofatumumab</Name><Drug id="42299">ofatumumab</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="62418">duvelisib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="29753">Infinity Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="62418" type="Drug"><TargetEntity id="676183" type="siDrug">INK-055</TargetEntity></SourceEntity><SourceEntity id="29753" type="Company"><TargetEntity id="4295915855" type="organizationId">Infinity Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="11183" type="Action"><TargetEntity id="2483" type="Mechanism">Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="11186" type="Action"><TargetEntity id="2489" type="Mechanism">Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="29753">Infinity Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11183">Phosphoinositide-3 kinase delta inhibitor</Action><Action id="11186">Phosphoinositide-3 kinase gamma inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1589">Apoptosis stimulator</Class><Class id="396">Immunosuppressant</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="168">Monoclonal antibody human</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>300</PatientCountEnrollment><DateChangeLast>2013-08-13T14:06:32Z</DateChangeLast><DateAdded>2013-08-13T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this  phase III, randomized trial was to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="62418"&gt;IPI-145&lt;/ulink&gt; in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [&lt;ulink linkType="Reference" linkID="1463227"&gt;1463227&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="62418"&gt;IPI-145&lt;/ulink&gt; (25 mg bid) or &lt;ulink linkType="Drug" linkID="42299"&gt;ofatumumab&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1463227"&gt;1463227&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-08-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="156065"><TitleDisplay>The effect of ginger on after delivery pain</TitleDisplay><TitleOfficial>The comparison effect of ginger and mefenamic acid on after delivery pain in multiparous women</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2013052613475N1</Identifier><Identifier type="Other">eth-737</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Ponstan (mefenamic acid)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Zintoma (ginger capsule)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1062195" type="Company"><TargetEntity id="5035553626" type="organizationId">Ahvaz Jundishapur University Of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1062195">Ahvaz Jundishapur University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>122</PatientCountEnrollment><DateStart>2013-05-10T00:00:00Z</DateStart><DateChangeLast>2019-04-18T10:55:22Z</DateChangeLast><DateAdded>2013-09-30T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Vice-chancellor for Research, Ahvaz Jundishapur University of Medical Sciences ; Golestan Blv Ahvaz Khuzestan Iran, Islamic Republic Of</Affiliation><Email>feghhi@yahoo.com</Email><Name>Mostafa Feghhi</Name><Phone>986113738383</Phone></Contact><Contact type="Public contact"><Affiliation>Ahvaz Jundishapur University of Medical Sciences ;  Golestan Street-Ahvaz Jundishapur University of Medical Sciences, Ahvaz,Iran ; Ahvaz ; khozestan ; Iran, Islamic Republic Of</Affiliation><Email>poormaleky.s@ajums.ac.ir</Email><Name>Somayeh Poormaleky</Name><Phone>00989333424185</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;People who have normal vaginal delivery&lt;/li&gt;&lt;li&gt;People who are multipar&lt;/li&gt;&lt;li&gt;Gestational age: 37 to 42 weeks&lt;/li&gt;&lt;li&gt;People who have after delivery pain&lt;/li&gt;&lt;li&gt;People who are not unread&lt;/li&gt;&lt;li&gt;Infant weight range is 2500 to 4000 g&lt;/li&gt;&lt;li&gt;Women's body mass index is 19.8 to 29&lt;/li&gt;&lt;li&gt;Mother should not use another palliative procedure&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Drugs could not sedate the mother and other interventions was necessary&lt;/li&gt;&lt;li&gt;People who have not hard labor&lt;/li&gt;&lt;li&gt;Those people who are not addict&lt;/li&gt;&lt;li&gt;People who have not history of allergy to ginger or other plants&lt;/li&gt;&lt;li&gt;Those have not history of c/s or other abdominal surgery&lt;/li&gt;&lt;li&gt;Those have not any history of postpartum hemorrhage&lt;/li&gt;&lt;li&gt;No underlying disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The intensity of after pain: visual pain scale</Description><Timeframe>Before intervention and four times after intervention</Timeframe></Measure><Measure><Description>The duration of pain: per minute</Description><Timeframe>After intervention</Timeframe></Measure><Measure><Description>The frequency of abnormal bleeding: according to national guidelines</Description><Timeframe>To 24 h after delivery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to compare the effects of ginger and mefenamic acid on pain after delivery in multiparous women [&lt;ulink linkType="Reference" linkID="1482337"&gt;1482337&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of two groups:&lt;br/&gt;Group1:patients would receive ginger (250 mg, po  per every 6 h for 24 h; Zintoma).&lt;br/&gt;Group 2: patients would receive mefenamic acid (250 mg, po q6h for 24 h; Ponstan) [&lt;ulink linkType="Reference" linkID="1482337"&gt;1482337&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Mashahr Hospital</Name><Address1>khozestan</Address1><Contacts><Contact type="Facility contact"><Name>Somayeh Poormaleky</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8419">Subjects with Visceral Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2013052613475N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25889"><Endpoint>Assessment of Other Measures of Pain Quality</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25892">Assessment of duration of pain</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25999">Pregnancy/Labor related outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22134"><Criterion>Subjects with Visceral Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22140">Subjects with labor pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22175"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34957"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22261">Pregnant women</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2013-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.71 Months</EnrollmentPeriod><EnrollmentRate>32.88 Patients/Month</EnrollmentRate><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="added"><Date>2019-04-18T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change><Change type="added"><Date>2019-04-18T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change></ChangeHistory></Trial><Trial id="178734"><TitleDisplay>Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease</TitleDisplay><TitleOfficial>Phase IV Study of Statins For Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01041729</Identifier><Identifier type="Organisational Study">STA-2009 NO-CRP</Identifier></Identifiers><Indications><Indication id="260">Peripheral vascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atorvastatin</Name><Drug id="2807">atorvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2807">atorvastatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1065444">Hospital Universitario de Getafe</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2807" type="Drug"><TargetEntity id="180072" type="siDrug">Atorvastatin calcium</TargetEntity></SourceEntity><SourceEntity id="1065444" type="Company"><TargetEntity id="5037142502" type="organizationId">Hospital Universitario de Getafe</TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"></TargetEntity><TargetEntity id="D016491" type="MeSH"></TargetEntity><TargetEntity id="-817414410" type="omicsDisease"></TargetEntity><TargetEntity id="260" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1065444">Hospital Universitario de Getafe</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2667">Antiarteriosclerotic</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="actual">2009-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-04-26T04:28:34Z</DateChangeLast><DateAdded>2014-04-09T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hospital Universitario Getafe</Affiliation><Name>Joaquin De Haro, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients at the time of diagnosis of Fontaine grade II peripheral arterial disease (PAD), confirmed by hemodynamic evaluation (Doppler ultrasound)&lt;/li&gt;&lt;li&gt;Age &gt; 18 years old&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients had previously undergone revascularization&lt;/li&gt;&lt;li&gt;Patients were receiving treatment with statins&lt;/li&gt;&lt;li&gt;Patients with contraindications to statin use&lt;/li&gt;&lt;li&gt;Patients with coexistence of chronic inflammatory diseases or steroidal medication&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>High sensitivity C-reactive protein (hsCRP) and nitrites plasma levels at baseline and after 1 month and one year of inclusion</Description><Timeframe>Baseline and after 1 month and one year of inclusion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Lipid profile</Description><Timeframe>Baseline and after 1 month and one year of inclusion</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this single-blind, phase IV study was to determine the long-term effects of statins, &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt;,      upon nitric oxide, as an endothelial function assessment, and C-reactive protein, an      inflammatory marker, levels in patients with peripheral arterial disease (PAD). These long-term      biological pleiotropic effects of statins would offer information on the role of endothelial      function and systemic inflammation in the etiopathogenesis of PAD.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with PAD  in Fontaine stage II would be randomized into two arms to receive either &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 40 mg/day  or no treatment for 12 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Hospital Universitario Getafe</Name><Address1>Getafe</Address1><Address2>Madrid</Address2><Address3>28905</Address3><CountrySubDivision>Madrid</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10141">Subjects with Intermittent Claudication</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01041729</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21865"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21868">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21875"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19212"><Criterion>Subjects with Inclusion Based On Rutherford"s Classification</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15989"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15993">Subjects co-morbid with inflammatory disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16032">Subjects with history/requiring statin therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16033"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16037">Hypersensitivity/contraindications to lipid lowering drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16045"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16048">Subjects with history/requiring peripheral revascularization</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2009-12-31T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="180030"><TitleDisplay>Crossover, Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions</TitleDisplay><TitleOfficial>A Single-Dose, Two-Period, Two-Treatment, Two-Sequence, Crossover, Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01570894</Identifier><Identifier type="Organisational Study">QUET-T25-PVFD-2</Identifier></Identifiers><Indications><Indication id="3114">Bipolar I disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>quetiapine fumarate (Roxane Laboratories)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>quetiapine IR</Name><Drug id="3317">quetiapine IR</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="22588" type="Company"><TargetEntity id="4296376248" type="organizationId">Roxane Laboratories Inc</TargetEntity></SourceEntity><SourceEntity id="3114" type="ciIndication"><TargetEntity id="10004939" type="MEDDRA"></TargetEntity><TargetEntity id="49" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22588">West-Ward Columbus</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term></TermsEndpoint><PatientCountEnrollment>42</PatientCountEnrollment><DateStart>2007-07-31T00:00:00Z</DateStart><DateEnd type="actual">2007-07-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T16:45:40Z</DateChangeLast><DateAdded>2014-04-09T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Positive test for HIV, hepatitis B, or hepatitis C&lt;/li&gt;&lt;li&gt;Treatment with known enzyme altering drugs&lt;/li&gt;&lt;li&gt;History of allergical  or adverse response to&lt;ulink linkType="Drug" linkID="3317"&gt;Seroquel&lt;/ulink&gt; or any comparable or similar product&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Bioequivalence determined by statistical comparison Cmax</Description><Timeframe>15 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to prove the bioequivalence of  Roxane Laboratories'      quetiapine fumarate 25 mg with that of &lt;ulink linkType="Drug" linkID="3317"&gt;Seroquel&lt;/ulink&gt; tablet under fed conditions.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive either Roxane Laboratories'      quetiapine fumarate 25 mg or  &lt;ulink linkType="Drug" linkID="3317"&gt;Seroquel&lt;/ulink&gt; 25 mg tablet.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Novum Pharmaceutical Research Services</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77042</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01570894</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bipolar disorder" id="5848"><Criterion>Subjects with Normal/Acceptable Physical Measurements</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bipolar disorder" id="7439"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7454"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7470"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7476">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7500"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-03-28T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="187548"><TitleDisplay>Exploratory Study to Evaluate the Effects of the Probiotics L Rhamnosus GR-1 and L Reuteri RC-14</TitleDisplay><TitleOfficial>A Single-Center, Exploratory Study to Evaluate the Effects of the Probiotics L Rhamnosus GR-1 and L Reuteri RC-14 on Subjects With Intermediate Nugent Scores</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02139839</Identifier><Identifier type="Organisational Study">500-10-0002</Identifier></Identifiers><Indications><Indication id="2240">Bacterial vaginosis</Indication></Indications><BiomarkerNames><BiomarkerName id="159" role="Therapeutic effect marker" type="Biochemical">Lactic Acid</BiomarkerName><BiomarkerName id="6540" role="Therapeutic effect marker" type="Biochemical">Glutamic acid</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>L reuteri RC-14</Name></Intervention><Intervention type="InterventionPrimary"><Name>L rhamnosus GR-1</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043527" type="Company"><TargetEntity id="4297906117" type="organizationId">Lawson Health Research Institute</TargetEntity></SourceEntity><SourceEntity id="1072058" type="Company"><TargetEntity id="5037087534" type="organizationId">Sekisui Integrated Research Inc</TargetEntity></SourceEntity><SourceEntity id="25008" type="Company"><TargetEntity id="5000030219" type="organizationId">University of Western Ontario</TargetEntity></SourceEntity><SourceEntity id="29838" type="Company"><TargetEntity id="5000174080" type="organizationId">Kimberly-Clark Worldwide Inc</TargetEntity></SourceEntity><SourceEntity id="2240" type="ciIndication"><TargetEntity id="D016585" type="MeSH"></TargetEntity><TargetEntity id="-1361925730" type="omicsDisease"></TargetEntity><TargetEntity id="5612" type="siCondition"></TargetEntity><TargetEntity id="912" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 0 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29838">Kimberly-Clark Worldwide Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043527">Lawson Health Research Institute</Company><Company id="1072058">Sekisui Integrated Research Inc</Company><Company id="25008">University of Western Ontario</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>14</PatientCountEnrollment><DateStart>2012-09-30T00:00:00Z</DateStart><DateEnd type="actual">2013-05-31T00:00:00Z</DateEnd><DateChangeLast>2015-02-28T10:10:03Z</DateChangeLast><DateAdded>2014-05-16T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Willing and able to read, understand, and sign the Informed Consent Form (ICF)&lt;/li&gt;&lt;li&gt;Post-menopausal females between the ages of 40 and 80 years old (subjects who have not had a menstrual period for the last 12 months)&lt;/li&gt;&lt;li&gt;Currently in a mutually monogamous sexual relationship or not sexually active&lt;/li&gt;&lt;li&gt;Agree to be sexually abstinent 72 h prior to each study visit. Also, agree to refrain from intercourse for 48 h after treatment administration&lt;/li&gt;&lt;li&gt;Agree to abstain from the use of any other intravaginal product (eg, gels, foams, lubricants, douches, etc) throughout the study period, from the time of screening until day 47&lt;/li&gt;&lt;li&gt;Willing and capable of following all study instructions and&lt;/li&gt;&lt;li&gt;Good general health&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Use of vaginal lubricants, or any products applied vaginally within three months prior to visit 1and throughout the duration of study participation&lt;/li&gt;&lt;li&gt;A history or currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy&lt;/li&gt;&lt;li&gt;A medical condition which might compromise immune system functions (such as cancer, leucopenia, HIV-positive, or organ transplant)&lt;/li&gt;&lt;li&gt;Antibiotics and/or antifungal medication use within the last 4 weeks&lt;/li&gt;&lt;li&gt;Oral probiotic supplement use within 3 months prior to visit 1 and throughout the duration of the study&lt;/li&gt;&lt;li&gt;Significant changes in diet during the course of the study based on self-report&lt;/li&gt;&lt;li&gt;Induced menopause due to surgical or medical interventions, such as bilateral oophorectomy, hysterectomy, chemotherapy or radiation treatment&lt;/li&gt;&lt;li&gt;Currently undergoing local or systemic estrogen therapy who are not willing to alter therapy during the course of the study&lt;/li&gt;&lt;li&gt;A Nugent score of 0 to 3 or &gt; 6&lt;/li&gt;&lt;li&gt;History of drug or alcohol abuse&lt;/li&gt;&lt;li&gt;Currently diagnosed with or being treated for a genital infection or urinary tract infection&lt;/li&gt;&lt;li&gt;Individuals with a sexually transmitted disease (self-reported or detected by the principal investigator)&lt;/li&gt;&lt;li&gt;At enrollment, have any social or medical condition, or psychiatric illness that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives&lt;/li&gt;&lt;li&gt;Participation in a clinical trial involving an investigational product/device within the past 3 months; subjects who are scheduled to participate in another clinical study concurrently; and&lt;/li&gt;&lt;li&gt;Known intolerance or allergy to L rhamnosus GR-1 or L reuteri RC-14 or to any product excipients&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change from baseline nugent score (arbitrary units) after treatment versus change from baseline nugent score after placebo: determine whether L rhamnosus GR-1 and L reuteri RC-14 delivered via capsules to the vagina of post-menopausal women over a 3 day course of treatment can restore and maintain a lactobacilli-dominated microbiota for 1 week as measured by a decrease in the nugent scores from an intermediate score (4 to 6) at baseline to a normal score (0 to 3) following treatment compared to a placebo</Description><Timeframe>Baseline, days 15 and 36, post treatment/control days 19 and 40</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in cytokine/chemokine levels: multiplex ELISA based assay will be used to evaluate the modulation of cytokine and chemokine levels known regulate inflammation and host defense response before and after probiotic and placebo treatment</Description><Timeframe>Untreated (days 1, 5, and 15), baseline treatment I (day 15), treatment I (days 19 and 26), baseline treatment II (day 36), treatment II (days 40 and 47)</Timeframe></Measure><Measure><Description>Change in global host gene expression: microarray analysis using GeneChip Human 2.0 ST array will be used to measure gene expression changes (by mRNA analysis) to determine whether there are differences in gene regulation between probiotic, placebo, and no treatment conditions</Description><Timeframe>Untreated (days 1, 5, and 15), baseline treatment I (day 15), treatment I (days 19 and 26), baseline treatment II (day 36), treatment II (days 40 and 47)</Timeframe></Measure><Measure><Description>Change in presence of metabolites: gas chromatography-mass spectrometry will be used to determine changes in metabolites (such as lactate, glutamic acid, and others) before and after probiotic and placebo treatments</Description><Timeframe>Untreated (days 1, 5, and 15), baseline treatment I (day 15), treatment I (days 19 and 26), baseline treatment II (day 36), treatment II (days 40 and 47)</Timeframe></Measure><Measure><Description>Change in self-reported vaginal symptoms: symptom analysis to evaluate whether probiotic treatment is associated with symptom relief</Description><Timeframe>Untreated (days 1, 5, and 15), baseline treatment I (day 15), treatment I (days 19 and 26), baseline treatment II (day 36), treatment II (days 40 and 47)</Timeframe></Measure><Measure><Description>Percent lactobacilli abundance: change in lactobacilli abundance before and after probiotic treatment and before and after placebo treatment.  Lactobacilli abundance will be calculated as percentage of number of lactobacilli taxon divided by the total number of taxons</Description><Timeframe>Untreated (days 1, 5, and 15), baseline treatment I (day 15), treatment I (days 19 and 26), baseline treatment II (day 36), treatment II (days 40 and 47)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether L rhamnosus GR-1 and L reuteri RC-14      delivered via capsules to the vagina of post-menopausal women over a 3 day course of      treatment can restore and maintain a lactobacilli-dominated microbiota. Exploratory analysis      of microbial ecology, human microarrays and multiplex immunological assessments would be included      to characterize potential effects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive L rhamnosus GR-1 and L reuteri RC-14 capsules (manufactured by Chr. Hansen) or placebo capsules to the vagina for 3 days.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Dorli Herman</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6J 0A8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02139839</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="211337"><TitleDisplay>World Trade Center (WTC) Renal</TitleDisplay><TitleOfficial>Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02246101</Identifier><Identifier type="Organisational Study">GCO 13-1847</Identifier><Identifier type="Secondary Organisational">1U01OH10716-01</Identifier></Identifiers><Indications><Indication id="3251">End stage renal disease</Indication><Indication id="57">Cardiovascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Disease marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="118" role="Disease marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="120" role="Disease marker" type="Genomic;Proteomic">Cystatin C</BiomarkerName><BiomarkerName id="213" role="Disease marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="289" role="Disease marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="418" role="Disease marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="1904" role="Disease marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="7895" role="Disease marker" type="Physiological">Estimated glomerular filtration rate</BiomarkerName><BiomarkerName id="9467" role="Disease marker" type="Anthropomorphic">Neck circumference</BiomarkerName><BiomarkerName id="9815" role="Disease marker" type="Anthropomorphic">Hip circumference</BiomarkerName><BiomarkerName id="10684" role="Disease marker" type="Cellular">Blood cells</BiomarkerName><BiomarkerName id="12058" role="Disease marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Disease marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="17697" role="Disease marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1093622" type="Company"><TargetEntity id="5037932601" type="organizationId">National Institute for Occupational Safety and Health</TargetEntity></SourceEntity><SourceEntity id="20631" type="Company"><TargetEntity id="4296623708" type="organizationId">Icahn School of Medicine at Mount Sinai</TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"></TargetEntity><TargetEntity id="D007676" type="MeSH"></TargetEntity><TargetEntity id="1890" type="siCondition"></TargetEntity><TargetEntity id="1604" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20631">Mount Sinai School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1093622">National Institute for Occupational Safety and Health</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>406</PatientCountEnrollment><DateStart>2014-07-31T00:00:00Z</DateStart><DateEnd type="actual">2016-09-16T00:00:00Z</DateEnd><DateChangeLast>2017-08-25T12:41:25Z</DateChangeLast><DateAdded>2014-10-01T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Icahn School of Medicine at Mount Sinai</Affiliation><Name>Mary Ann McLaughlin, MD, MPH</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;WTC responders who were enrolled in the WTC-CHEST program&lt;/li&gt;&lt;li&gt;World trade center responders who are currently enrolled in the world trade center health program-clinical center of excellence, formerly known as the WTC medical monitoring and treatment program&lt;/li&gt;&lt;li&gt;Age &gt; 39 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Estimated glomerular filtration rate (eGFR): kidney function - to quantify the risk of kidney damage and the relationship to particulate matter exposure among first responders to the WTC attack</Description><Timeframe>Day 1</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Echocardiography: cardiac structure - to examine the relationship between kidney damage and cardiac structure and function among first responders to the WTC attack</Description><Timeframe>Day 1</Timeframe></Measure><Measure><Description>High sensitivity C-reactive protein (hsCRP): endothelial dysfunction - to explore potential mechanisms for kidney and cardiovascular damage among first responders to the WTC attack</Description><Timeframe>Day 1</Timeframe></Measure><Measure><Description>Urine albumin level: cardiac function - to examine the relationship between kidney damage and cardiac structure and function among first responders to the WTC attack</Description><Timeframe>Day 1</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The long-term goal was to minimize the risk of chronic kidney disease (CKD) and cardiovascular disease (CVD) among      individuals exposed to inhaled toxins. The primary objective of this research is to quantify      the risk of kidney damage among first responders to the WTC attack and to determine the      relationship to particulate matter exposure as well as determine an association between      renal and cardiovascular damage in first responders and to explore potential mechanisms.&lt;/para&gt;&lt;para&gt;The      central hypothesis was that exposure to inhaled particulate matter causes systemic      inflammation and endothelial dysfunction that result in chronic kidney and cardiovascular      damage. This hypothesis will be investigated in a subgroup of participants from a previously      conducted NIOSH-funded study 'Pulmonary Function Abnormalities, Diastolic Dysfunction and      WTC Exposure: Implications for Diagnosis and Treatment'  ('WTC-CHEST,' PI Mary Ann      McLaughlin).&lt;/para&gt;&lt;para&gt;The proposed study aws to capitalize on unique resources in WTC-CHEST, including the      standardized collection of data on particulate matter exposure and shared risk factors for      CKD and cardiovascular disease, and cardiopulmonary function testing. The output from this      proposal is anticipated to have a broad impact on understanding the health effects of      inhaled particulate matter.&lt;/para&gt;&lt;para&gt;The aims of the study were:&lt;br/&gt;Specific aim I : to quantify the risk of kidney damage and the relationship to particulate      matter exposure among first responders to the WTC attack. Urine samples are collected on two occasions for albumin and creatinine.  If, as hypothesized, the      investigators find that albuminuria (UACR &gt;/= 30 mg/g) is more common among WTC responders, this simple and      non-invasive measure may be useful in monitoring programs to identify responders at      increased risk for adverse outcomes. EGFR is calculated using the Chronic Kidney      Disease Epidemiology Consortium (CKD-EPI) equations.&lt;/para&gt;&lt;para&gt;Specific aim II : to examine the relationship between kidney damage and cardiac structure and      function among first responders to the WTC attack. Cardiovascular disease risk screening : in order to identify an independent relationship      between CKD and cardiac dysfunction, the investigators  comprehensively evaluate      potential confounders.  Participants undergo an evaluation of traditional CVD risk      factors as accounted for in both the Framingham Risk Score and Reynold's score (medical      history, medication use and baseline risk for CVD: smoking status, family history of      premature coronary disease, blood pressure, heart rate, height, weight, waist, hip and neck      circumference). Laboratory evaluation  includes: lipid panel, complete blood count,      HbA1C, serum creatinine and cystatin C. Standard questionnaires on chest pain, shortness of      breath, depression, sleep apnea and stress, IPSS.&lt;/para&gt;&lt;para&gt;Specific aim III : to explore potential mechanisms for kidney and cardiovascular damage among      first responders to the WTC attack.     An established marker of systemic inflammation and serum hsCRP are measured in all      participants. Flow-mediated dilatation, a validated non-invasive measure of endothelial      function, are measured in a subgroup of participants. Heavy metal assays are      performed and  compared between participants with and without evidence of kidney      damage (albuminuria or decreased eGFR) or proximal tubular dysfunction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;World Trade Center responders would be observed for renal and cardiovascular impairment.&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Icahn School of Medicine at Mount Sinai</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10029</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02246101</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2016-09-16T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-09-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="218930"><TitleDisplay>Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes</TitleDisplay><TitleOfficial>A Multi-Institutional Chart Review to Compare the Outcomes of Robotic, Laparoscopic and Open Surgery for Gastric Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02325453</Identifier><Identifier type="Organisational Study">001</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="127">Stomach tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="46825" role="Therapeutic effect marker" type="Cellular">Granulocytes/Lymphocytes ratio</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Laparoscopic surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Open surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Robotic surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1104347" type="Company"><TargetEntity id="4296734998" type="organizationId">Fondazione Cassa di Risparmio di Terni e Narni</TargetEntity></SourceEntity><SourceEntity id="1104348" type="Company"><TargetEntity id="5044195751" type="organizationId">Logix Srl</TargetEntity></SourceEntity><SourceEntity id="1107717" type="Company"><TargetEntity id="5037857188" type="organizationId">Azienda Ospedaliera S Maria di Terni</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1107717">Azienda Ospedaliera Santa Maria Terni</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1104347">Fondazione CARIT</Company><Company id="1104348">LOGIX srl</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>7000</PatientCountEnrollment><DateStart>2015-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-01-31T00:00:00Z</DateEnd><DateChangeLast>2017-08-18T09:43:29Z</DateChangeLast><DateAdded>2015-01-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>djdesi85@hotmail.it</Email><Name>Jacopo Desiderio, MD</Name><Phone>+393497531121</Phone></Contact><Contact type="Scientific contact"><Affiliation>Azienda Ospedaliera S. Maria di Terni</Affiliation><Name>Amilcare Parisi, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically proven gastric cancer&lt;/li&gt;&lt;li&gt;Preoperative staging work-up performed by upper endoscopy/endoscopic ultrasound, and CT scan&lt;/li&gt;&lt;li&gt;Early gastric cancer&lt;/li&gt;&lt;li&gt;Advanced gastric cancer&lt;/li&gt;&lt;li&gt;Patients treated with curative intent in accordance to international guidelines&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Locally advanced tumor infiltrating neighboring organs&lt;/li&gt;&lt;li&gt;Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, Krukenberg tumors, involvement of other organs&lt;/li&gt;&lt;li&gt;Patients with high operative risk as defined by the American Society of Anesthesiologists (ASA) score &gt;/= 4&lt;/li&gt;&lt;li&gt;History of gastric surgery&lt;/li&gt;&lt;li&gt;Remnant gastric cancer&lt;/li&gt;&lt;li&gt;Synchronous other major abdominal surgery&lt;/li&gt;&lt;li&gt;Synchronous malignancy in other organs&lt;/li&gt;&lt;li&gt;Palliative surgery cases&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Compare robotic and laparoscopic surgery with the open approach in terms of safety and feasibility: intraoperative complications</Description><Timeframe>Intraoperative</Timeframe></Measure><Measure><Description>Verify the respect of oncological principles through minimally invasive approaches in relation to the stage and location of the tumor by comparing results with open surgery: number of lymph nodes retrieved</Description><Timeframe>Intraoperative</Timeframe></Measure><Measure><Description>Compare the three treatment arms in terms of recovery of gastrointestinal functions and physical status allowing the discharge of the patient: days of hospitalization after surgery until discharge</Description><Timeframe>Assessment during an average period of 10 days after surgery</Timeframe></Measure><Measure><Description>Compare the incidence, types and severity of early postoperative complications after gastrectomy by the three approaches: score based on the Clavien-Dindo classification system</Description><Timeframe>Assessment during an average period of 10 days after surgery</Timeframe></Measure><Measure><Description>Verify whether minimally invasive approaches ensure the same effectiveness than open surgery: overall survival</Description><Timeframe>Assessment at one, three and five years from surgery</Timeframe></Measure><Measure><Description>Compare the three treatment arms in terms of tumor recurrence after treatment: disease-free survival</Description><Timeframe>Assessment at one, three and five years from surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Compare the intracorporeal anastomosis with the extracorporeal anastomosis to evaluate post-operative recovery: days of hospitalization after surgery until discharge.</Description><Timeframe>Assessment during an average period of 10 days after surger</Timeframe></Measure><Measure><Description>Verify the safety of intracorporeal anastomosis in comparison with extracorporeal anastomosis: anastomotic leakage</Description><Timeframe>Assessment during an average period of 10 days after surgery</Timeframe></Measure><Measure><Description>Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress: granulocyte to lymphocyte ratio</Description><Timeframe>Assessment during an average period of 10 days after surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a  multicenter study with a large number of patients to investigate the      safety and efficacy as well as long-term outcomes of robotic surgery, traditional      laparoscopy and the open surgery approach. The overall purpose is to develop a multi-institutional database comprising information      regarding surgical, clinical and oncological features of patients undergoing surgery for      gastric cancer with robotic, laparoscopic or open approaches and subsequent follow-up at      participating centers.&lt;/para&gt;&lt;para&gt;Main objectives are:&lt;br/&gt;To determine the surgical, clinical, and oncological outcomes in both the short and           long term.&lt;br/&gt;To compare results according to the type of intervention, device used and manner of           execution of different surgical phases.&lt;br/&gt;To relate results of different surgeries with baseline characteristics of patients and           stage of disease.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who underwent gastric surgery through the use of robotic surgery or traditional      laparoscopy or the open approach will be observed for the safety and efficacy as well as long-term outcomes of the procedures.&lt;/para&gt;&lt;para&gt;Clinical relevance:&lt;br/&gt;At present, a multicenter registry may represent the best research tool to assess the role      of minimally invasive approaches by comparing the methods with traditional open surgery.&lt;br/&gt;Therefore, for this project, a large registry will be created by collecting data from the      different participating centers to create a working basis for analyzing outcomes of interest      and obtaining directions for further investigation.&lt;br/&gt;The data collected will clarify the role of laparoscopic and robotic surgery versus the open      approach in terms of:&lt;br/&gt;Safety and feasibility based on the intraoperative outcomes.&lt;br/&gt;Respect of oncological principles in relation to the stage and location of the tumor.&lt;br/&gt;Recovery of gastrointestinal function considering the outcomes measured during the           postoperative hospital stay.&lt;br/&gt;Incidence, types and severity of postoperative complications.&lt;br/&gt;Overall survival and disease-free survival.&lt;/para&gt;&lt;para&gt;Duration of study:&lt;br/&gt;The beginning of the trial will be scheduled for January 2015. It will be expected to end the chart      review within one year.&lt;/para&gt;&lt;para&gt;Type of data collection:&lt;br/&gt;In this study, the following information will be collected:&lt;br/&gt;Patient demographics.&lt;br/&gt;Surgical procedure details.&lt;br/&gt;Tumor characteristics.&lt;br/&gt;Operative findings.&lt;br/&gt;Post-operative clinical findings.&lt;br/&gt;Post-operative complications.&lt;br/&gt;Follow-up details.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Name>Department of Digestive Surgery, St. Mary's Hospital, University of Perugia</Name><Address1>Terni</Address1><Address3>05100</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>amilcareparisi@virgilio.it</Email><Name>Amilcare Parisi</Name></Contact><Contact type="Facility contact backup"><Email>djdesi85@hotmail.it</Email><Name>Jacopo Desiderio</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8004">Subjects with Early Gastric Cancer (EGC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8010">Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02325453</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stomach tumor" id="12148"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12149"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12168"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12170">Assessment of functional status</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12200"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12207"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12212"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12213">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12229">Assessment of Procedure Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="44929"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12224">Assessment of Feasibility</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stomach tumor" id="12207"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12212"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12213">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12229">Assessment of Procedure Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stomach tumor" id="7910"><Criterion>Subjects with Early Gastric Cancer (EGC)</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7913"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7943"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7949">Subjects with history of surgery/procedure for gastric cancer</SubCriterion><SubCriterion disease="Stomach tumor" id="12900">Subjects with history of endoscopic intervention (EMR/ESD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7960"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stomach tumor" id="9472"><Criterion>Subjects with Locally Advanced Gastric Cancer</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9483"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9484"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9511"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9517">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9523"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-12-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-01-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="220987"><TitleDisplay>Primary Insufficiency of the GSV With a Diameter &gt;/= 12 mm, Antero-Lateral Branches, or Below the Knee</TitleDisplay><TitleOfficial>Registry of the Treatment of Primary Insufficiency of the Great Saphenous Vein With a Diameter &gt;/= 12 mm, Antero-Lateral Branches, or Great Saphenous Vein Insufficiency Below the Knee With Mechano-Chemical Endovenous Ablation (MOCA)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02345018</Identifier><Identifier type="Organisational Study">1079-101114</Identifier><Identifier type="Other">2014-003341-10</Identifier><Identifier type="Other">NL47979.091.14</Identifier><Identifier type="Trial Acronym">MOCA-XL</Identifier></Identifiers><Indications><Indication id="3216">Venous insufficiency</Indication><Indication id="741">Varicosis</Indication></Indications><BiomarkerNames><BiomarkerName id="15381" role="Disease marker" type="Structural (imaging)">Saphenous vein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Aethoxysklerol</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ClariVein</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Mechano-chemical ablation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1038732" type="Company"><TargetEntity id="5035542543" type="organizationId">StAntonius Hospital</TargetEntity></SourceEntity><SourceEntity id="1038798" type="Company"><TargetEntity id="5035559595" type="organizationId">OOnze Lieve Vrouwe Gasthuis</TargetEntity></SourceEntity><SourceEntity id="1039234" type="Company"><TargetEntity id="5035542479" type="organizationId">Rijnstate Hospital</TargetEntity></SourceEntity><SourceEntity id="1092794" type="Company"><TargetEntity id="5041072070" type="organizationId">Stichting Rijnstate Ziekenhuis</TargetEntity></SourceEntity><SourceEntity id="1163835" type="Company"><TargetEntity id="5040258659" type="organizationId">BovenIJ Ziekenhuis Stg</TargetEntity></SourceEntity><SourceEntity id="3216" type="ciIndication"><TargetEntity id="10057320" type="MEDDRA"></TargetEntity><TargetEntity id="D014689" type="MeSH"></TargetEntity><TargetEntity id="-1456968197" type="omicsDisease"></TargetEntity><TargetEntity id="1700" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039234">Rijnstate Hospital</Company><Company id="1092794">Rijnstate Hospital Arnhem</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1038732">St.Antonius Hospital</Company><Company id="1038798">Onze Lieve Vrouwe Gasthuis Amsterdam</Company><Company id="1163835">Bovenij Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>90</PatientCountEnrollment><DateStart>2016-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-04-26T13:32:12Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Rijnstate Hospital</Affiliation><Name>Michel Reijnen</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Symptomatic varicose veins, C2 to C5&lt;/li&gt;&lt;li&gt;Ultrasound criteria:&lt;ul&gt;&lt;li&gt;Diameter supragenual great saphenous vein (GSV)&amp;gt;/= 12 mm , not tortuous&lt;/li&gt;&lt;li&gt;Insufficient antero-lateral branch&lt;/li&gt;&lt;li&gt;Insufficient below knee GSV&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Signed informed consent&lt;/li&gt;&lt;li&gt;Patient consents to follow-up&lt;/li&gt;&lt;li&gt;Age&amp;gt; 18 years and &amp;lt; 80 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient is not capable to provide informed consent&lt;/li&gt;&lt;li&gt;Pregnancy and lactation&lt;/li&gt;&lt;li&gt;C6 varicose veins&lt;/li&gt;&lt;li&gt;Previous surgery or endovenous ablation at to treated segment&lt;/li&gt;&lt;li&gt;Deep venous vein thrombosis in medical history&lt;/li&gt;&lt;li&gt;Oral anti-coagulant therapy&lt;/li&gt;&lt;li&gt;Contraindications or allergy for sclerosant&lt;/li&gt;&lt;li&gt;Immobilization&lt;/li&gt;&lt;li&gt;Coagulant disorders or increased risk for thrombo-embolic complications: known coagulant disorders such as hemophilia A, hemophilia B, Von Willebrand disease, Glanzmann disease, factor VII-deficiency, idiopathic thrombo-cytopenic purpura, factor V Leiden disease and deep venous thrombosis or lung emboli in medical history&lt;/li&gt;&lt;li&gt;Fontaine III of IV peripheral arterial disease&lt;/li&gt;&lt;li&gt;Severe kidney disease: known GFR&amp;lt; 30 ml/min&lt;/li&gt;&lt;li&gt;Liver diseases accompanied by changes in coagulation of the blood, anamnestic indications for tendency towards haemorrhage , such as epistaxis and spontaneous hematoma, known liver cirrhosis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anatomical success: occlusion rate, evaluated using ultrasound scan</Description><Timeframe>4 weeks plus one year</Timeframe></Measure><Measure><Description>Clinical success: CEAP, VCSS</Description><Timeframe>4 weeks plus one year</Timeframe></Measure><Measure><Description>Peri-operative pain: VAS-score</Description><Timeframe>Peri-operative</Timeframe></Measure><Measure><Description>Post-operative pain during 2 weeks post-treatment: VAS-score, used pain medication</Description><Timeframe>During 2 weeks post-treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease specific and general health status: AVVQ, SF-36</Description><Timeframe>4 weeks plus one year</Timeframe></Measure><Measure><Description>Duration of the intervention using MOCA</Description><Timeframe>Peroperative</Timeframe></Measure><Measure><Description>Post-operative complications</Description><Timeframe>4 weeks plus one year</Timeframe></Measure><Measure><Description>Time to return to normal daily activities and work</Description><Timeframe>Post-treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this registry study is to provide insight in the safety and efficacy of      treatment with mechano-chemical ablation (MOCA) for primary insufficiency of the great saphenous vein (GSV) with a diameter &amp;gt;/=12 mm,      insufficient antero-lateral branches and insufficiency of the GSV below the knee.&lt;/para&gt;&lt;para&gt;The main objective of this trial is to provide insight in the safety and efficay of treatment with the ClariVein device for primary insufficiency of the great saphenous vein (GSV) supragenual (&gt;/= 12 mm), insuffucient infragenual GSV, and antero-lateral branch insufficiency.&lt;/para&gt;&lt;para&gt;The secondary objective of this trial is to evaluate per-operative pain measured with the VAS score, post-operative pain during the first 2 weeks, disease specific and general healt questionnaires, time to resume daily activities and work, intervention duration.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with primary insufficiency of the GSV with diameters &gt;/= 12 mm, insufficient antero-lateral branches or below-knee GSV insufficiency criteria will be included and observed in this study. Patients will undergo MOCA using      the ClariVein system where intentional mechanical damage to the endothelium      of the vene by means of a rotating catheter occurs. At the same time a sclerosans (Aethoxysklerol) will be injected and thus vene occludes. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Name>Rijnstate Hospital</Name><Address1>Arnhem</Address1><Address2>Gelderland</Address2><Address3>6815 AD</Address3><CountrySubDivision>Gelderland</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10157">Subjects with History of PAD Interventions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02345018</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2014-003341-10</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="26295">Pain scores</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21928"><Endpoint>Assessment of Success</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21932">Clinical Success</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21954"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21778"><Endpoint>Assessment of Interventional/Surgical Procedures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="26275">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="26291">Aberdeen varicose vein questionnaire (AVVQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21852"><Endpoint>Assessment of complications</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21970"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21977">Physical activity level</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="22008">Procedure time</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="26263"><Endpoint>Health Economic Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Peripheral vascular disease" id="21936"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19210"><Criterion>Subjects with Venous Insufficiency</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19226"><Criterion>Subjects with Inclusion Based On Location/Anatomy of Vessel</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19234">Target vessel diameter as per the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19287"><Criterion>Subjects with PAD Interventions</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="34464"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19328">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15950"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15941">Subjects with deep vein thrombosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15960"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15966">Subjects co-morbid with coagulation disorder/dysfunction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15976"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15980"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16026">Subjects with history of anticoagulant medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16033"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16065"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16084">Subjects with inability/unwillingness to sign informed consent form</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16097">Subjects with major surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25761"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16095">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="26291"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16009">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-01-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-05-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="227200"><TitleDisplay>A study to compare two different drugs for acute blood pressure control during pregnancy</TitleDisplay><TitleOfficial>A randomized trial to compare the effectiveness of oral nifedipine and intravenous Hydralazine in acute hypertensive emergencies of pregnancy</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2014/12/005285</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hydralazine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>nifedipine</Name><Drug id="47178">nifedipine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1077420" type="Company"><TargetEntity id="5038045228" type="organizationId">Dr. Rajendra Prasad Government Medical College</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1077420">Dr Rajendra Prasad Government Medical College</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><PatientCountEvaluable>60</PatientCountEvaluable><DateStart>2014-12-15T00:00:00Z</DateStart><DateChangeLast>2018-03-07T09:18:18Z</DateChangeLast><DateAdded>2015-05-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Dr Rajendra Prasad Government Medical College Kangra at Tanda (HP) Tanda at Kangra (HP)</Affiliation><Email>cdsharma2006@gmail.com</Email><Name>Chanderdeep Sharma</Name><Phone>9218925471</Phone></Contact><Contact type="Scientific contact"><Affiliation>Dr Rajendra Prasad Government Medical College Kangra at Tanda (HP)</Affiliation><Email>cdsharma2006@gmail.com</Email><Name>Chanderdeep Sharma</Name><Phone>9218925471</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 18 to 45 years&lt;/li&gt;&lt;li&gt;Period of gestation &gt; 24 weeks of gestation&lt;/li&gt;&lt;li&gt;Maternal heart rate is 60 to 90 bpm&lt;/li&gt;&lt;li&gt;Reassuring fetal heart rate&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known case of heart disease (pre-existing angina)&lt;/li&gt;&lt;li&gt;Non-pregnancy related hypertension (diagnosed cases of chronic or secondary hypertension)&lt;/li&gt;&lt;li&gt;Allergy to either of the drug&lt;/li&gt;&lt;li&gt;Need for any acute emergency for cesarean section (Abruptio placente, severe fetal bradycardia etc)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time required to achieve target systolic BP of 150 mmHg or lower and diastolic BP of 100 mmHg or lower (both targets had to be fulfilled)</Description><Timeframe>2 h after delivery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse maternal and neonatal effects</Description></Measure><Measure><Description>Total number of antihypertensive dosages required to achieve the target BP (systolic BP of 150 mmHg or lower and diastolic BP of 100 mmHg or lower, both to be fulfilled)</Description><Timeframe>2 h after delivery</Timeframe></Measure><Measure><Description>Maternal heart rate profile during the study period</Description><Timeframe>2 h after delivery</Timeframe></Measure><Measure><Description>Maternal hypotension (BP &lt; 90/60 mmHg)</Description><Timeframe>2 h after delivery</Timeframe></Measure><Measure><Description>Side effects profile (nausea, vomiting, headache, dizziness, urticaria, flushing, pruritis, nasal congestion, conjunctivitis, palpitations)</Description><Timeframe>2 h after delivery</Timeframe></Measure><Measure><Description>Perinatal outcome</Description><Timeframe>2 h after delivery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 2017, results were published. Statistically significant higher occurrence of vomiting (9/30 versus 2/30, respectively, p = 0.042) was observed with intravenous hydralazine. In either group, there were no serious adverse maternal or perinatal side effects [&lt;ulink linkType="Reference" linkID="2011106"&gt;2011106&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a randomized, double-blind, controlled trial to compare the effectiveness of oral &lt;ulink linkType="Drug" linkID="47178"&gt;nifedipine&lt;/ulink&gt; and intravenous hydralazine in acute hypertensive emergencies of pregnancy.&lt;/para&gt;&lt;para&gt;From December 2014 through September 2015,  a total of 60 patients were enrolled [&lt;ulink linkType="Reference" linkID="2011106"&gt;2011106&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2017, results were published. In both groups (intravenous hydralazine and oral nifedipine; interquartile interval 5 and 40 min, respectively, p = 0.809), the median time to achieve target blood pressure was found to be 40 min. In both groups, the median dose requirement was found to be 2 (intravenous hydralazine and oral nifedipine; interquartile range 1 and 2 doses, respectively, p = 0.625) [&lt;ulink linkType="Reference" linkID="2011106"&gt;2011106&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of two groups:&lt;br/&gt;Group 1:  hydralazine would be administered iv every 20 min with till the target BP (systolic 150 mmHg and diastolic 100 mmHg) would be achieved in consecutive doses of ie, 5, 10, 10, and 10 mg, to a maximum of four doses. If still after four doses target BP was not achieved crossover to opposite regimen would be done. Such therapy would be followed till target BP (SBP150 and DBP100 mmHg) was obtained.&lt;br/&gt;Group 2: nifedipine 10 mg po would be repeated every 20 min till target BP would be achieved (systolic 150 mmHg and diastolic 100mmHg) to maximum four doses. If still after four doses target BP was not achieved crossover to opposite regimen would be done. Such therapy would be followed till target BP (SBP150 and DBP100 mmHg) was obtained. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive intravenous hydralazine injection in doses of 5, 10, 10, and 10 mg and a placebo tablet or nifedipine (10 mg po tablet up to four doses) and intravenous saline injection every 20 min until the target blood pressure of 150 mm Hg systolic and &amp;lt;/= 100 mm Hg diastolic was achieved. Crossover treatment was administered if the initial treatment failed [&lt;ulink linkType="Reference" linkID="2011106"&gt;2011106&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>hydralazine</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>9</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>nifedipine</Name><Drug id="47178">nifedipine</Drug><Dose unit="milligram dose">10.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>30</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="519447">hydralazine</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>10 milligram</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="519448">nifedipine</Intervention><Treatments><Treatment><Dose>10 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Dr R.P. Govt. Medical; College Kangra at Tanda</Name><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Affiliation>Dr R.P. Govt. Medical; College Kangra at Tanda (HP)</Affiliation><Email>cdsharma2006@gmail.com</Email><Name>Chanderdeep Sharma</Name><Phone>9218925471</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pregnancy Induced Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="11156">Subjects with Other Hypertensive Disorders of Pregnancy</PatientSegment><SubSegments><SubSegment id="11157">Gestational hypertension subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2014/12/005285</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24427"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24429">Diastolic blood pressure (DBP)</SubEndpoint><SubEndpoint disease="Pregnancy Induced Hypertension" id="24431">Systolic blood pressure (SBP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pregnancy Induced Hypertension" id="24427"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24431">Systolic blood pressure (SBP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pregnancy Induced Hypertension" id="24436"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24435">Assessment of heart rate</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pregnancy Induced Hypertension" id="24446"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Pregnancy Induced Hypertension" id="24473"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pregnancy Induced Hypertension" id="21159"><Criterion>Pregnancy Related Other Inclusions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="21174">Protocol specified gestational age</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pregnancy Induced Hypertension" id="21184"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="21193">Subjects with no clinically significant abnormality on physical examination, ECG, vitals or labs</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pregnancy Induced Hypertension" id="18729"><Criterion>Subjects with Primary/Essential Hypertension</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18730">Subjects with chronic hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18776"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18819"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18821">Subjects with planned/history of pregnancy related surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18840"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18841">Subjects co-morbid with angina</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-03-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-03-07T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2018-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="227651"><TitleDisplay>Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02412553</Identifier><Identifier type="Organisational Study">2014P001134</Identifier></Identifiers><Indications><Indication id="337">Ulcerative colitis</Indication><Indication id="84">Crohns disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="3098" role="Therapeutic effect marker" type="Genomic;Proteomic">Calprotectin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>elemental diet</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>specific carbohydrate diet</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"></TargetEntity><TargetEntity id="10011401" type="MEDDRA"></TargetEntity><TargetEntity id="D003424" type="MeSH"></TargetEntity><TargetEntity id="-248155260" type="omicsDisease"></TargetEntity><TargetEntity id="395" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2014-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T16:20:53Z</DateChangeLast><DateAdded>2015-05-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Massachusetts General Hospital</Affiliation><Email>aananthakrishnan@mgh.harvard.edu</Email><Name>Ashwin N Ananthakrishnan, MD, MPH</Name><Phone>617-726-0267</Phone></Contact><Contact type="Public contact"><Email>cywong4@mgh.harvard.edu</Email><Name>Christina Y Wong</Name><Phone>617-724-7559</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;At least 18 years of age&lt;/li&gt;&lt;li&gt;Able to provide written informed consent prior to screening and to comply with the requirements of the study protocol&lt;/li&gt;&lt;li&gt;Established diagnosis of small bowel or colonic CD or ulcerative colitis&lt;/li&gt;&lt;li&gt;Confirmation of active CD or UC with recent (within 1 month) objective evidence of active disease on colonoscopy&lt;/li&gt;&lt;li&gt;Any medications being currently used for IBD must remain stable during the study period with the exception of tapering of corticosteroids&lt;/li&gt;&lt;li&gt;Current disease activity defined as a Harvey Bradshaw index&amp;gt; 4 at baseline (week 0) or SCCAI &amp;gt; 3&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;If female, is pregnant or is breast feeding&lt;/li&gt;&lt;li&gt;Known celiac disease or subjects with a positive screen for celiac disease (elevated tissue transglutaminase antibodies)&lt;/li&gt;&lt;li&gt;Inability to provide informed consent or unwilling to participate&lt;/li&gt;&lt;li&gt;Evidence of untreated infection eg, clostridium difficile&lt;/li&gt;&lt;li&gt;Presence of stoma or J pouch&lt;/li&gt;&lt;li&gt;Presence of enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period&lt;/li&gt;&lt;li&gt;Bowel surgery within 12 weeks prior to screen and/or has surgery planned or deemed likely for IBD during the study period&lt;/li&gt;&lt;li&gt;Fixed symptomatic stenosis of small bowel or colon&lt;/li&gt;&lt;li&gt;Chronic use of narcotics for chronic pain defined as a daily use of one or more doses of narcotic containing medication&lt;/li&gt;&lt;li&gt;Use of oral or iv antibiotics within 4 weeks prior to screening&lt;/li&gt;&lt;li&gt;Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Clinical remission: Harvey Bradshaw index &lt; 4 or SCCAI &lt; 3</Description><Timeframe>Week 6</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Biochemical response - CRP: change in serum C-reactive protein from baseline</Description><Timeframe>Week 6</Timeframe></Measure><Measure><Description>Biochemical response - fecal calprotectin: change in fecal calprotectin from baseline</Description><Timeframe>Week 6</Timeframe></Measure><Measure><Description>Clinical response: reduction in HBI by &gt;/= 3 or SCCAI by &gt;/= 2</Description><Timeframe>Week 6</Timeframe></Measure><Measure><Description>Change in gut microbiome: change in fecal microbiome pattern assessed using 16sRNA sequencing and shotgun metagenomic sequencing</Description><Timeframe>Weeks 6 and 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study is proposed as a two-year, single-site, open-label clinical trial of enteral      nutrition or the specific carbohydrate diet in patients with active crohn's disease (CD) or ulcerative colitis (UC).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;All patients will be required to have a diagnosis of CD or UC confirmed      using standard clinical, endoscopic, and histological criteria. Eligible patients will      complete an office visit to confirm eligibility for the study and informed consent will be      obtained. They will then be scheduled for a routine colonoscopy as part of their standard      clinical care to objectively confirm active disease and obtain biopsies for microbiome and      gene expression. The investigators will obtain prior authorization from the patient's      insurance company for such colonoscopy, or if it is not covered by the insurance, the      investigators will use study funds to pay for the procedure.  They will then be assigned to      one of two dietary intervention arms based on their preference and will meet with the study      registered dietician at the MGH Clinical Research Center (CRC) metabolism and nutrition      unit. There, they will receive instruction on the components of the assigned dietary therapy      arm - partial elemental diet (enteral nutrition) (to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet), or specific carbohydrate diet (to meet 100% of the caloric requirements of the patient), and will      complete a baseline food record (FR). They will adhere to the dietary therapy for 6 weeks      after which they can resume normal diet. Clinical, biochemical, nutritional, and      microbiological parameters will be measured during and for 6 weeks following the study. They      will have five study visits during this time.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ulcerative colitis</Disease><PatientSegments><PatientSegment><PatientSegment id="8784">Subjects with Active Ulcerative Colitis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8788">Subjects with History of Use of Ulcerative Colitis Medication</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Crohns disease</Disease><PatientSegments><PatientSegment><PatientSegment id="3404">Subjects with Active Crohns Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3425">Subjects with H/O Treatment with Crohns Disease Medication</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02412553</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Crohns disease" id="6316"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6319">Harvey Bradshaw index (HBI) score &lt; or = 4</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Crohns disease" id="6407"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="27838">Assessment by simple clinical colitis index (SCCAI)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Ulcerative colitis" id="15887"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15888">Assessment of clinical remission</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Ulcerative colitis" id="15921"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15904">Assessment by simple clinical colitis index (SCCAI)</SubEndpoint><SubEndpoint disease="Ulcerative colitis" id="27837">Harvey bradshw index(HBI)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Crohns disease" id="6309"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6315">Clinical response measured by Harvey Bradshaw Index (HBI) score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6368"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6371">Fecal calprotectin</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6407"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="27838">Assessment by simple clinical colitis index (SCCAI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15881"><Endpoint>Assessment of Clinical Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15921"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15904">Assessment by simple clinical colitis index (SCCAI)</SubEndpoint><SubEndpoint disease="Ulcerative colitis" id="27837">Harvey bradshw index(HBI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15939"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15943">Assessment of fecal calprotectin</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="16721"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="16724">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="43912"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6369">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Crohns disease" id="6471"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6470">Genomics/Proteomics Evaluation</SubEndpoint><SubEndpoint disease="Crohns disease" id="6472">Assessment of microbial flora</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Ulcerative colitis" id="15950"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15956">Microbiological/serological assays</SubEndpoint><SubEndpoint disease="Ulcerative colitis" id="16727">Assessment by genetic expression/analysis</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Ulcerative colitis" id="15971"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Crohns disease" id="3162"><Criterion>Subjects with Active Crohn's Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3204"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3211">Steroids</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3240"><Criterion>Subjects with Abnormal Laboratory Parameters</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3244">Colonoscopy and other imaging indicative of crohn's disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3248"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3252">Outsubjects/non-hospitalized subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15774"><Criterion>Subjects with Active Ulcerative Colitis</Criterion></Inclusion><Inclusion disease="Ulcerative colitis" id="15780"><Criterion>Subjects Included Based on Disease Activity Scores</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15784">Subjects enrolled based on simple clinical colitis index (SCCAI)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15811"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15814">Subjects with history of/requiring steroid use</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15826"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15828">Subjects assessed by/indicated for endoscopic examination</SubCriterion><SubCriterion disease="Ulcerative colitis" id="15829">Subjects assessed by/indicated for histologic examination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15841"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15848">Outsubjects/non-hospitalized subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="34351"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3249">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="34407"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15846">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Crohns disease" id="4360"><Criterion>Subjects with Specific Disease Patterns Based on the Primary Behavior</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4363">Fibrostenotic/obstructing/stricturing crohn's disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4381"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4403"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4407"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4416">Subjects co-morbid with abdominal abscess</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4455"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4457">Subjects unwilling/unable to provide informed consent</SubCriterion><SubCriterion disease="Crohns disease" id="4469">Subjects on total parenteral nutrition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13116"><Criterion>Subjects with Complications of Ulcerative Colitis</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13117">Subjects with bowel obstruction/perforation/stenosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13120"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13138"><Criterion>Subjects with/Predisposed to Local/Systemic Infections</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13154"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13159">Subjects with a history/current use of protocol prohibited antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13164"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13166"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13168">Subjects unwilling/unable to provide informed consent</SubCriterion><SubCriterion disease="Ulcerative colitis" id="13170">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Ulcerative colitis" id="13178">Subjects on total parenteral nutrition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="25742"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4460">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-04-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="229015"><TitleDisplay>Phase Ib exploratory study of SP-333 in mild-to-moderate ulcerative colitis patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="337">Ulcerative colitis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dolcanatide</Name><Drug id="64871">dolcanatide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64871">dolcanatide</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="25766">Synergy Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="64871" type="Drug"><TargetEntity id="679241" type="siDrug">Dolcanatide</TargetEntity></SourceEntity><SourceEntity id="25766" type="Company"><TargetEntity id="4295901050" type="organizationId">Synergy Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1b Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25766">Synergy Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="8467">Guanylate cyclase receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1332">Gastrointestinal system agent</Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>28</PatientCountEnrollment><PatientCountEvaluable>28</PatientCountEvaluable><DateChangeLast>2016-08-10T06:04:04Z</DateChangeLast><DateAdded>2015-05-20T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with mild-to-moderate ulcerative colitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In January 2016, positive results were published. Dolcanatide was  safe and well tolerated [&lt;ulink linkType="Reference" linkID="1726394"&gt;1726394&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this double-blind, placebo-controlled, 4-week study was to investigate the effect of &lt;ulink linkType="Drug" linkID="64871"&gt;SP-333&lt;/ulink&gt; in mild-to-moderate ulcerative colitis patients [&lt;ulink linkType="Reference" linkID="1610869"&gt;1610869&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1658785"&gt;1658785&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1726394"&gt;1726394&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1786584"&gt;1786584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, the study was initiated [&lt;ulink linkType="Reference" linkID="1610869"&gt;1610869&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2016, positive results were published.  Results demonstrated clear signals of improvement and efficacy in dolcanatide-treated patients compared to placebo [&lt;ulink linkType="Reference" linkID="1726394"&gt;1726394&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive SP-333 or placebo [&lt;ulink linkType="Reference" linkID="1610869"&gt;1610869&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1658785"&gt;1658785&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  received SP-333 or placebo [&lt;ulink linkType="Reference" linkID="1726394"&gt;1726394&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-01-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-01-13T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="234724"><TitleDisplay>The Comparison of Fentanyl and Ketorolac With PCA Pump for Post-Abdominal Hysterectomy Pain Control</TitleDisplay><TitleOfficial>The Comparison of Fentanyl and Ketorolac With PCA Pump for Post-Abdominal Hysterectomy Pain Control</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201503288677N5</Identifier><Identifier type="Secondary Organisational">1930596733</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2095" role="Toxic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="10260" role="Toxic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fentanyl</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ketorolac</Name><Drug id="3422">ketorolac</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3422">ketorolac</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1058060">Guilan University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3422" type="Drug"><TargetEntity id="90718" type="siDrug">Ketorolac</TargetEntity></SourceEntity><SourceEntity id="1058060" type="Company"><TargetEntity id="5035560611" type="organizationId">Guilan University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="132" type="Action"><TargetEntity id="405" type="Mechanism">Cyclooxygenase (COX) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1058060">Guilan University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="132">Cyclooxygenase inhibitor</Action><Action id="406">Oxidoreductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class><Class id="2955">Non-steroidal anti-inflammatory</Class><Class id="329">Prostaglandin synthesis inhibitor</Class></Class><Technologies><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>108</PatientCountEnrollment><DateStart>2015-06-22T00:00:00Z</DateStart><DateChangeLast>2017-04-14T07:04:44Z</DateChangeLast><DateAdded>2015-08-01T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Guilan University of Medical Sciences</Affiliation><Name>Hedyeh Nemati</Name></Contact><Contact type="Scientific contact"><Affiliation>Guilan University of Medical Science</Affiliation><Email>arcguilan1392@gmail.com; farnoush_farzi@gmail.com</Email><Name>Farnoush Farzi</Name><Phone>0098133229524 00989113311653</Phone></Contact><Contact type="Public contact"><Affiliation>Guilan University of Medical Sciences</Affiliation><Email>arcguilan1392@gmail.com; Farnoush_farzi@gmail.com</Email><Name>Farnoush Farzi</Name><Phone>0098133229524 00989113311653</Phone></Contact><Contact type="Public contact"><Affiliation>Guilan University of Medical Sciences</Affiliation><Email>nematihedieh@gmail.com</Email><Name>Hedyeh Nemati</Name><Phone>00981333310434 009111320677</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 20 to 60 years old&lt;/li&gt;&lt;li&gt;ASA I and II&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Allergic reaction to fentanyl or ketorolac&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain: Visual Analog Score (VAS)</Description><Timeframe>Baseline 6 and 12 weeks after surgery</Timeframe></Measure><Measure><Description>Sedation: sedation score</Description><Timeframe>1, 6, 12 and 24 h after surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Heart rate</Description><Timeframe>1, 6, 12 and 24 h after surgery</Timeframe></Measure><Measure><Description>Respiratory rate</Description><Timeframe>1, 6, 12 and 24 h after surgery</Timeframe></Measure><Measure><Description>Mean arterial pressure</Description><Timeframe>1, 6, 12 and 24 h after surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to compare fentanyl and &lt;ulink linkType="Drug" linkID="3422"&gt;ketorolac&lt;/ulink&gt; with patient controlled analgesia (PCA) pump for post-abdominal hysterectomy pain control.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will  be  divided into two groups randomly:&lt;br/&gt;Group 1: patients will receive fentanyl with PCA pump 100 cc (750 microg of fentanyl and time-consuming saline) at a rate of 0.4 microg/kg/h at 30 min before the end of the surgery.&lt;br/&gt;Group 2: patients will receive ketorolac with PCA pump 100 cc (90 mg ketorolac and 30 mg/ml time-consuming saline) at a speed 0.05 microg/kg/h  at 30 min before the end of the surgery.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Al-Zahra Hospital</Name><Address1>Rasht</Address1><Address2>Guilan</Address2><CountrySubDivision>Guilan</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Farnoush Farzi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201503288677N5</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25929"><Endpoint>Assessment of Procedural Analgesia/Anesthesia</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25932">Assessment of sedation level</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="26009"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22173">Subjects with pre-specified physical status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-12-22T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>17.91 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-08-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-01-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="242433"><TitleDisplay>Jumping to Health</TitleDisplay><TitleOfficial>Comprehensive Study for the Prevention of Obesity and Non-Communicable Chronic Disease, SALTEN</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN16804726</Identifier><Identifier type="Other">10.1186/ISRCTN16804726</Identifier><Identifier type="Trial Acronym">SALTEN</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fruits diet</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>physical activity</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1099863" type="Company"><TargetEntity id="5043460880" type="organizationId">International Life Sciences Institute</TargetEntity></SourceEntity><SourceEntity id="15512" type="Company"><TargetEntity id="4295903091" type="organizationId">Coca-Cola Co</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1099863">International Life Sciences Institute, Argentina</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15512">The Coca-Cola Co</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><DateStart>2013-01-07T00:00:00Z</DateStart><DateEnd type="actual">2014-11-28T00:00:00Z</DateEnd><DateChangeLast>2018-07-02T05:44:37Z</DateChangeLast><DateAdded>2015-10-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Prof Kovalskys</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children in fourth hand fifth grade (aged 9 to 11 years)&lt;/li&gt;&lt;li&gt;Attending participating schools&lt;/li&gt;&lt;li&gt;Received parental consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Children with severe intellectual difficulties&lt;/li&gt;&lt;li&gt;Children with limitations to engage in physical activity&lt;/li&gt;&lt;li&gt;Children suffering from illnesses compromising nutrition or food selection&lt;/li&gt;&lt;li&gt;Children taking medication known to affect body weight&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anthropometric measures (weight, height, waist circumference and BMI Z-score) measured at baseline and at 18 months (end of follow-up). Weight measured using an electronic scale to the nearest 0.1 kg. Height measured with a wall-mounted stadiometer to the nearest 0.1 cm. Waist circumference measured using an anthropometric tape to the nearest 0.1cm. BMI z-score calculated using the 2007 WHO reference growth charts</Description><Timeframe>At baseline and at 18 months (end of follow-up)</Timeframe></Measure><Measure><Description>Dietary intake was measured using a modified and trans-culturally adapted version of the child nutrition questionnaire at baseline and subsequently</Description><Timeframe>At 6, 12 and 18 months</Timeframe></Measure><Measure><Description>Physical activity level (during school-breaks, after school, and during weekend) was assessed with the interviewer based part of a culturally adapted and modified version of the child and adolescent physical activity and nutrition survey</Description><Timeframe>At baseline, 6, 12 and 18 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Dietary habits and attitudes, and level of engagement and attitudes towards physical activity measured using the self-report part of the child nutrition questionnaire and the child and adolescent physical activity and nutrition survey</Description><Timeframe>At baseline, 6, 12 and 18 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to find out whether the applying the SALTEN programme in schools could help to reduce obesity in children. &lt;/para&gt;&lt;para&gt;This was a multi-component behavioural and educational intervention aimed to improve physical activity and healthy eating habits of fourth and fifth grade boys and girls of eight schools (4 intervention; 4 control) matched for socio demographic characteristics.&lt;br/&gt;The hypothesis of the study: children of public schools of Argentina, aged 9 to 11 years, were more likely to develop healthy eating habits and improve physical activity levels if they were exposed to culturally appropriate environmental and educational stimuli during two consecutive school years.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study  would include two arms:&lt;br/&gt;Intervention arm: subjects would receive daily access to fruits during school-breaks, water fountains were installed in the school playgrounds, and a physical activity (PA) instructor encourages moderate to vigorous physical activity during school breaks on playgrounds that were accordingly re-designed, painted and equipped for this goal. The educational component would consist of 13 units focused on healthy lifestyle that were delivered by their teachers.  &lt;br/&gt;Control arm: subjects would receive two classroom workshops aimed at providing knowledge regarding healthy eating and physical activity respectively.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Contacts></Contacts></Site><Site><Name>Alte. Guillermo Brown</Name><Contacts></Contacts></Site><Site><Name>Gral. Manuel Belgrano</Name><Contacts></Contacts></Site><Site><Name>José Hernández</Name><Contacts></Contacts></Site><Site><Name>José de San Martín</Name><Contacts></Contacts></Site><Site><Name>Manuel Dorrego</Name><Contacts></Contacts></Site><Site><Name>Monseñor Miguel de Andrea</Name><Contacts></Contacts></Site><Site><Name>Teniente General Julio A. Roca</Name><Contacts></Contacts></Site><Site><Name>Tomás Espora</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN16804726</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20653"><Endpoint>Assessment of Physical Examination</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20402">Assessment of waist circumference</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="34455"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19791">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion><SubCriterion disease="Obesity" id="15411">Subjects on/treated with weight loss medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15367">Subjects with inability to exercise or perform physical activity</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2013-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>4.81 Months</EnrollmentPeriod><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-10-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="272210"><TitleDisplay>HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients</TitleDisplay><TitleOfficial>HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02908763</Identifier><Identifier type="Organisational Study">3RD-SYSU-I-CURE-4</Identifier></Identifiers><Indications><Indication id="152">Hepatitis B virus infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>peginterferon alfa-2a</Name><Drug id="23625">peginterferon alfa-2a</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>peginterferon alfa-2b</Name><Drug id="3364">peginterferon alfa-2b</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="23625">peginterferon alfa-2a</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1009044">Peking University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1053334">Nanchang University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059124">First People's Hospital of Foshan</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1071134">The Third Affiliated Hospital of Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1072875">The First People's Hospital of Shunde</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074827">Tangdu Hospital, the Fourth Military Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1091428">Huizhou Municipal Central Hospital, Guangdong</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1094744">First Affiliated Hospital of Kunming Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1122219">Yuebei People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="CM27909">Huazhong University of Science and Technology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3364">peginterferon alfa-2b</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1009044">Peking University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1053334">Nanchang University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059124">First People's Hospital of Foshan</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1071134">The Third Affiliated Hospital of Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1072875">The First People's Hospital of Shunde</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074827">Tangdu Hospital, the Fourth Military Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1091428">Huizhou Municipal Central Hospital, Guangdong</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1094744">First Affiliated Hospital of Kunming Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1122219">Yuebei People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="CM27909">Huazhong University of Science and Technology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3364" type="Drug"><TargetEntity id="214807" type="siDrug">Peginterferon alfa-2b</TargetEntity></SourceEntity><SourceEntity id="23625" type="Drug"><TargetEntity id="261662" type="siDrug">Peginterferon alfa-2a</TargetEntity></SourceEntity><SourceEntity id="1009044" type="Company"><TargetEntity id="5000020996" type="organizationId">Peking University</TargetEntity></SourceEntity><SourceEntity id="1053334" type="Company"><TargetEntity id="5036200001" type="organizationId">Nanchang University</TargetEntity></SourceEntity><SourceEntity id="1059124" type="Company"><TargetEntity id="5035552308" type="organizationId">First Peoples Hospital Of Foshan</TargetEntity></SourceEntity><SourceEntity id="1071134" type="Company"><TargetEntity id="5037630255" type="organizationId">Third Affiliated Hospital of Sun Yat-Sen University</TargetEntity></SourceEntity><SourceEntity id="1072875" type="Company"><TargetEntity id="5037843888" type="organizationId">Shunde Hospital of Southern Medical University</TargetEntity></SourceEntity><SourceEntity id="1074827" type="Company"><TargetEntity id="5037941636" type="organizationId">Second Affiliated Hospital of the Air Force Military Medical University</TargetEntity></SourceEntity><SourceEntity id="1091428" type="Company"><TargetEntity id="5040928234" type="organizationId">Huizhou Municipal Central Hospital</TargetEntity></SourceEntity><SourceEntity id="1094744" type="Company"><TargetEntity id="5042242018" type="organizationId">First Affiliated Hospital of Kunming Medical University</TargetEntity></SourceEntity><SourceEntity id="1122219" type="Company"><TargetEntity id="5050720671" type="organizationId">Yuebei People's Hospital</TargetEntity></SourceEntity><SourceEntity id="CM27909" type="Company"><TargetEntity id="5000047779" type="organizationId">Huazhong University of Science and Technology</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1071134">The Third Affiliated Hospital of Sun Yat-Sen University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1009044">Peking University</Company><Company id="1053334">Nanchang University</Company><Company id="1059124">First People's Hospital of Foshan</Company><Company id="1072875">The First People's Hospital of Shunde</Company><Company id="1074827">Tangdu Hospital, the Fourth Military Medical University</Company><Company id="1091428">Huizhou Municipal Central Hospital, Guangdong</Company><Company id="1094744">First Affiliated Hospital of Kunming Medical University</Company><Company id="1122219">Yuebei People's Hospital</Company><Company id="CM27909">Huazhong University of Science and Technology</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="214">Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1532">Viral replication inhibitor</Class><Class id="1545">Anticancer</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="80">Peptide</Technology><Technology id="208">Protein conjugation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2016-08-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:43:13Z</DateChangeLast><DateAdded>2016-09-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University</Affiliation><Email>zhilianggao@21cn.com</Email><Name>Zhi-Liang Gao, Professor</Name><Phone>86-20-85252373</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Hepatitis B surface antigen (HBsAg) positive and&amp;lt; 1000 IU/ml&lt;/li&gt;&lt;li&gt;Hepatitis B surface antibody (HBsAb) negative&lt;/li&gt;&lt;li&gt;Hepatitis B e antigen (HBeAg) negative&lt;/li&gt;&lt;li&gt;Hepatitis B virus DNA&amp;lt; 2000 IU/ml&lt;/li&gt;&lt;li&gt;Absence of previous antiviral therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with active alcohol and/or drugs consumption&lt;/li&gt;&lt;li&gt;Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies&lt;/li&gt;&lt;li&gt;Patients with other factors causing liver diseases&lt;/li&gt;&lt;li&gt;Pregnant and lactating women&lt;/li&gt;&lt;li&gt;Patients with concomitant HIV infection or congenital immune deficiency diseases&lt;/li&gt;&lt;li&gt;Patients with diabetes, autoimmune diseases&lt;/li&gt;&lt;li&gt;Patients with important organ dysfunctions&lt;/li&gt;&lt;li&gt;Patients with mental illness&lt;/li&gt;&lt;li&gt;Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months&lt;/li&gt;&lt;li&gt;Patients who can't come back to clinic for follow-up on schedule&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>HBsAg Clearance Rate: percentage of Participants with HBsAg negative</Description><Timeframe>96 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>HBsAg Seroconversion Rate: Percentage of Participants with HBsAg negative and anti-HBsAg positive</Description><Timeframe>96 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The      purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg      loss/seroconversion therapy in low replicative chronic HBV infection patients with low Level      HBsAg.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;After giving informed consent, patients will be  treated with weekly subcutaneous injections of      &lt;ulink linkType="Drug" linkID="23625"&gt;peginterferon alfa-2a&lt;/ulink&gt; 180 microg/week or &lt;ulink linkType="Drug" linkID="3364"&gt;peginterferon alfa-2b&lt;/ulink&gt; 80 microg/week fot at most 96  weeks. Observing group will be only observed and followed up. The use of other      immune suppressive or regulatory drugs and other antiviral drugs will be prohibited during the      course of the study.&lt;/para&gt;&lt;para&gt;In this study, treatment endpoint is  HBsAg loss(&amp;lt; 0.05 IU/ml) and anti-HBs positive(&gt; 10      mIU/ml) defined as seroconversion. Depending on the decline of      HBsAg level, treatment will be either continued for a prolonged period (no more than 96 weeks)      until the endpoint was achieved, or terminated in case of nonresponse. Treatment will be       proceeded if HBsAg level continued to decline until HBsAg seroconversion is achieved and      the anti-HBs level is above 200 mIU/ml. If the patients are not willing to extend      treatment, the therapy will be ended at the time of HBsAg loss, or stopped without further      decline of HBsAg levels.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510630</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>zhilianggao@21cn.com</Email><Name>Zhi-Liang Gao, Professor</Name><Phone>86-20-85252373</Phone></Contact><Contact type="Facility contact backup"><Email>0628zhuxiang@163.com</Email><Name>Xiang Zhu, Doctor</Name><Phone>86-20-85252372</Phone></Contact><Contact type="Facility investigator"><Name>Zhi-Liang Gao, Professor</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis B virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10115">Treatment Naive Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19014">Subjects with Hepatitis B Infection</PatientSegment><SubSegments><SubSegment id="10101">HBeAG negative subjects</SubSegment><SubSegment id="10102">HBsAG positive subjects</SubSegment><SubSegment id="10103">HBsAG negative, antibody positive subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02908763</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis B virus infection" id="18288"><Endpoint>Assessment of Viral Antigens</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B virus infection" id="18290">Assessment of HBsAg changes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hepatitis B virus infection" id="18288"><Endpoint>Assessment of Viral Antigens</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B virus infection" id="18290">Assessment of HBsAg changes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B virus infection" id="18301"><Endpoint>Assessment of Immune Response</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Hepatitis B virus infection" id="18309"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis B virus infection" id="16775"><Criterion>Subjects with Chronic Hepatitis B Infection</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="16777">HBeAG negative subjects</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="16778">HBsAG positive subjects</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="16779">HBsAG negative, antibody positive subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B virus infection" id="16799"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Hepatitis B virus infection" id="16814"><Criterion>Subjects with Protocol Specified HBV DNA Levels</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatitis B virus infection" id="14259"><Criterion>Subjects with Hepatocellular Carcinoma</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14260"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="14262">Subjects co-morbid with Liver cirrhosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14269"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="14303">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14274"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14275"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="14276">Subjects immunocompromized with HIV infection</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="14277">Subjects immunocompromised with cancer/malignancy</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="14278">Subjects on immunomodulators/corticosteroids/chemotherapeutic drugs</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="14279">Subjects with other immunological disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B virus infection" id="24949"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="24737">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-08-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="274568"><TitleDisplay>Copper prescription in pregnancy</TitleDisplay><TitleOfficial>Evaluating the effect of copper supplement during pregnancy on premature and pregnancy outcome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201008112624N7</Identifier><Identifier type="Secondary Organisational">896.1</Identifier></Identifiers><Indications><Indication id="411">Pregnancy disorder</Indication><Indication id="455">Premature labor</Indication></Indications><BiomarkerNames><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="9842" role="Therapeutic effect marker" type="Anthropomorphic">Birth weight</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>copper</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1035896" type="Company"><TargetEntity id="5035541621" type="organizationId">Iran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="411" type="ciIndication"><TargetEntity id="562" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="455" type="ciIndication"><TargetEntity id="O60" type="ICD10"></TargetEntity><TargetEntity id="10036600" type="MEDDRA"></TargetEntity><TargetEntity id="D007752" type="MeSH"></TargetEntity><TargetEntity id="-699701292" type="omicsDisease"></TargetEntity><TargetEntity id="567" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1035896">Iran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2010-10-23T00:00:00Z</DateStart><DateChangeLast>2017-04-13T10:47:12Z</DateChangeLast><DateAdded>2016-11-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>maryamkashanian@yahoo.com</Email><Name>Maryam Kashanian</Name><Phone>00982155633244</Phone></Contact><Contact type="Public contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>maryamkashanian@yahoo.com</Email><Name>Maryam Kashanian</Name><Phone>00982155633244</Phone></Contact><Contact type="Public contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>maryamkashanian@yahoo.com</Email><Name>Maryam Kashanian</Name><Phone>00982155633244</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Nuliparity&lt;/li&gt;&lt;li&gt;Age between 18 to 35&lt;/li&gt;&lt;li&gt;Second trimester of pregnancy, and having written consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Multiple pregnancy&lt;/li&gt;&lt;li&gt;History of any systemic disorders or drug use except iron supplement&lt;/li&gt;&lt;li&gt;Known copper sensitivity, polyhydramnios, fetal death, fetal anomalies, smoking, alcohol consumption and drug abuse&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Preterm premature rupture of membranes and premature rupture of membranes: questionnaire</Description><Timeframe>9 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Pregnancy outcome: questionnaire</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Anemia: hemoglobin</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Birth weight: questionnaire</Description><Timeframe>Delivery</Timeframe></Measure><Measure><Description>Drug adverse effects: questionnaire</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Infection: questionnaire</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Placental abruption, placenta previa, hemorrhage during pregnancy: questionnaire</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Preeclampsia: questionnaire</Description><Timeframe>9 months</Timeframe></Measure><Measure><Description>Preterm labor: questionnaire</Description><Timeframe>9 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the present study is to evaluate the effect of copper supplementation during pregnancy on the preterm premature rupture of membranes (PPROM), premature rupture of membranes (PROM) and pregnancy outcomes. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study will be conducted as a triple-blind, randomized clinical trial. The participants (200) will randomly be divided into the two groups. In one group copper in a dose of 1000 mg and in the other group, placebo will be prescribed orally from 16th week of pregnancy. Then the pregnancy outcome including PROM, PPROM, birth weight, placental abruption, placenta previa, hemorrhage during pregnancy, anemia, infection, preterm labor, and preeclampsia will be compared between the two groups. Drug adverse effects will be evaluated too.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Tehran prenatal care centers</Name><Address1>Tehran</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gynecological disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="17543">Women  giving birth/Obstetrics</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18260">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="18740">Subjects with Labor Complications</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201008112624N7</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gynecological disorder" id="43238"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gynecological disorder" id="43005"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gynecological disorder" id="43238"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gynecological disorder" id="43656"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gynecological disorder" id="33094"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gynecological disorder" id="24055"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="24303"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2012-03-19T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>16.90 Months</EnrollmentPeriod><EnrollmentRate>11.83 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="276970"><TitleDisplay>A Study to Describe the Safety and Efficacy of Higher-Evening Differential Dose of Clobazam as Add-On Therapy in Patients with Night-Time/Early Morning Seizures</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="119">Epilepsy</Indication><Indication id="717">Seizure disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>clobazam (Lennox-Gastaut syndrome/anxiety), Lundbeck</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1011349" type="Company"><TargetEntity id="5000007233" type="organizationId">Lundbeck LLC</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="717" type="ciIndication"><TargetEntity id="10039911" type="MEDDRA"></TargetEntity><TargetEntity id="D012640" type="MeSH"></TargetEntity><TargetEntity id="-1663650866" type="omicsDisease"></TargetEntity><TargetEntity id="4242" type="siCondition"></TargetEntity><TargetEntity id="1353" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1011349">Lundbeck Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>27</PatientCountEnrollment><PatientCountEvaluable>27</PatientCountEvaluable><DateChangeLast>2016-10-26T16:01:08Z</DateChangeLast><DateAdded>2016-10-27T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with night-time/early morning seizures or refractory epilepsy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to describe the safety and efficacy of higher-evening differential dose of &lt;ulink linkType="Drug" linkID="79850"&gt;clobazam&lt;/ulink&gt; as add-on therapy in patients with night-time/early morning seizures [&lt;ulink linkType="Reference" linkID="1866783"&gt;1866783&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2016, results were published. A higher median total clobazam dose of 0.8 mg/kg/day in patients with differential dosing compared to 0.6 mg/kg/day in controls was tolerated at first follow-up. Median percentage of total clobazam dose administered in evening was 66.7% in patients with differential dose. Differential dose patients versus controls reported a median seizure reduction of 75 versus 50%, respectively (p &amp;lt; 0.005). Differential dosing was most effective in patients with generalized seizures with a median seizure reduction of 77.5% compared to 50% in controls (p = 0.017) [&lt;ulink linkType="Reference" linkID="1866783"&gt;1866783&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients treated with clobazam differential dosing with higher evening dosing started based on a high proportion of seizures (&gt; 80%) at nighttime (6 pm to 6 am) [&lt;ulink linkType="Reference" linkID="1866783"&gt;1866783&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="291541"><TitleDisplay>Pharmacokinetic study on single dose of bovine carnal kidney bean (TJ-107) in healthy person</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">JapicCTI-173509</Identifier></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>TJ-107</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20446" type="Company"><TargetEntity id="4295878528" type="organizationId">Tsumura &amp; Co</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20446">Tsumura &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>21</PatientCountEnrollment><DateStart>2017-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-03-14T22:04:37Z</DateChangeLast><DateAdded>2017-03-24T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy Japanese males, age 20 to 44&lt;/li&gt;&lt;li&gt;Those who have a degree of obesity (BMI) of 18.5 or more and less than 25.0&lt;/li&gt;&lt;li&gt;Subjects who provided written consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects whose weight is less than 50 kg&lt;/li&gt;&lt;li&gt;Subjects who have a history of drug allergy, food allergy&lt;/li&gt;&lt;li&gt;Those who participated in other clinical trials within the past 16 weeks with the first hospital day as the starting date&lt;/li&gt;&lt;li&gt;Those who donated more than 400 ml / donated blood within the last 12 weeks with the first hospital day as the starting day&lt;/li&gt;&lt;li&gt;Those who have a history of serious respiratory disease, liver disease&lt;/li&gt;&lt;li&gt;People with a history of gastrointestinal diseases (peptic ulcer, reflux esophagitis, etc) (excluding history of appendicitis)&lt;/li&gt;&lt;li&gt;Subjects who had a history of resection of the gastrointestinal tract (except for appendectomy)&lt;/li&gt;&lt;li&gt;Those who can not abstain from drinking or quitting smoking for each period from the hospitalization date to the end of each term&lt;/li&gt;&lt;li&gt;Those who can not suspend drugs and supplements other than the study drug over the test period (from the date of consent acquisition to the end of three terms)&lt;/li&gt;&lt;li&gt;Those who are judged inappropriate by the investigator and the test sharing doctor  in the screening test or the first hospital day inspection, deviating from the reference range of the clinical examination&lt;/li&gt;&lt;li&gt;HCV antibody, HBs antigen, HIV antigen antibody, TP antibody positive&lt;/li&gt;&lt;li&gt;In addition, those who judged inappropriate by the investigator&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Pharmacokinetics</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The pharmacokinetics and safety  of Tsumura bovine carnacle kidney powder extract granule will be examined in a randomized crossover study for healthy adult males.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Three doses of 7.5 g (1 capsule 2.5 g × 3 capsules), 5.0 g (1 capsule 2.5 g × 2 capsules), 2.5 g (1 capsule 2.5 g × 1 capsule) of Tsumura Otoken Kidney Circular Extract granule is orally administered in a single dose divided into 3 doses (3 stages) for the same subject. A washout period of 14 days or more is set as the interval of each period.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-173509</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="291857"><TitleDisplay>A randomized, controlled, comparative study to evaluate the effect of fenofibrate alone or in combination with pentoxifylline on the measured biochemical parameters, inflammatory pathyway and liver stiffness in patients with non-alcoholic fatty liver disease</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="3288">Non alcoholic fatty liver disease</Indication></Indications><BiomarkerNames><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="319" role="Therapeutic effect marker" type="Genomic;Proteomic">Transforming growth factor beta 1</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1238" role="Therapeutic effect marker" type="Biochemical">Hyaluronic acid</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2310" role="Therapeutic effect marker" type="Physiological">Liver Stiffness</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fenofibrate (micronized), Fournier/Abbott</Name><Drug id="16986">fenofibrate (micronized), Fournier/Abbott</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>fenofibrate (micronized), Fournier/Abbott</Name><Drug id="16986">fenofibrate (micronized), Fournier/Abbott</Drug></Intervention><Intervention type="InterventionPrimary"><Name>pentoxifylline</Name><Drug id="44306">pentoxifylline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16986">fenofibrate (micronized), Fournier/Abbott</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1055246">Tanta University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16986">fenofibrate (micronized), Fournier/Abbott</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1055246">Tanta University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44306">pentoxifylline</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1055246">Tanta University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44306" type="Drug"><TargetEntity id="143975" type="siDrug">Pentoxifylline</TargetEntity></SourceEntity><SourceEntity id="1055246" type="Company"><TargetEntity id="5035550592" type="organizationId">Tanta University Hospitals</TargetEntity></SourceEntity><SourceEntity id="3288" type="ciIndication"><TargetEntity id="K76.0" type="ICD10"></TargetEntity><TargetEntity id="-468189475" type="omicsDisease"></TargetEntity><TargetEntity id="2263" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3033" type="Action"><TargetEntity id="893" type="Mechanism">PPARalpha Agonists</TargetEntity><TargetEntity id="2789" type="Mechanism">PPARalpha Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="7624" type="Action"><TargetEntity id="4395" type="Mechanism">Lipoprotein Lipase (LPL) Activators</TargetEntity></SourceEntity><SourceEntity id="8052" type="Action"><TargetEntity id="466" type="Mechanism">Phosphodiesterase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1055246">Tanta University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3033">PPAR alpha agonist</Action><Action id="7624">Lipoprotein lipase stimulator</Action><Action id="8052">Phosphoric diester hydrolase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="753">Microparticle formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><PatientCountEvaluable>90</PatientCountEvaluable><DateChangeLast>2017-03-28T16:00:22Z</DateChangeLast><DateAdded>2017-03-29T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with non-alcoholic fatty liver disease&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Fasting blood sample was obtained before and 24 weeks after treatment for biochemical analysis of liver and lipid panels, tumor necrosis factor-alpha, hyaluronic acid, transforming growth factor beta 1, fasting plasma insulin and fasting glucose</Description></Measure><Measure><Description>Liver stiffness measurement was carried out using fibro-scan</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, controlled, comparative study was to evaluate the effect of &lt;ulink linkType="Drug" linkID="16986"&gt;fenofibrate&lt;/ulink&gt; alone or in combination with &lt;ulink linkType="Drug" linkID="44306"&gt;pentoxifylline&lt;/ulink&gt; on the measured biochemical parameters, inflammatory pathyway and liver stiffness in patients with non-alcoholic fatty liver disease [&lt;ulink linkType="Reference" linkID="1912086"&gt;1912086&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 2015, results were published. When compared to fenofibrate alone, pentoxifylline in combination with fenofibrate did not provide a beneficial effect on lipid panel, but showed a beneficial effect on indirect biochemical markers of hepatic fibrosis, a direct marker linked to matrix deposition (hyaluronic acid), a cytokine/growth factor linked to liver fibrosis (transforming growth factor beta 1), the inflammatory pathway, insulin resistance and liver stiffness [&lt;ulink linkType="Reference" linkID="1912086"&gt;1912086&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive either fenofibrate (300 mg, daily) or fenofibrate (300 mg, daily) in combination with pentoxifylline (1200 mg/day in three divided doses) for 24 weeks [&lt;ulink linkType="Reference" linkID="1912086"&gt;1912086&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="684846">fenofibrate (micronized), Fournier/Abbott</Intervention><Treatments><Treatment><Dose>300 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="684845">pentoxifylline</Intervention><Treatments><Treatment><Dose>1200 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Egypt"><Sites><Site><Name>Internal Medicine Department at Tanta University Hospital</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="298839"><TitleDisplay>High- Versus Low-Dose Dexamethasone on Complications in the Immediate Post-operative Phase After Nephrectomy</TitleDisplay><TitleOfficial>High- Versus Low-Dose Dexamethasone on Complications in the Immediate Post-operative Phase After Nephrectomy (DEX-NEF)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03160729</Identifier><Identifier type="Organisational Study">DEXNEF01</Identifier><Identifier type="Other">2017-000505-20</Identifier><Identifier type="Trial Acronym">DEX-NEF</Identifier></Identifiers><Indications><Indication id="110">Emesis</Indication><Indication id="20">Pain</Indication><Indication id="226">Nausea</Indication><Indication id="2979">Surgical procedure</Indication><Indication id="746">Infectious disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043344" type="Company"><TargetEntity id="5035555022" type="organizationId">Rigshospitalet  Denmark</TargetEntity></SourceEntity><SourceEntity id="110" type="ciIndication"><TargetEntity id="R11.1" type="ICD10"></TargetEntity><TargetEntity id="10047700" type="MEDDRA"></TargetEntity><TargetEntity id="D014839" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="226" type="ciIndication"><TargetEntity id="R11.0" type="ICD10"></TargetEntity><TargetEntity id="10028813" type="MEDDRA"></TargetEntity><TargetEntity id="D009325" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2979" type="ciIndication"><TargetEntity id="10042613" type="MEDDRA"></TargetEntity><TargetEntity id="D013514" type="MeSH"></TargetEntity><TargetEntity id="3645" type="siCondition"></TargetEntity><TargetEntity id="1381" type="siCondition"></TargetEntity><TargetEntity id="1045" type="siCondition"></TargetEntity><TargetEntity id="1043" type="siCondition"></TargetEntity><TargetEntity id="1036" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"></TargetEntity><TargetEntity id="D007239" type="MeSH"></TargetEntity><TargetEntity id="-367065996" type="omicsDisease"></TargetEntity><TargetEntity id="799" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043344">Rigshospitalet, Denmark</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>45</PatientCountEnrollment><DateStart>2017-04-24T00:00:00Z</DateStart><DateEnd type="actual">2018-11-23T00:00:00Z</DateEnd><DateChangeLast>2018-12-21T10:02:27Z</DateChangeLast><DateAdded>2017-05-23T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Rigshospitalet</Affiliation><Email>kristin.julia.steinthorsdottir.01@regionh.dk</Email><Name>Kristin J Steinthorsdottir, MD</Name><Phone>004535451003</Phone></Contact><Contact type="Scientific contact"><Affiliation>Rigshospitalet, Denmark</Affiliation><Name>Kristin J Steinthorsdottir, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Planned open kidney resection, heminephrectomy, nephrectomy&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Scheduled nephrectomy in the study period&lt;/li&gt;&lt;li&gt;Signed informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Chronic/ongoing use of systemic glucocorticoids (except inhalation therapy)&lt;/li&gt;&lt;li&gt;Ongoing use of immunosuppressive therapy&lt;/li&gt;&lt;li&gt;Insulin dependent diabetes&lt;/li&gt;&lt;li&gt;Pregnancy/breastfeeding&lt;/li&gt;&lt;li&gt;Allergies toward study medication, or medication in a standard treatment&lt;/li&gt;&lt;li&gt;Previous kidney resection on same side&lt;/li&gt;&lt;li&gt;Thrombectomy in vena cava above diaphragma&lt;/li&gt;&lt;li&gt;Surgery cannot be performed&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Post-operative complications: number of patients with complications requiring treatment in the PACU according to discharge criteria</Description><Timeframe>24 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Analgesics: self-reported use of pain medication other than standard treatment (days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Antiemetics: use of antiemetics other than standard treatment (days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Complications: complications requiring treatment in the ward post surgery or until discharge</Description><Timeframe>24 h</Timeframe></Measure><Measure><Description>Discharge score: discharge score (according to discharge criteria) in the operating theater</Description><Timeframe>1 h</Timeframe></Measure><Measure><Description>Discharge score: discharge score (according to discharge criteria) in the PACU</Description><Timeframe>24 h</Timeframe></Measure><Measure><Description>Length of stay, PACU: total length of stay in PACU</Description><Timeframe>24 h</Timeframe></Measure><Measure><Description>Length of stay, hospital: total length of stay in hospital</Description><Timeframe>1 month</Timeframe></Measure><Measure><Description>Mental status: self-reported feelings of anxiety, unrest, sadness (days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Pain postoperative: self-reported pain (worst and average, days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Post operative nausea and vomiting (PONV): self-reported ponv (worst and average, days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Sleep: self-reported quality of sleep (days 0 to 4). Questionnaire</Description><Timeframe>4 days</Timeframe></Measure><Measure><Description>Readmissions: any readmissions</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Wound complications: wound complications/infections</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Complications/readmissions the first 30 days after operation</Description><Timeframe>130 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to investigate the effect of a single pre-operative high versus low dose intravenous dexamethasone injection on complications in the immediate postoperative phase after open kidney      surgery (kidney resection, heminephrectomy, nephrectomy). Primary outcome was complications      in the post anesthesia care unit (PACU). Secondary outcomes were organ specific complications      in the post anesthesia phase, pain and nausea the first 5 days, seroma and wound infection      the first 14 days and readmissions the first 30 days after surgery. Main objective complications was to demand treatment in the post anaesthesia care unit (PACU) (pain, nausea).&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial were to evaluate:&lt;br/&gt;Pain and nausea the first 5 days after operation.&lt;br/&gt;Quality of sleep the first 5 days after operation.&lt;/para&gt;&lt;para&gt;The investigators hypothesized that the frequency of transfer to the PACU and organ specific      complications were to be lower among patients receiving high-dose dexamethasone. The      investigators hypothesized, that there were no difference in wound infections, seroma or      readmissions.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive high-dose 24 mg or low-dose 8 mg of dexamethasone pre-operative as  single-shot injection.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial had been terminated due to slow recruitment, changes in standard treatment.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Rigshospitalet</Name><Address1>Copenhagen</Address1><Address3>2100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03160729</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2017-000505-20</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26054">Assessment of postoperative complications</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25983"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26029"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26030">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26054">Assessment of postoperative complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="44332"><Endpoint>Assessment of Anxiety by Protocol Specified Scales</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-11-23T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-05-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="301441"><TitleDisplay>TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor</TitleDisplay><TitleOfficial>Study of DC Vaccine Loaded Tumor Specific Antigen in Treating Patients With Gastrointestinal Solid Tumor</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03185429</Identifier><Identifier type="Organisational Study">BGI-002</Identifier></Identifiers><Indications><Indication id="131">Gastrointestinal tumor</Indication><Indication id="3658">Metastatic colorectal cancer</Indication><Indication id="3666">Metastatic stomach cancer</Indication><Indication id="3713">Advanced solid tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>Tumor Specific Antigen-loaded Dendritic Cells (TSA-DC)</Name></Intervention><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1052389" type="Company"><TargetEntity id="5035549098" type="organizationId">Fujian Province Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="1110104" type="Company"><TargetEntity id="5040276003" type="organizationId">Beijing Institute of Genomics Chinese Academy of Sciences</TargetEntity></SourceEntity><SourceEntity id="131" type="ciIndication"><TargetEntity id="C26" type="ICD10"></TargetEntity><TargetEntity id="159" type="ICD9"></TargetEntity><TargetEntity id="10061174" type="MEDDRA"></TargetEntity><TargetEntity id="D005770" type="MeSH"></TargetEntity><TargetEntity id="-1015825676" type="omicsDisease"></TargetEntity><TargetEntity id="602" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"></TargetEntity><TargetEntity id="595" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"></TargetEntity><TargetEntity id="647" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1110104">Beijing Institute Of Genomics Chinese Academy Of Sciences</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1052389">Fujian Cancer Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2017-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:50:45Z</DateChangeLast><DateAdded>2017-06-16T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Fujian Cancer Hospital</Affiliation><Name>ZengQing Guo, Professor</Name></Contact><Contact type="Public contact"><Email>fannychenling05@sina.com</Email><Name>Yu Chen, Doctor</Name><Phone>13859089836</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Be &gt;/= 18 years and&amp;lt;/= 70 years, no gender based&lt;/li&gt;&lt;li&gt;Expression of HLA-A0201/1101/2402&lt;/li&gt;&lt;li&gt;Histopathological documentation of gastrointestinal solid tumors(stomach cancer or colorectal cancer ) concurrent with the diagnosis of metastatic disease, and the tumor is Measurable&lt;/li&gt;&lt;li&gt;Patients must have adequate tissue (fresh or paraffin block) for DNA extraction, which is used for gene sequencing, and prognoses the tumor specific antigen in turn can predict to have new tumor antigens with high affinity for MHC molecules&lt;/li&gt;&lt;li&gt;Failure in conventional treatment, or though benefit from chemotherapy the patient can't tolerant subjectively&lt;/li&gt;&lt;li&gt;Have an Eastern Cooperative Oncology Group (ECOG) performance status of&amp;lt;/= 2 and an anticipate life expectancy of at least 3 months, be cooperate to adverse reactions monitoring and therapeutic evaluation of the treatment&lt;/li&gt;&lt;li&gt;Participants of child-bearing potential must agree to use adequate contraceptive methods up to 12 months after the pretreatment&lt;/li&gt;&lt;li&gt;Serology: seronegative for HIV antibody,seronegative for hepatitis C antibody&lt;/li&gt;&lt;li&gt;Hematology: absolute neutrophil count &gt;/= 1000/mm3 without the support of filgrastim , WBC &gt;/= 3000/mm3, lymphocyte count &gt;/= 800/mm3, platelet count &gt;/= 100,000/mm3, hemoglobin &gt;/=  9.0 g/dl&lt;/li&gt;&lt;li&gt;Chemistry: serum ALT/AST&amp;lt;/=  2.5 times the upper limit of normal, serum creatinine &amp;lt;/= 1.6 mg/dl, total bilirubin  &amp;lt;/=  1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin &amp;lt;/= 3.0 mg/dl&lt;/li&gt;&lt;li&gt;Patients or their legal representatives are willing and able to understand and written informed consent form for the trial&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Is pregnant or breastfeeding,or expecting to conceive&lt;/li&gt;&lt;li&gt;Have a history of severe immediate hypersensitivity reaction to any of the agents used in this study&lt;/li&gt;&lt;li&gt;Suffered grade 3 to 4 major organ immune-related adverse events after anti-PD1/PDL1 antibody treatment&lt;/li&gt;&lt;li&gt;Once received allogeneic organ transplantation (including bone marrow transplantation and peripheral stem cell transplantation, except for corneal transplantation)&lt;/li&gt;&lt;li&gt;Have clinical symptoms of central nervous system metastasis&lt;/li&gt;&lt;li&gt;Have used a large number of glucocorticoids or other immunosuppressive agents within 4 weeks&lt;/li&gt;&lt;li&gt;Have any active autoimmune disease&lt;/li&gt;&lt;li&gt;Be in active infection or undergo an unknown cause fever &gt; 38.5degC during screening or before the first administration(except tumor fever which evaluated by the researchers have no effect to enrollment)&lt;/li&gt;&lt;li&gt;Received chemotherapy or small molecule targeted drug therapy in 4 weeks prior to chemotherapy pretreatment&lt;/li&gt;&lt;li&gt;Received any antibody drug therapy (including PD-1 and CTLA-4) within 6 weeks before the treatment period&lt;/li&gt;&lt;li&gt;Severe liver and kidney dysfunction or uncontrollable diabetes, hypertension and other chronic systemic diseases; severe coagulation disorders, mental illness, cardiopulmonary disease, hydrothorax or ascites&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety endpoint: all the local or systemic reactions, adverse events and serious adverse events that occurred between the first and the second TSA-DC administration</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Overall Response Rate: percentage of cases whose tumor shrinks to a certain extent and remains for a certain period of time</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Secondary safety endpoint: all local or systemic reactions, adverse events and serious adverse events that occurred from entering the trial until 30 days after the last treatment</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>A 6-month DCR(CRR+PRR+SDR): percentage of cases with no progression (CR + PR + SD) in 6 months after initiation of treatment</Description><Timeframe>6 month</Timeframe></Measure><Measure><Description>Duration of Response(DOR): the time from the first tumor evaluation of remission(CR + PR ) till the first assessment of PD or the end the study</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Progression-free survival(PFS): the time from entering the trial till the subject has been diagnosed with progression of disease or died</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Rate of 12-month survival: percentage of cases with 12 months survival after initiation of treatment in all the subjects</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Quality score of life improvement: evaluated by the questionnaire of life improvement quality collected from the screening to treatment periods</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this study is to learn about the safety and tolerance of autologous tumor specific antigen-loaded dendritic cells (TSA-DC) cell and evaluate the efficacy and feasibility of  the cell therapy compared to the subjects past standard regimen.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 20 gastrointestinal solid tumors subjects failed from at least one systemic therapy will be enrolled into the trial. Subjects will be given subcutaneous injection of 5.0 x 10(6) to 1.0 x 10(7) TSA-DC on week s 1, 3, 5, 11, 17, 23, 35, 47. Before the first cell infusion, the subjects should undergo a non-myeloablative chemotherapy regimen of Cyclophosphamide 300 mg/m2 iv before the first cell infusion. Radiological tumor assessment will be repeated every 8 weeks during treatment, until time of progression. Treatment will continue until disease progression, intolerance of toxic, withdrawal from the study, study completion, or study termination.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Fujian Cancer Hospital</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3814">Subjects with Colon Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3860">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="3861">Subjects with chemotherapy resistant disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8010">Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8022">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03185429</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8430">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9147">Assessment of toxicities</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12207"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12208">Assessment of toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12209"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8453">Efficacy/feasibility Assessment</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Stomach tumor" id="44929"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12224">Assessment of Feasibility</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4468"><Criterion>Subjects with Colon Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4470"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Colorectal tumor" id="4529">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4544"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4545">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Colorectal tumor" id="4547">Subjects with history of anti-cancer biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4558"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4573"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5403">Subjects who have recovered from adverse events/toxicity of previous therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7913"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7922"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7927"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7933">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7934"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7935">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Stomach tumor" id="7936">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Stomach tumor" id="7937">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7943"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7944">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="7946">Subjects with history of anti-cancer biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7952"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7953"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7954">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Stomach tumor" id="7955">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7960"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7967">Subjects recovered from prior therapy/therapies</SubCriterion><SubCriterion disease="Stomach tumor" id="7969">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7981"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="22498"><Criterion>Subjects with HLA Positive Protein</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34019"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7956">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34105"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7970">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="34144"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4591">Men with adequate contraception</SubCriterion><SubCriterion disease="Colorectal tumor" id="4592">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion><SubCriterion disease="Colorectal tumor" id="4593">Non Pregnant/Non lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="34341"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4578">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34411"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7964">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34884"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7966">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="34919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4579">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5826">Subjects with brain metastases or leptomeningeal carcinomatosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5876"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5883">Subjects with autoimmune diseases/disorders</SubCriterion><SubCriterion disease="Colorectal tumor" id="5885">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Colorectal tumor" id="5886">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5889"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5918"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5921">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5954"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5959">Subjects with history of/scheduled for transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5962"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5979"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5996">Subjects unsuitable for study as per investigator's assessment</SubCriterion><SubCriterion disease="Colorectal tumor" id="7811">Subjects with concurrent/history of toxicity to prior therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9484"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9485"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9494"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9498">Subjects with abnormal pulmonary functions</SubCriterion><SubCriterion disease="Stomach tumor" id="9542">Subjects failing to meet protocol specified laboratory criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9503"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9508">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9519"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9520"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9523"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9536">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="20283"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="25503"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9530">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="25740"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5987">Subjects of reproductive potential without  adequate contraception</SubCriterion><SubCriterion disease="Colorectal tumor" id="5989">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="26358"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9495">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Stomach tumor" id="9496">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Stomach tumor" id="9497">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="26838"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9514">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="26978"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9537">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="27793"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5981">Subjects who are unable to follow study procedures/comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="27827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9528">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-06-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="308343"><TitleDisplay>Mental Ability Challenge Study in Adults With and Without HIV</TitleDisplay><TitleOfficial>Cholinergic Correlates of Impaired Cognitive Ability in HIV-Associated Neurocognitive Disorders</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03244488</Identifier><Identifier type="Organisational Study">150929</Identifier></Identifiers><Indications><Indication id="159">HIV-1 infection</Indication><Indication id="353">Cognitive disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>mecamylamine</Name></Intervention><Intervention type="InterventionPrimary"><Name>scopolamine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20693" type="Company"><TargetEntity id="4296216897" type="organizationId">Vanderbilt University</TargetEntity></SourceEntity><SourceEntity id="353" type="ciIndication"><TargetEntity id="10057668" type="MEDDRA"></TargetEntity><TargetEntity id="D019965" type="MeSH"></TargetEntity><TargetEntity id="-1363718134" type="omicsDisease"></TargetEntity><TargetEntity id="98" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20693">Vanderbilt University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2015-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2017-08-19T09:35:12Z</DateChangeLast><DateAdded>2017-08-14T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Email>asante.r.kamkwalala@vanderbilt.edu</Email><Name>Asante R Kamkwalala, BS</Name><Phone>6153222082</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 35 years of age or older&lt;/li&gt;&lt;li&gt;HIV-positive (must be on ART's for at least 6 months, most recent viral load (within 6 months)&amp;lt; 50, CD4+ count &amp;gt; 200, must be diagnosed HIV-positive at least five years) or HIV-negative, At-risk individuals&lt;/li&gt;&lt;li&gt;Able and willing to give written informed consent&lt;/li&gt;&lt;li&gt;Negative urine pregnancy test&lt;/li&gt;&lt;li&gt;Adequate visual and auditory acuity to allow neuropsychological testing&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unmanaged HIV Infection, identified by no current medication regimen or the presence of one or more AIDS-defining conditions&lt;/li&gt;&lt;li&gt;Fagerstrom cigarettes per day (CPD) score of '2' indicating heavy use of nicotine&lt;/li&gt;&lt;li&gt;An ART regimen including a Protease Inhibitor Medication&lt;/li&gt;&lt;li&gt;A documented history of cardiac disease or abnormal ECG at Screening&lt;/li&gt;&lt;li&gt;Current alcohol or substance abuse, particularly intravenously&lt;/li&gt;&lt;li&gt;Current use of psychoactive medications (antipsychotics, benzodiazepines, etc)&lt;/li&gt;&lt;li&gt;Current Axis I or Axis II psychiatric disorder&lt;/li&gt;&lt;li&gt;History of myocardial infarction in the past year or unstable or severe cardiovascular disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cognitive outcome  : lower verbal memory score: cognitive performance will be more significantly impaired by study medications in HIV-positive participants relative to HIV-negative participants, indicating impairment of cholinergic neurotransmitter system</Description><Timeframe>2 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Age and HIV-status interaction : slower CRTreaction time: older age and positive HIV status will interact to more significantly impair cognitive performance as measured by reaction time on the Choice Reaction Time task under the influence of study medications, than either variable alone</Description><Timeframe>2 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the contribution of the neuronal      cholinergic receptor system to the cognitive impairments seen in adults aging with chronic      HIV Infection. By using anti-cholinergic challenge drugs to reversibly 'stress' cognitive      functioning, the investigators hope to understand whether the presence of the HIV virus in      the brain impairs the neural system necessary for normal cognition, more than will be      expected from normal cognitive aging.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;HIV-positive or negative patients will be administered each of four possible treatments: high-dose (iv 5 microg/kg) scopolamine, high-dose (po 20 mg) mecamylamine, a low-dose combination (iv 2.5 microg/kg and po10 mg) of scopolamine and mecamylamine, or placebo.&lt;br/&gt;This study will be intended to evaluate the involvement of the neuronal cholinergic receptor      system in the accelerated cognitive aging profile seen in adults living with chronic HIV-1      infection. This study will use      a well-established anti-cholinergic drug challenge model to evaluate cognitive performance in      domains of cognitive functioning relevant to cholinergic functioning. Under conditions of      temporary muscarinic or nicotinic blockade, or a combination of both,investigator aim to explore the      contribution of putative cholinergic receptor dysfunction to the observed symptoms of HAND. Investigator      also intend to determine whether age and HIV-status interact to produce an accelerated      pattern of cholinergic cognitive aging that will indicate that older adults with HIV will be at      higher risk for more rapid cognitive aging than HIV-negative patients.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Vanderbilt University Medical Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37212</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>asante.r.kamkwalala@vanderbilt.edu</Email><Name>Asante Kamkwalala, BS</Name><Phone>615-322-2082</Phone></Contact><Contact type="Facility investigator"><Name>Asante Kamkwalala, BS</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7061">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7117">Others</PatientSegment><SubSegments><SubSegment id="7118">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03244488</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9238"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9295"><Endpoint>Assessment of Neuropsychological Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="45211"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5263"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion></Inclusion><Inclusion disease="HIV infection" id="5317"><Criterion>Subjects with Protocol Specified HIV Viral Load</Criterion></Inclusion><Inclusion disease="HIV infection" id="5322"><Criterion>Subjects with Protocol Specified CD4+ T Cell Counts </Criterion></Inclusion><Inclusion disease="HIV infection" id="5328"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5314">HIV negative subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5344"><Criterion>Subjects on Prior/Concurrent Antiretroviral Therapy</Criterion></Inclusion><Inclusion disease="HIV infection" id="33281"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="22465">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="34441"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5364">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="34917"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5367">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6824"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="HIV infection" id="6834"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6891">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6874"><Criterion>Subjects on Prior/Concurrent Antiretroviral Drugs</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6875">Subjects on prior/concurrent protease retroviral therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6951"><Criterion>Subjects with AIDS/AIDS Defining Events</Criterion></Exclusion><Exclusion disease="HIV infection" id="25093"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6883">Smokers</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-07-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="329691"><TitleDisplay>Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting</TitleDisplay><TitleOfficial>Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03437928</Identifier><Identifier type="Organisational Study">SHETH_UH3</Identifier><Identifier type="Other">H-43036</Identifier><Identifier type="Other">NCT03964194</Identifier></Identifiers><Indications><Indication id="4898">Major depressive disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Boston Scientific Vercise DBS</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Directional Deep Brain Stimulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20534" type="Company"><TargetEntity id="5035456284" type="organizationId">Baylor College of Medicine</TargetEntity></SourceEntity><SourceEntity id="25623" type="Company"><TargetEntity id="5035524287" type="organizationId">University of California Los Angeles</TargetEntity></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"></TargetEntity><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="-1357758656" type="omicsDisease"></TargetEntity><TargetEntity id="54" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="20534">Baylor College of Medicine</Company></CompaniesSponsor><CompaniesCollaborator><Company id="25623">University of California Los Angeles</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2019-08-01T00:00:00Z</DateStart><DateEnd type="estimated">2024-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-05-31T11:28:53Z</DateChangeLast><DateAdded>2018-02-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Baylor College of Medicine</Affiliation><Name>Sameer A Sheth, MD, PhD</Name></Contact><Contact type="Public contact"><Email>sameer.sheth@bcm.edu</Email><Name>Sameer A Sheth, MD, PhD</Name><Phone>713-798-5060</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of California, Los Angeles</Affiliation><Name>Nader Pouratian, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Men and women (non-pregnant) between ages 22 and 70&lt;/li&gt;&lt;li&gt;DSM-5 diagnosis (assessed by Structured Clinical Interview for DSM-5 Axis I disorders SCID-5) of major depression disorder (MDD) as the primary diagnosis. A current major depressive episode (MDE), recurrent or single episode with first episode before age 60, secondary to nonpsychotic unipolar major depressive disorder&lt;/li&gt;&lt;li&gt;Chronic illness with current MDE &gt;/= 24 months duration and/or recurrent illness with at least a total of 2 lifetime episodes (including current episode &gt; 12 months)&lt;/li&gt;&lt;li&gt;Treatment resistance (defined by criteria on the Antidepressant Treatment History Form ATHF): Failure (ie, persistence of the major depressive episode) to respond to a minimum of four adequate depression treatments from at least two different treatment categories (eg, SSRIs, SNRIs, TCAs, other antidepressants, lithium-addition, irreversible MAOIs, antidepressant augmentation with an atypical antipsychotic medication)&lt;/li&gt;&lt;li&gt;Previous trial of Electroconvulsive Therapy (ECT) (lifetime): either did not respond, relapsed, poorly tolerated or refused. If refused, will discuss reasons and ensure subject understands relative risks of ECT versus DBS. We will try to enrich sample with patients who had previously shown response to ECT (or another intervention) that was partial or un-sustained&lt;/li&gt;&lt;li&gt;A prior trial of ketamine will not be required because it is not FDA approved and durable responses have not been demonstrated, nevertheless, subjects will be informed about this possible off-label option&lt;/li&gt;&lt;li&gt;Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17) &gt;/= 20&lt;/li&gt;&lt;li&gt;The HDRS17 must remain greater than or equal to 20 on two separate assessments (at initial screening and 1 week before surgery), over a 1-month period&lt;/li&gt;&lt;li&gt;Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) &gt;/= 27 to be met at assessment one-week pre-op&lt;/li&gt;&lt;li&gt;Lifetime exposure to minimal 6 weeks of psychotherapy without sustained response&lt;/li&gt;&lt;li&gt;Normal brain MRI within 3 months of surgery&lt;/li&gt;&lt;li&gt;Stable antidepressant medication regimen for the month preceding surgery&lt;/li&gt;&lt;li&gt;Modified mini-mental state examination (MMSE) score &gt;/= 24&lt;/li&gt;&lt;li&gt;Normal thyroid stimulating hormone (TSH) level within 12 months of study entry&lt;/li&gt;&lt;li&gt;Other medical conditions must be stable for at least 6 months&lt;/li&gt;&lt;li&gt;Able and willing to give informed consent and agree to attend regular clinic visits for at least 12 months following surgery&lt;/li&gt;&lt;li&gt;Able to have a treating psychiatrist or close relative present for discussions about the study and co-sign informed consent&lt;/li&gt;&lt;li&gt;Willingness to sign Treatment Contract&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;DSM-5 Axis I Disorders: any lifetime history of psychotic disorder (eg, schizophrenia, schizoaffective disorder)&lt;/li&gt;&lt;li&gt;Bipolar disorder with rapid cycling and history of manic episode requiring hospitalization within the past five years&lt;/li&gt;&lt;li&gt;Clinically significant Cluster A or B personality disorder&lt;/li&gt;&lt;li&gt;Active alcohol or substance use disorder within 6 months, excluding nicotine&lt;/li&gt;&lt;li&gt;Urine drug test positive for illicit drugs&lt;/li&gt;&lt;li&gt;Current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or made a suicide attempt within the last year or as identified as C-SSRS&lt;/li&gt;&lt;li&gt;Neurological/Medical condition that makes the patient, in the opinion of the surgeon, a poor surgical candidate (eg, progressive neurodegenerative disorder, significant cardiopulmonary disorder, need for chronic anticoagulation)&lt;/li&gt;&lt;li&gt;Any history of seizure disorder or hemorrhagic stroke&lt;/li&gt;&lt;li&gt;Any medical contraindication to surgery such as infection&lt;/li&gt;&lt;li&gt;Coagulopathy: Bleeding propensity and/or one of the following: INR &gt; 1.5 prolonged activated partial thromboplastin time (aPTT) &gt;/= 45 s platelet count&amp;lt; 100 x 10(3)/micrl&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (systolic &gt; 185 mmHg and/or diastolic &gt; 110 mmHg), demonstrated on each of three repeated measurements taken within one hour regardless of whether or not the patient is taking antihypertensive medications&lt;/li&gt;&lt;li&gt;Participation in another drug, device, or biological trial within 90 days&lt;/li&gt;&lt;li&gt;Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators including spinal cord stimulators and deep brain stimulators&lt;/li&gt;&lt;li&gt;Pregnant or has plans to become pregnant in the next 24 months&lt;/li&gt;&lt;li&gt;Anticipated need for MRI&lt;/li&gt;&lt;li&gt;Need for Diathermy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in depressive symptoms: response will be defined as 50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline. The range is from 0 to 60 and a score higher than 20 indicates moderate to severe depression</Description><Timeframe>54 to 60 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of the study was to address the unmet need of TRD patients by identifying brain      networks critical for treating depression and to use next generation precision DBS with      steering capability to engage these targeted networks. The investigators employ an innovative approach, including      subacute invasive neurophysiological monitoring with which they aim to gain insight into the      networks underlying depression symptomatology, confirm the ability to predict the effects of      precision DBS on network activity, and harmonize these insights to implement network-guided      DBS for TRD.&lt;/para&gt;&lt;para&gt;The study's goal would be achieved      through three specific aims:&lt;br/&gt;Demonstrate device capability to selectively and predictably engage distinct brain           networks.&lt;br/&gt;Delineate depression-relevant networks and demonstrate behavioral changes with           network-targeted stimulation.&lt;br/&gt;Demonstrate that chronic DBS using steered, individualized targeting is feasible and           safe for reducing depressive symptoms.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would undergo directional deep brain stimulation. &lt;ulink linkType="Company" linkID="27847"&gt;Boston Scientific&lt;/ulink&gt; Vercise DBS leads and 16-channel implanted pulse generators (IPGs) would be implanted to control the shape and size of stimulation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The trial has been withdrawn due to PI left institution. &lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Baylor College of Medicine</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yumeih@bcm.edu</Email><Name>Claire (Yu-Mei) Huang, PhD</Name><Phone>713-798-1717</Phone></Contact><Contact type="Facility contact backup"><Email>sameer.sheth@bcm.edu</Email><Name>Sameer A Sheth, MD, PhD</Name><Phone>713-798-5060</Phone></Contact><Contact type="Facility investigator"><Name>Sameer A Sheth, MD, PhD</Name></Contact></Contacts></Site><Site><Name>University of California, Los Angeles</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>areinholtz@mednet.ucla.edu</Email><Name>Alison Reinholtz</Name><Phone>310-267-4331</Phone></Contact><Contact type="Facility contact backup"><Email>NPouratian@mednet.ucla.edu</Email><Name>Nader Pouratian</Name><Phone>310-825-5111</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Depression</Disease><PatientSegments><PatientSegment><PatientSegment id="7449">Subjects with Major Depressive Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7457">Subjects with Relapse/Recurrent Depression</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7458">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03437928</Identifier><Identifier>NCT03964194</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Depression" id="10730"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="10739"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10742">Assessment by Montgomery-Asberg Depression Scale (MADRS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Depression" id="10756"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10757">Assessment of behavior</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Depression" id="10791"><Endpoint>Assessment of Brain Structure and Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Depression" id="10804"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Depression" id="34517"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10772">Assessment of feasibility/acceptability of therapy</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Depression" id="6402"><Criterion>Subjects with Major Depressive Disorder</Criterion></Inclusion><Inclusion disease="Depression" id="6420"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Depression" id="6424"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Depression" id="6432"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Depression" id="6435">Subjects diagnosed by Montgomery-Asberg Depression Rating Scale (MADRS)</SubCriterion><SubCriterion disease="Depression" id="6436">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6474"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Depression" id="6475">Subjects with history of selective serotonin reuptake inhibitors (SSRIs)</SubCriterion><SubCriterion disease="Depression" id="6476">Subjects with history of serotonin and norepinephrine reuptake inhibitors (SNRI) therapy</SubCriterion><SubCriterion disease="Depression" id="6477">Subjects with history of tricyclic antidepressants (TCAs)/heterocyclics</SubCriterion><SubCriterion disease="Depression" id="6478">Subjects with history of monoamine oxidase inhibitors (MAOIs)</SubCriterion><SubCriterion disease="Depression" id="6481">Subjects with history of antipsychotics</SubCriterion><SubCriterion disease="Depression" id="6485">Subjects with history of magnetic therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6506"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Depression" id="6507"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Depression" id="6510"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="6517">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="33177"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Depression" id="33316"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion><Inclusion disease="Depression" id="34436"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="6511">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Depression" id="8069"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Depression" id="8075">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8086"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Depression" id="8089">Subjects co-morbid with schizophrenia</SubCriterion><SubCriterion disease="Depression" id="8091">Subjects with personality disorders</SubCriterion><SubCriterion disease="Depression" id="8092">Subjects with substance related disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8093"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Depression" id="8088">Subjects co-morbid with bipolar disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8138"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Depression" id="8148"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="8151">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="24915"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Depression" id="25477"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="8154">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Depression" id="8159">Subjects who have previously participated (completed/withdrawn) in the trial</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="26984"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Depression" id="29352"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2023-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-01-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-02-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="33940"><TitleDisplay>Olanzapine Versus Comparator in the Treatment of Bipolar Disorder</TitleDisplay><TitleOfficial>Olanzapine Versus Lithium Carbonate in the Treatment of Bipolar Disorder, Manic or Mixed Episodes</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">7598</Identifier><Identifier type="NCT">NCT00485680</Identifier><Identifier type="Secondary Organisational">F1D-GH-LOBV</Identifier></Identifiers><Indications><Indication id="653">Bipolar disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>olanzapine</Name><Drug id="3738">olanzapine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>lithium carbonate</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3738">olanzapine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3738" type="Drug"><TargetEntity id="177756" type="siDrug">Olanzapine</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"></TargetEntity><TargetEntity id="296" type="ICD9"></TargetEntity><TargetEntity id="10057667" type="MEDDRA"></TargetEntity><TargetEntity id="D001714" type="MeSH"></TargetEntity><TargetEntity id="-1667300745" type="omicsDisease"></TargetEntity><TargetEntity id="47" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1191" type="Action"><TargetEntity id="126" type="Mechanism">Dopamine D3 Antagonists</TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="148" type="Action"><TargetEntity id="124" type="Mechanism">Dopamine D1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="801" type="Action"><TargetEntity id="127" type="Mechanism">Dopamine D4 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1191">Dopamine D3 receptor antagonist</Action><Action id="13">5-HT 2 receptor antagonist</Action><Action id="148">Dopamine D1 receptor antagonist</Action><Action id="150">Dopamine D2 receptor antagonist</Action><Action id="801">Dopamine D4 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2943">Antipsychotic</Class><Class id="2970">Anti-emetic</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="743">Granule</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>140</PatientCountEnrollment><PatientCountEvaluable>140</PatientCountEvaluable><DateStart>2003-12-31T00:00:00Z</DateStart><DateEnd type="actual">2005-06-30T00:00:00Z</DateEnd><DateChangeLast>2013-12-02T16:06:26Z</DateChangeLast><DateAdded>2008-11-06T10:00:13Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female in- or out-patients at least 18 years of age&lt;/li&gt;&lt;li&gt;Patient must have a diagnosis of bipolar I disorder and currently display acute manic or mixed episodes (with or without psychotic features) according to the DSM-IV based on clinical assessment&lt;/li&gt;&lt;li&gt;Patients must have a level of understanding sufficient to agree to all tests and examinations required by the protocol&lt;/li&gt;&lt;li&gt;Patients must have a Y-MRS total score of &gt;/=  20 at both visits 1 and 2&lt;/li&gt;&lt;li&gt;Patients must be considered reliable&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry&lt;/li&gt;&lt;li&gt;Serious, unstable illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrinological, neurological, immunological, or hematological disease such that death is anticipated within one year or intensive care unit hospitalization for the disease is anticipated within 6 months&lt;/li&gt;&lt;li&gt;Current or past diagnosis of schizophrenia or other psychotic disorder (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV&lt;/li&gt;&lt;li&gt;Documented history of intolerance to&lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; or lithium carbonate
&lt;/li&gt;&lt;li&gt;Treatment with clozapine within 4 weeks prior to visit 2&lt;/li&gt;&lt;li&gt;Treatment with other antipsychotic drugs or mood stabilizers within 2 days prior to visit 2&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Investigate the efficacy of olanzapine once a day orally for 4 weeks to lithium carbonate orally in the treatment of Chinese patients with bipolar I disorder, manic or mixed episodes, with or without psychotic features as measured by the Clinical Global Impressions-Bipolar Version Overall Severity of Illness (CGI-BP)  Severity</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Assess the efficacy of olanzapine compared with lithium carbonate in improving clinical symptomatology in patients diagnosed with bipolar disorder, manic or mixed episodes after acute treatment as measured by the Young Mania Rating Scale (YMRS)</Description></Measure><Measure><Description>Assess the efficacy of olanzapine compared with lithium carbonate in improving clinical symptomatology in patients diagnosed with bipolar disorder, manic or mixed episodes after acute treatment as measured by the Brief Psychiatric Rating Scale (BPRS), Montgomery-Asberg Depression Rating Scale (MADRS)</Description></Measure><Measure><Description>Assess the safety of olanzapine compared with lithium carbonate. Treatment-emergent adverse events, change in vital signs, laboratory analytes and ECG will be measured</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was compare the efficacy of &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; and lithium carbonate  in the treatment of bipolar disorder, manic or mixed episodes, in Chinese patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2008, results were published. A significantly greater mean change was observed in patients receiving &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; compared to patients receiving lithium carbonate in CGI-BP (overall severity; p = 0.009), YMRS (p = 0.013), BPRS (p = 0.032), and CGI-BP (severity of mania; p = 0.012) scores. A greater number of patients on &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; had a clinically significant weight increase (&gt;/= 7% of baseline weight) compared to patients on lithium carbonate (p = 0.009). More &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; patients (91.3%) completed the study compared to lithium carbonate patients (78.9%) (p = 0.057). In comparison to lithium carbonate patients,  more patients on &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; experienced at least one adverse event possibly related to study drug (p = 0.038) [&lt;ulink linkType="Reference" linkID="1073498"&gt;1073498&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; (5 to 20 mg/day, n = 69) or lithium carbonate (600 to 1800 mg/day, n = 7 1), for 4 weeks [&lt;ulink linkType="Reference" linkID="1073498"&gt;1073498&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; (5 to 20 mg/day, n = 69) or lithium carbonate (600 to 1800 mg/day, n = 7 1), for 4 weeks [&lt;ulink linkType="Reference" linkID="1073498"&gt;1073498&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="68125">lithium carbonate</Intervention><Treatments><Treatment><Dose>600 milligram</Dose><Route></Route></Treatment><Treatment><Dose>1800 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="68124">olanzapine</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route></Route></Treatment><Treatment><Dose>20 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bipolar disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7290">Subjects with Bipolar I Disorder</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00485680</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bipolar disorder" id="9968"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9954">Assessment by Clinical Global Impression (CGI)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bipolar disorder" id="9927"><Endpoint>Assessment of Manic Symptoms by Specific Scales</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9932">Assessment by Young Mania Rating Scale (YMRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="9934"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9937">Assessment by Montgomery-Asberg Depression Scale (MADRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10007"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10013"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10016"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10026"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="44859"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9926">Assessment of symptom improvement</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Bipolar disorder" id="10006"><Endpoint>Anthropometric Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10011"><Endpoint>Assessment of Organ Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10013"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10009">Assessment of blood pressure</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10020"><Endpoint>Assessment of Metabolic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10025"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10027">Assessment of extra pyramidal symptoms</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10026"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10045"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bipolar disorder" id="5787"><Criterion>Subjects with Bipolar Disorder</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5788">Subjects with bipolar I disorder</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5795"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5796">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5802"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5805">Subjects with mania</SubCriterion><SubCriterion disease="Bipolar disorder" id="5806">Subjects with depression and mania</SubCriterion><SubCriterion disease="Bipolar disorder" id="5808">Subjects with psychosis</SubCriterion><SubCriterion disease="Bipolar disorder" id="5809">Subjects without psychotic features</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5810"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5815">Protocol specified scores of Young Mania Rating Scale (YMRS)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bipolar disorder" id="7427"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7430">Subjects co-morbid with psychotic disorders</SubCriterion><SubCriterion disease="Bipolar disorder" id="7436">Subjects with substance related disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7439"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7440">Subjects with other central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Bipolar disorder" id="7442">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Bipolar disorder" id="7444">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Bipolar disorder" id="7446">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Bipolar disorder" id="7448">Subjects with endocrine diseases/disorders</SubCriterion><SubCriterion disease="Bipolar disorder" id="7450">Subjects with immune system disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7441"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7443"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7445"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7470"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7471">Hypersensitivity/Contraindication to mood stabilizers</SubCriterion><SubCriterion disease="Bipolar disorder" id="7474">Hypersensitivity/Contraindication to anti-psychotics</SubCriterion><SubCriterion disease="Bipolar disorder" id="7476">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7488"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7489">Subjects with history of mood stabilizer therapy</SubCriterion><SubCriterion disease="Bipolar disorder" id="7491">Subjects with history /scheduled to receive antipsychotics</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-06T10:00:13Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="340210"><TitleDisplay>Klotho in Chronic Kidney Disease-associated Pruritis (CKD-aP)</TitleDisplay><TitleOfficial>Klotho and Fibroblast Growth Factor 23 in Chronic Kidney Disease-associated Pruritus and Their Response to Narrowband Ultraviolet B</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03532568</Identifier><Identifier type="Organisational Study">DERMATOLOGY 8</Identifier></Identifiers><Indications><Indication id="279">Pruritus</Indication><Indication id="3251">End stage renal disease</Indication></Indications><BiomarkerNames><BiomarkerName id="2200" role="Disease marker;Therapeutic effect marker" type="Genomic;Proteomic">Fibroblast growth factor 23</BiomarkerName><BiomarkerName id="5319" role="Disease marker;Therapeutic effect marker" type="Genomic;Proteomic">Klotho</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>narrowband ultraviolet B radiation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>skin biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043313" type="Company"><TargetEntity id="5035544740" type="organizationId">Cairo University</TargetEntity></SourceEntity><SourceEntity id="279" type="ciIndication"><TargetEntity id="L29" type="ICD10"></TargetEntity><TargetEntity id="10037087" type="MEDDRA"></TargetEntity><TargetEntity id="D011537" type="MeSH"></TargetEntity><TargetEntity id="-1077505647" type="omicsDisease"></TargetEntity><TargetEntity id="489" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"></TargetEntity><TargetEntity id="D007676" type="MeSH"></TargetEntity><TargetEntity id="1890" type="siCondition"></TargetEntity><TargetEntity id="1604" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043313">Cairo University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2018-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:46:32Z</DateChangeLast><DateAdded>2018-05-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Cairo University</Affiliation><Name>Maha Fathy Elmasry</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with CKD on dialysis&lt;/li&gt;&lt;li&gt;Age&amp;gt; 18 years old&lt;/li&gt;&lt;li&gt;Both sexes&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 years old&lt;/li&gt;&lt;li&gt;Any contraindication to phototherapy (eg, past skin cancer) for those with pruritus&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Estimation of tissue levels of Klotho and FGF23 by ELISA in chronic kidney disease-associated pruritis and chronic kidney disease patients and comparing them with healthy control subjects</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Estimation of tissue levels of Klotho and FGF23 BY ELISA after treatment with narrowband ultraviolet B in chronic kidney disease-associated patients</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study aims at knowing whether Klotho and fibroblast growth factor 23 (FGF23) have a role in uremic pruritus (UP) and whether      their expression change by narrowband ultraviolet B (NB-UVB) with the improvement of pruritus.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Chronic kidney disease (CKD) participants with pruritis, without pruritis and normal healthy participants will undergo 4 mm punch skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue. Patients with CKD-aP will receive narrowband ultraviolet B radiation therapy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Egypt"><Sites><Site><Name>Cairo University</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pruritus</Disease><PatientSegments><PatientSegment><PatientSegment id="9253">Subjects with Pruritus Associated with Systemic Disorders</PatientSegment><SubSegments><SubSegment id="9255">Subjects with renal disorders/diseases/dysfunction</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9274">Others</PatientSegment><SubSegments><SubSegment id="9275">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03532568</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pruritus" id="21136"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pruritus" id="21116"><Endpoint>Assessment of Clinical Response</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pruritus" id="18924"><Criterion>Subjects with Pruritus Associated with Systemic Disorders</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="18926">Subjects with renal disorders/undergoing dialysis(uremic pruritus)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pruritus" id="18949"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pruritus" id="34661"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="18950">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pruritus" id="16897"><Criterion>Subjects co-morbid with dermatological disease/disorder</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="16900">Subjects with skin malignancies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pruritus" id="16922"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pruritus" id="16931"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-04-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="340846"><TitleDisplay>Circuit Training in Children With Cerebral Palsy</TitleDisplay><TitleOfficial>The Effects of Circuit Training on Lower Extremities Functionality and Postural Control in Children With Cerebral Palsy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03529682</Identifier><Identifier type="Organisational Study">2017/51-21</Identifier></Identifiers><Indications><Indication id="2620">Cerebral palsy</Indication></Indications><BiomarkerNames><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName><BiomarkerName id="47058" role="Therapeutic effect marker" type="Physiological">Muscle tonus</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Circuit exercise training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>traditional physiotherapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1126230" type="Company"><TargetEntity id="5037242876" type="organizationId">Dogu Akdeniz Universitesi</TargetEntity></SourceEntity><SourceEntity id="2620" type="ciIndication"><TargetEntity id="G80" type="ICD10"></TargetEntity><TargetEntity id="10008129" type="MEDDRA"></TargetEntity><TargetEntity id="D002547" type="MeSH"></TargetEntity><TargetEntity id="-967985093" type="omicsDisease"></TargetEntity><TargetEntity id="163" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1126230">Eastern Mediterranean University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>62</PatientCountEnrollment><DateStart>2018-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:40:09Z</DateChangeLast><DateAdded>2018-05-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>unal.deger@emu.edu.tr</Email><Name>UNAL DEGER, MSc</Name><Phone>05428532184</Phone></Contact><Contact type="Scientific contact"><Affiliation>Eastern Mediterranean University</Affiliation><Name>UNAL DEGER, MSc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The children who were diagnosed with Spastic type Cerebral Palsy&lt;/li&gt;&lt;li&gt;Is aged between 6 to 18&lt;/li&gt;&lt;li&gt;Is on the I, II and III levels according to Gross Motor Function Classification System&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Having any surgical operation related to lower extremities for the last one year&lt;/li&gt;&lt;li&gt;Having botulinum toxin injection or intrathecal pump for the last 6 months&lt;/li&gt;&lt;li&gt;Taking a new medicine or medicine change for the last 1 month&lt;/li&gt;&lt;li&gt;Visual, hearing and epilepsy problem&lt;/li&gt;&lt;li&gt;Inability to contınuously attend the exercise program&lt;/li&gt;&lt;li&gt;Mental problem that could not be cooperated&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Gross Motor Function will be evaluated: as for the Gross Motor Function evaluation, the Gross Motor Function Scale (GMFS) will be used and only its D and E sections (standing, walking, running, jumping evaluation parts) will be used. By considering the instructions in to be tested parts in the scale, the case is expected to do the motor functions actively. Without the consideration of the quality of the movement, the case will be observed whether she / he started, was able to continue and completed the movement as well as whether she / he needed any support so that points between 0 to 3 will be given according to the level. The obtained total score determines the interaction severity of gross motor function</Description><Timeframe>Change from baseline GMFS at 10 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Activity and participation level will be evaluated: a Canadian Occupational Performance Test (COPM) will be used in order to evaluate activity and participation level. COPM is an interview based method and the participant is asked to express the daily activities they needed, desired and they are not able to do. They are asked to express these activities under three headlines (self care activities, productivity and free time activities) and they are asked to determine these according to the priority for themselves. The first desire / problem is ten points, and last is one point</Description><Timeframe>Change from baseline COPM at 10 weeks</Timeframe></Measure><Measure><Description>Functional motor performance will be evaluated: for the determination of functional motor performance, sitting and getting up test of Motor Assessment Scale will be used. Without a back and arm support, the chair sitting and getting up number in 1 min will be recorded</Description><Timeframe>Change from baseline functional motor performance at 10 weeks</Timeframe></Measure><Measure><Description>Functional muscular strength of the trunk and the lower extremities will be evaluated: in order to determine the functional muscular strength of the body and the lower extremities, the step number will be recorded by taking straight step to the stair test and taking side step to the stair test in 15 s</Description><Timeframe>Change from baseline Functional muscular strength at 10 weeks</Timeframe></Measure><Measure><Description>Isometric strength of bilateral lower extremity muscles and trunk muscles will be evaluated: for the evaluation of isometric strength of bilateral lower extremity muscles and body muscles, a hand held dynamometer will be used which is in standard positions and independent from the gravity and the obtained measurement will be recorded by adjusting it to the body weight. The strength obtained by isometric contraction and by equipment resistance applied on key chosen muscles, will be recorded as a numerical value</Description><Timeframe>Change from baseline isometric strength at 10 weeks</Timeframe></Measure><Measure><Description>Muscular tonus in lower extremities will be evaluated: the muscular tonus in lower extremities will be evaluated as bilateral by Modified Ashworth Scale (MAS). The joint will be moved passively, fast and reverse to the muscular functions that will be tested in this scale which is used for the determination of spasticity severity. According to the resistivity occurred, scoring is done between 0 to 4 points</Description><Timeframe>Change from baseline muscular tonus at 10 weeks</Timeframe></Measure><Measure><Description>Quality of life will be evaluated: for the evaluation of life quality, Life Quality Scale for Children (LQSC) will be used (PedsQL) (5 to 7 age SP family reported model, 5 to 7 age SP model, 8 to 12 age SP model, 13 to 18 age SP model). 23 questions will be used for the case which consists of 0 to 4 points and Working/Job Functions, Social, Physical and Emotional Functions in the last 1 month. The obtained point gives information about the life quality</Description><Timeframe>Change from baseline LQSC at 10 weeks</Timeframe></Measure><Measure><Description>Satisfaction of children from the exercises will be evaluated: for the measurement of satisfaction of children from the exercises to be applied, Physical Activity Enjoyment Scale (PACES) will be used. The children will be asked to mark the numbers suitable for themselves after reading child items in the five likert point scale. The points taken on the scale, change between 5 and 25</Description><Timeframe>At 10 weeks</Timeframe></Measure><Measure><Description>Walking speed and main mobility will be evaluated: for the determination of walking speed and main mobility, timed up and go (TUG) test will be used. 3 m walking distance will be recorded</Description><Timeframe>Change from baseline walking speed and main mobility at 10 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to   reveal  the results of circuit training to be applied to the      children with Cerebral Palsy (CP) for improving their muscular strength and trunk control and      also to determine their effects in terms of activity limitations and participation limits.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;According the power analyzes totally 62 children, as 31 per each group, who were diagnosed      with Spastic type CP and accepting participation for the study will be included in this      study. For every case, socio-demographic data and clinical features will be recorded. In the      first session their gross motor function, muscular tonus in lower extremities, isometric      strength of lower extremity muscles, functional muscular strength of the trunk and the lower      extremities, walking speed and main mobility, functional motor performance will be assessed      by a physiotherapist. Also satisfaction of children from the exercises, activity and      participation level and quality of life will be evaluated. Then Covariant Focused      Randomization Method will be used for having similarity in terms of factors such as; age,      gender and motor function levels and also for having a balanced and equal case number of      control and intervention group. &lt;/para&gt;&lt;para&gt;This study consist of two groups:&lt;br/&gt;Group 1(Circuit Training Group): circuit exercise training will be given to the experimental group participants during 10 weeks, 60 min in a day and three times a week. A 10 min warm-up exercises and stretching exercises, 40 mın consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mın cooling down exercises and stretching exercises will be applied.&lt;br/&gt;Group 2 (Control Group): the control group participants will continue to their own previous physiotherapy approaches (traditional physiotherapy) as the same as minimum three times a week and total 3 h. A 60 mın in a day and three times in a week traditional physiotherapy program will be applied.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Cyprus"><Sites><Site><Name>Eastern Mediterranean University</Name><Address1>Famagusta</Address1><Address3>99450</Address3><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>UNAL DEGER, MSc</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16683">Others</PatientSegment><SubSegments><SubSegment id="16704">Children and adolescents</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16210">Subjects with Cerebral Palsy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03529682</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43427"><Endpoint>Assessment of motor function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43427"><Endpoint>Assessment of motor function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43430"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32590"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32975">Subjects co-morbid with cerebral palsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32903">Children and adolescents</SubCriterion><SubCriterion disease="Other neurological disease" id="32964">Gross Motor Function Classification System (GMFCS) level I</SubCriterion><SubCriterion disease="Other neurological disease" id="32965">Gross Motor Function Classification System (GMFCS) level II</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24402"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="26002"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="27242"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="27919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24149">Subjects unwilling/unable to comply with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="29153"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-05-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="34189"><TitleDisplay>ALF-STONE: Alfuzosin in Uretheric Stones</TitleDisplay><TitleOfficial>Alfuzosin in Uretheric Stones</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">L_9795</Identifier><Identifier type="NCT">NCT00454402</Identifier><Identifier type="Secondary Organisational">EudraCT # : 2005-005481-36</Identifier></Identifiers><Indications><Indication id="1241">Prostate hyperplasia</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>alfuzosin</Name><Drug id="2474">alfuzosin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2474">alfuzosin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2474" type="Drug"><TargetEntity id="90436" type="siDrug">Alfuzosin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="1241" type="ciIndication"><TargetEntity id="10051482" type="MEDDRA"></TargetEntity><TargetEntity id="D011470" type="MeSH"></TargetEntity><TargetEntity id="-1410482198" type="omicsDisease"></TargetEntity><TargetEntity id="362" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="32" type="Action"><TargetEntity id="36" type="Mechanism">alpha1-Adrenoceptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1009547">Sanofi SA</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="32">Alpha 1 adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>220</PatientCountEnrollment><DateStart>2006-08-31T00:00:00Z</DateStart><DateEnd type="actual">2007-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-03-07T16:21:35Z</DateChangeLast><DateAdded>2008-11-07T07:54:35Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanofi-Aventis</Affiliation><Name>Carlos Santos, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with imagiologic evidence of uretheric stones&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Women pregnant or breast feeding&lt;/li&gt;&lt;li&gt;Patients with renal impairment (creatinine&amp;gt; 2 mg/dl)&lt;/li&gt;&lt;li&gt;The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety: General clinical safety by collection of spontaneously reported adverse events at each visit.</Description><Timeframe>At each visit</Timeframe></Measure><Measure><Description>Efficacy: Percentage of patients without imagiologic evidence of any stone</Description><Timeframe>72 to 96 h after ESWL</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage of patients without imagiologic evidence of any stone</Description><Timeframe>24 h after ESWL</Timeframe></Measure><Measure><Description>Percentage of patients with clinical evidence of stones clearance</Description><Timeframe>72 to 96 h after ESWL</Timeframe></Measure><Measure><Description>Time for stone clearance (clinical evaluation)</Description></Measure><Measure><Description>Numeric Rating Scale scores</Description><Timeframe>At 24 h, (48 h, if applicable), 72 to 96 h and 7 days</Timeframe></Measure><Measure><Description>Need for rescue analgesic medication</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to assess the effect of &lt;ulink linkType="Drug" linkID="2474"&gt;alfuzosin&lt;/ulink&gt; compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to Extracorporeal Shock Wave Lithotripsy (ESWL), namely in the percentage of patients without imagiologic evidence of any stone after 72 to 96 h.
 This study was also to specifically focus on the evaluation of time of stone clearance and of pain reduction (numeric rating scale).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Portugal"><Sites><Site><Name>Sanofi-Aventis</Name><Address1>Lisbon</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate hyperplasia</Disease><PatientSegments><PatientSegment><PatientSegment id="11526">Subjects with Surgical Treatment</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11531">Subjects with Medical Therapy</PatientSegment><SubSegments><SubSegment id="11532">Subjects with alpha-1-blockers</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Urolithiasis</Disease><PatientSegments><PatientSegment><PatientSegment id="11582">Subjects with Urolithiasis</PatientSegment><SubSegments><SubSegment id="11585">Subjects with bladder stones</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11600">Subjects with History of/Scheduled for Therapy</PatientSegment><SubSegments><SubSegment id="11603">Subjects with histroy/scheduled for extracorporeal shock wave lithotripsy (ESWL)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00454402</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EudraCT # : 2005-005481-36</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate hyperplasia" id="22642"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate hyperplasia" id="22654"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Urolithiasis" id="22911"><Endpoint>Assessment of Stone/Calculi Clearance</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Urolithiasis" id="22937"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate hyperplasia" id="22613"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="26777">Numeric rating scale scores(NRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22647"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22652"><Endpoint>Assessment of Co-morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Urolithiasis" id="22908"><Endpoint>Assessment of Stone/Calculi</Endpoint><SubEndpoints><SubEndpoint disease="Urolithiasis" id="22910">Assessment of stone fragmentation</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Urolithiasis" id="22911"><Endpoint>Assessment of Stone/Calculi Clearance</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Urolithiasis" id="22915"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Urolithiasis" id="30479">Numeric rating scale(NRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Urolithiasis" id="44086"><Endpoint>Assessment of Pain Relief</Endpoint><SubEndpoints><SubEndpoint disease="Urolithiasis" id="22933">Assessment of analgesic use</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Urolithiasis" id="20717"><Criterion>Subjects with Urolithiasis</Criterion><SubCriteria><SubCriterion disease="Urolithiasis" id="20720">Subjects with bladder stones</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Urolithiasis" id="17440"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17880"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2007-03-29T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-07T07:54:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="3584"><TitleDisplay>Effects of Colesevelam HCl On Bile Acid Kinetics</TitleDisplay><TitleOfficial>Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">KM-11B</Identifier><Identifier type="NCT">NCT00476710</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="3057" role="Therapeutic effect marker" type="Biochemical">Bile acids and salts</BiomarkerName><BiomarkerName id="32942" role="Therapeutic effect marker" type="Physiological">Basal metabolic rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>colesevelam</Name><Drug id="11290">colesevelam</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11290">colesevelam</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007827">University Medical Center Groningen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1017375">KineMed Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="1033389">Diabetes and Glandular Disease Clinic</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="11290" type="Drug"><TargetEntity id="222457" type="siDrug">Colesevelam hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1007827" type="Company"><TargetEntity id="5001408709" type="organizationId">University Medical Center Groningen</TargetEntity></SourceEntity><SourceEntity id="1017375" type="Company"><TargetEntity id="4297024628" type="organizationId">KineMed Inc</TargetEntity></SourceEntity><SourceEntity id="1017506" type="Company"><TargetEntity id="4295880584" type="organizationId">Daiichi Sankyo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1033389" type="Company"><TargetEntity id="5035563597" type="organizationId">Diabetes And Glandular Disease Clinic</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1017375">KineMed Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1007827">University Medical Center Groningen</Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Company id="1033389">Diabetes and Glandular Disease Clinic</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="466">Bile acid sequestrant</Class><Class id="71">Antihypercholesterolemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="751">Film coating</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2007-05-31T00:00:00Z</DateStart><DateEnd type="actual">2009-04-30T00:00:00Z</DateEnd><DateChangeLast>2015-04-03T07:17:37Z</DateChangeLast><DateAdded>2007-08-09T08:44:27Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>KineMed, Inc.</Affiliation><Name>Elizabeth Murphy</Name></Contact><Contact type="Scientific contact"><Affiliation>University Medical Centre Groningen</Affiliation><Name>Folkert Kuipers</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Have given written informed consent&lt;/li&gt;&lt;li&gt;BMI 25 to 35 kg/m(2), inclusive&lt;/li&gt;&lt;li&gt;Normal liver and thyroid function&lt;/li&gt;&lt;li&gt;No history of liver, biliary, or intestinal disease&lt;/li&gt;&lt;li&gt;Diabetic Subjects&lt;ul&gt;&lt;li&gt;Diagnosed type 2 diabetes mellitus&lt;/li&gt;&lt;li&gt;HbA1C = 6.7 to 10%&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Normal subjects&lt;ul&gt;&lt;li&gt;About2 h OGTT glucose&amp;lt;140 mg/dl&lt;/li&gt;&lt;li&gt;Fasting glucose&amp;lt;100 mg/dl&lt;/li&gt;&lt;li&gt;TG&amp;lt; 150 mg/dl&lt;/li&gt;&lt;li&gt;HDL cholesterol &gt;/= 40 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Impaired glucose tolerance subjects&lt;ul&gt;&lt;li&gt;About 2 h OGTT glucose &gt;/=140 and&amp;lt; 200 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;T1DM or history of diabetic ketoacidosis&lt;/li&gt;&lt;li&gt;Treatment with blood pressure lowering therapy that has not been stable for three months before screening&lt;/li&gt;&lt;li&gt;Colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months&lt;/li&gt;&lt;li&gt;Treatment with thiazolidinedione (TZD) at any time&lt;/li&gt;&lt;li&gt;Treatment with insulin within past 6 months&lt;/li&gt;&lt;li&gt;Treatment with antibiotics within last 3 months&lt;/li&gt;&lt;li&gt;Extreme sportsmen&lt;/li&gt;&lt;li&gt;Treatment with medication affecting liver or intestinal function within the last 3 months&lt;/li&gt;&lt;li&gt;Allergic or toxic reaction to colesevelam HCl&lt;/li&gt;&lt;li&gt;History of dysphagia, swallowing disorders, or intestinal motility disorder&lt;/li&gt;&lt;li&gt;Serum Triglycerides &gt;500 mg/dl at visit 1&lt;/li&gt;&lt;li&gt;Serum LDL-C&amp;lt;60 mg/dl at visit 1
&lt;/li&gt;&lt;li&gt;Any condition or therapy investigator believes not in subjects best interest&lt;/li&gt;&lt;li&gt;Use of any investigational drug within 30 days before screening&lt;/li&gt;&lt;li&gt;Chronic treatment with oral corticosteroids at any time or acute treatment within last three months&lt;/li&gt;&lt;li&gt;Hyperthyroidism or treatment with thyroid hormone/levothyroxine&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Bile Acid Pool Size and Kinetic Parameters</Description><Timeframe>60 days of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Resting Metabolic Rate</Description><Timeframe>60 days of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes.  We hypothesize that bile acids will behave differently in these groups.  We will also explore the effects of &lt;ulink linkType="Drug" linkID="11290"&gt;colesevelam HCl&lt;/ulink&gt;, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups.  We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Diabetes &amp; Glandular Disease Research Associates, Inc.</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="103">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="168">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19588">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="94">Subjects with Prediabetes/Impaired Glucose Tolerance</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00476710</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="610">Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1044"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="6692"><Criterion>Subjects with Prediabetes/Impaired Glucose Tolerance</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="607">Subjects with Poor/Inadequate Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="849"><Criterion>Subjects  with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="851">Subjects with type 1 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="879"><Criterion>Subjects with Dyslipidemia</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="882">Subjects with high LDL cholesterol levels</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="911"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="932"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="953">Subjects on/treated with thiazolidinediones</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="959"><Criterion>Conditions Altering Blood Glucose Levels</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="961">Subjects on glucocorticoid/steroid therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="978">Subjects on/treated with thyroid preparations</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="990">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="883">Subjects co-morbid with hypertriglyceridemia</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-04-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-08-09T08:44:27Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="365397"><TitleDisplay>Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)</TitleDisplay><TitleOfficial>A Phase I Study Of Palbociclib (IND 141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03792256</Identifier><Identifier type="Organisational Study">AINV18P1</Identifier></Identifiers><Indications><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><Indication id="1730">T-cell acute lymphoblastic leukemia</Indication><Indication id="311">T-cell lymphoma</Indication><Indication id="316">B-cell lymphoma</Indication></Indications><BiomarkerNames><BiomarkerName id="7" role="Therapeutic effect marker" type="Genomic;Proteomic">Antigen KI-67</BiomarkerName><BiomarkerName id="12" role="Therapeutic effect marker" type="Genomic;Proteomic">Cyclin-dependent kinase inhibitor 1B</BiomarkerName><BiomarkerName id="83" role="Therapeutic effect marker" type="Genomic;Proteomic">Cell division protein kinase 4</BiomarkerName><BiomarkerName id="486" role="Therapeutic effect marker" type="Genomic;Proteomic">Cell division protein kinase 6</BiomarkerName><BiomarkerName id="716" role="Therapeutic effect marker" type="Genomic;Proteomic">Retinoblastoma-associated protein</BiomarkerName><BiomarkerName id="1855" role="Therapeutic effect marker" type="Proteomic">CD3 Antigens</BiomarkerName><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="1880" role="Therapeutic effect marker" type="Cellular">T-Helper Lymphocytes</BiomarkerName><BiomarkerName id="2473" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD1a </BiomarkerName><BiomarkerName id="3447" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD8 alpha chain</BiomarkerName><BiomarkerName id="3564" role="Therapeutic effect marker" type="Genomic;Proteomic">G1/S-specific cyclin-D3</BiomarkerName><BiomarkerName id="46505" role="Therapeutic effect marker" type="Cellular">Cytotoxic T-Lymphocytes</BiomarkerName><BiomarkerName id="46905" role="Therapeutic effect marker" type="Cellular">Blast cells</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cytarabine</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>hydrocortisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><Intervention type="InterventionPrimary"><Name>palbociclib</Name><Drug id="10271">palbociclib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>pegaspargase</Name><Drug id="2573">pegaspargase</Drug></Intervention><Intervention type="InterventionPrimary"><Name>prednisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>vincristine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10271">palbociclib</Drug><IndicationsPioneer><Indication id="1730">T-cell acute lymphoblastic leukemia</Indication><Indication id="311">T-cell lymphoma</Indication></IndicationsPioneer><Companies><Company><Company id="1041378">Children's Oncology Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2573">pegaspargase</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1041378">Children's Oncology Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2573" type="Drug"><TargetEntity id="126670" type="siDrug">Pegaspargase</TargetEntity></SourceEntity><SourceEntity id="10271" type="Drug"><TargetEntity id="345543" type="siDrug">Palbociclib</TargetEntity></SourceEntity><SourceEntity id="1041378" type="Company"><TargetEntity id="5035543450" type="organizationId">Children's Oncology Group</TargetEntity></SourceEntity><SourceEntity id="1729" type="ciIndication"><TargetEntity id="-903738911" type="omicsDisease"></TargetEntity><TargetEntity id="1883" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1730" type="ciIndication"><TargetEntity id="2492" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"></TargetEntity><TargetEntity id="D016399" type="MeSH"></TargetEntity><TargetEntity id="-664594417" type="omicsDisease"></TargetEntity><TargetEntity id="704" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"></TargetEntity><TargetEntity id="-1829786210" type="omicsDisease"></TargetEntity><TargetEntity id="699" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4314" type="Action"><TargetEntity id="984" type="Mechanism">CDK4 Inhibitors</TargetEntity><TargetEntity id="1721" type="Mechanism">CDK4/Cyclin D1 Inhibitors</TargetEntity><TargetEntity id="3006" type="Mechanism">CDK4/Cyclin D3 Inhibitors</TargetEntity><TargetEntity id="3181" type="Mechanism">CDK4/Cyclin D Inhibitors</TargetEntity><TargetEntity id="3182" type="Mechanism">CDK4/Cyclin D2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4318" type="Action"><TargetEntity id="1234" type="Mechanism">CDK6 Inhibitors</TargetEntity><TargetEntity id="2255" type="Mechanism">CDK6/Cyclin D3 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1041378">Children's Oncology Group</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="19467">Retinoblastoma associated protein modulator</Action><Action id="4314">Cyclin-dependent kinase-4 inhibitor</Action><Action id="4318">Cyclin-dependent kinase-6 inhibitor</Action><Action id="517">Asparaginase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="805">Daily dosing</Technology><Technology id="72">Enzyme</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>15</PatientCountEnrollment><DateStart>2019-04-11T00:00:00Z</DateStart><DateEnd type="estimated">2020-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-06-06T02:06:00Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Children's Oncology Group</Affiliation><Name>Elizabeth Raetz, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Laura and Isaac Perlmutter Cancer Center at NYU Langone</Affiliation><Name>Elizabeth A. Raetz</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with recurrent or refractory B- or T-lineage lymphoblastic leukemia and lymphoma&lt;/li&gt;&lt;li&gt;Patients with leukemia must have &gt;/= 5% (M2 or M3) bone marrow blasts with or without an extramedullary site of relapse. Morphologic relapse for M2 should be confirmed using flow cytometry, FISH and/or cytogenetics or molecular techniques&lt;/li&gt;&lt;li&gt;Patients with LL must have either measurable or evaluable disease&lt;/li&gt;&lt;li&gt;Patients with first or greater relapsed T-lineage ALL or LL and second or greater relapsed B-lineage ALL or LL are eligible&lt;/li&gt;&lt;li&gt;Patients with primary refractory disease with at least two prior induction attempts or first relapse refractory to at least one prior re-induction attempt are eligible&lt;/li&gt;&lt;li&gt;Karnofsky&amp;gt;/= 50% for patients &amp;gt; 16 years of age and Lansky &amp;gt;/= 50 for patients &amp;lt;/= 16 years of age&lt;ul&gt;&lt;li&gt;Note: patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, eg, blood count criteria, the patient is considered to have recovered adequately&lt;ul&gt;&lt;li&gt;Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. See DVL homepage for commercial and Phase 1 investigational agent classifications. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment&lt;ul&gt;&lt;li&gt;A waiting period prior to enrollment is not required for patients receiving standard cytotoxic maintenance chemotherapy (ie, corticosteroid, vincristine, 6MP, and/or methotrexate)&lt;/li&gt;&lt;li&gt;Intrathecal cytotoxic therapy: no waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone. Intrathecal chemotherapy given at the time of diagnostic LP to evaluate for relapse prior to study enrollment is allowed&lt;/li&gt;&lt;li&gt;A 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy. Additionally, patients must have fully recovered from all acute toxic effects of prior therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;NOTE: cytoreduction with hydroxyurea in patients can be initiated and continued for up to 24 h prior to the start of protocol therapy&lt;/li&gt;&lt;li&gt;Note: intrathecal chemotherapy that is given up to 72 h prior to initiation of systemic chemotherapy per AINV18P1 counts as protocol therapy and not prior anti-cancer therapy. Intrathecal chemotherapy given&amp;gt; 72 h prior does not count as protocol therapy&lt;ul&gt;&lt;li&gt;Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or ANC counts):&amp;gt;/= 7 days after the last dose of agent. See DVL homepage for commercial and phase I investigational agent classifications. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment&lt;ul&gt;&lt;li&gt;NOTE: cytoreduction with prednisone or methylprednisolone for&amp;lt;/= 120 h (5 days) in patients can be initiated and continued for up to 24 h prior to the start of protocol therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Antibodies:&amp;gt;/= 21 days must have elapsed from infusion of last dose of antibody with the exception of blinatumomab, and toxicity related to prior antibody therapy must be recovered to Grade &amp;lt;/= 1. Patients must have been off blinatumomab infusion for at least 14 days and all drug related toxicity must have resolved to Grade &amp;lt;/= 1&lt;/li&gt;&lt;li&gt;Corticosteroids: if used to modify immune adverse events related to prior therapy,&amp;gt;/= 14 days must have elapsed since last dose of corticosteroid and toxicity related to prior immune therapy must be recovered to Grade &amp;lt;/= 1 off corticosteroids&lt;/li&gt;&lt;li&gt;Hematopoietic growth factors:&amp;gt;/= 14 days after the last dose of a long-acting growth factor (eg, pegfilgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator&lt;/li&gt;&lt;li&gt;Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors):&amp;gt;/= 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors) &lt;/li&gt;&lt;li&gt;Stem cell Infusions (with or without TBI):&lt;ul&gt;&lt;li&gt;Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including DLI or boost infusion:&amp;gt;/= 84 days after infusion and no evidence of GVHD&lt;/li&gt;&lt;li&gt;Autologous stem cell infusion including boost infusion:&amp;gt;/= 42 days&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cellular therapy:&amp;gt;/= 30 days after the completion of any type of cellular therapy (eg, modified T cells, NK cells, dendritic cells, etc,)&lt;/li&gt;&lt;li&gt;XRT/External Beam Irradiation including protons:&amp;gt;/= 14 days after local XRT; &amp;gt;/= 150 days after TBI, craniospinal XRT or if radiation to &amp;gt;/= 50% of the pelvis; &amp;gt;/= 42 days if other substantial BM radiation&lt;/li&gt;&lt;li&gt;Patients must not have received prior exposure to palbociclib or another CDK4/6 inhibitor&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate Renal Function Defined as:&lt;ul&gt;&lt;li&gt;Creatinine clearance or radioisotope GFR &gt;/= 70 ml/min/1.73 m2 or&lt;/li&gt;&lt;li&gt;A serum creatinine based on age/gender as follows:&lt;ul&gt;&lt;li&gt;Age: 1 to&amp;lt; 2 years; male: 0.6 mg/dl; female: 0.6 mg/dl&lt;/li&gt;&lt;li&gt;Age: 2 to&amp;lt; 6 years; male: 0.8 mg/dl; female: 0.8 mg/dl&lt;/li&gt;&lt;li&gt;Age: 6 to&amp;lt; 10 years; male: 1 mg/dl; female: 1 mg/dl&lt;/li&gt;&lt;li&gt;Age: 10 to&amp;lt; 13 years; male: 1.2 mg/dl; female: 1.2 mg/dl&lt;/li&gt;&lt;li&gt;Age: 13 to&amp;lt; 16 years; male: 1.5 mg/dl; female: 1.4 mg/dl&lt;/li&gt;&lt;li&gt;Age:&amp;gt;/= 16 years; Male: 1.7 mg/dl; female: 1.4 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate Liver Function Defined as:&lt;ul&gt;&lt;li&gt;Bilirubin (sum of conjugated + unconjugated)&amp;lt;/= 1.5 x upper limit of normal (ULN) for age&lt;/li&gt;&lt;li&gt;SGPT (ALT)&amp;lt;/= 225 U/l unless disease-related. For the purpose of this study, the ULN for SGPT is 45 U/l&lt;/li&gt;&lt;li&gt;Serum albumin&amp;gt;/= 2 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate Cardiac Function Defined As:&lt;ul&gt;&lt;li&gt;Shortening fraction of&amp;gt;/= 27% by echocardiogram, or&lt;/li&gt;&lt;li&gt;Ejection fraction of&amp;gt;/= 50% by gated radionuclide study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Based on the mechanism of action, palbociclib may be expected to cause fetal harm if used during pregnancy. Pregnancy tests must be obtained in girls who are post-menarche. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy. Women of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose of palbociclib. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose of palbociclib. Animal data suggests that palbociclib may affect male fertility&lt;/li&gt;&lt;li&gt;Prednisone or methylprednisolone for&amp;lt;/= 120 h (5 days) may be administered for cytoreduction up to 24 h prior to the start of protocol therapy and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency. Corticosteroids are not allowed for other indications. If used to modify immune adverse events related to prior therapy, &gt;/= 14 days must have elapsed since last dose of corticosteroid&lt;/li&gt;&lt;li&gt;Patients who are currently receiving another investigational drug&lt;/li&gt;&lt;li&gt;Patients who are currently receiving other anti-cancer agents are not eligible (except patients receiving hydroxyurea, which may be continued until 24 h prior to start of protocol therapy)&lt;/li&gt;&lt;li&gt;Patients who are currently receiving drugs that are strong inhibitors and/or inducers of CYP3A4 or sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic range are not eligible. Strong inducers or inhibitors of CYP3A4 are prohibited from 14 days prior to enrollment to the end of the study&lt;/li&gt;&lt;li&gt;Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant&lt;/li&gt;&lt;li&gt;Patients must be able to swallow intact capsules or liquid. Patients that are unable to swallow oral medications may receive palbociclib through an NG tube. G tube administration is not allowed&lt;/li&gt;&lt;li&gt;Patients who have an uncontrolled infection defined as below:&lt;ul&gt;&lt;li&gt;Fever above 38.2degC within 48 h of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 h prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability&lt;/li&gt;&lt;li&gt;A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection&lt;/li&gt;&lt;li&gt;Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 h and signs or symptoms of active infection have resolved. For patients with c. difficile diarrhea, at least 72 h of antibacterial therapy must have elapsed and stools must have normalized to baseline&lt;/li&gt;&lt;li&gt;Active viral or protozoal infection requiring IV treatment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients known to have one of the following concomitant genetic syndromes: down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachmann syndrome or any other known bone marrow failure syndrome&lt;/li&gt;&lt;li&gt;Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum tolerated dose (MTD) of palbociclib: MTD will be the maximum dose at which fewer than one-third of patients experience dose limiting toxicities</Description><Timeframe>Up to 32 days</Timeframe></Measure><Measure><Description>Incidence of adverse events: will be graded using the Common Terminology Criteria for adverse events version 4.0</Description><Timeframe>Up to four years</Timeframe></Measure><Measure><Description>Pharmacokinetics of palbociclib: time to maximum plasma concentration (Tmax): palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit)</Description><Timeframe>Pre-dose, and at 1, 2, 4, 8 and 24 h post-dose of palbociclib on Days 1 and 11</Timeframe></Measure><Measure><Description>Pharmacokinetics of palbociclib: maximum plasma concentration (Cmax): palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit)</Description><Timeframe>Pre-dose, and at 1, 2, 4, 8 and 24 h post-dose of palbociclib on days 1 and 11</Timeframe></Measure><Measure><Description>Pharmacokinetics of palbociclib: terminal phase half-life (t1/2): palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit)</Description><Timeframe>Pre-dose, and at 1, 2, 4, 8 and 24 h post-dose of palbociclib on days 1 and 11</Timeframe></Measure><Measure><Description>Pharmacokinetics of palbociclib: area under the plasma concentration (AUC): palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit)</Description><Timeframe>Pre-dose, and at 1, 2, 4, 8 and 24 h post-dose of palbociclib on days 1 and 11</Timeframe></Measure><Measure><Description>Pharmacokinetics of palbociclib: plasma clearance (CI/F): palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit)</Description><Timeframe>Pre-dose, and at 1, 2, 4, 8 and 24 h post-dose of palbociclib on days 1 and 11</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Antitumor activity of palbociclib as assessed by absolute peripheral blast count: as an early measure of response to single agent palbociclib, the absolute peripheral blast count will be measured at baseline and after 72 h of drug exposure in patients with ALL and peripheral blood circulating blasts &gt; 1000/mm(3)</Description><Timeframe>Baseline and after 72 h</Timeframe></Measure><Measure><Description>Antitumor activity of palbociclib as assessed by response rates at the end of the treatment cycle: a bone marrow aspirate will be performed on Day 32 in patients with ALL and morphological bone marrow blast percentage will be determined. The clinical response of any extramedullary disease sites will also be assessed. The blast percentage in the bone marrow in conjunction with the clinical response in any involved extramedullary disease sites will be used to determine the overall response designation at the end of the treatment cycle in patients with ALL</Description><Timeframe>Day 32</Timeframe></Measure><Measure><Description>Antitumor activity of palbociclib as assessed by response rates at the end of the treatment cycle: imaging studies will be performed on Day 32 in patients with LL. Morphological evaluation of the bone marrow (if involved at diagnosis) will also be performed on Day 32 in patients with LL. Disease response will be determined using the new International Pediatric Non-Hodgkin Lymphoma Response Criteria and the major response designations will be established by CT or MRI of involved sites in conjunction with morphologic evaluation of bone marrow (BM) if involved at diagnosis</Description><Timeframe>Day 32</Timeframe></Measure><Measure><Description>Biologic activity of palbociclib will be assessed with assays measuring cell cycle inhibition: cell cycle analyses will also be performed before and after drug exposure using standard flow cytometry methods combining surface staining for ALL markers (e.g., CD1a, CD3, CD4, CD8) and intracellular staining for the cell cycle (and apoptosis) markers Ki67 and DAPI. These assays will also be performed at the end of the treatment cycle in residual blasts in those patients who have failed to achieve remission</Description><Timeframe>Day 32</Timeframe></Measure><Measure><Description>Biologic activity of palbociclib will be assessed with assays measuring cell cycle inhibition: bone marrow (or peripheral blood if the absolute blast count is &gt; 1000/mm3) samples will be collected pre-study and on Day 4 after 72 h of single agent palbociclib exposure. Participation in these studies is optional. Expression of RB1, phospho-RB1, Cyclin D3, CDK4, CDK6 and p27Kip1 will be performed using Western Blotting (immunoblotting)</Description><Timeframe>Day 4</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Primary objectives: &lt;br/&gt;To estimate the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of      &lt;ulink linkType="Drug" linkID="10271"&gt;palbociclib&lt;/ulink&gt; administered in combination with re-induction chemotherapy in pediatric patients      with relapsed B- or T-lineage ALL/LL.&lt;br/&gt;To define and describe the toxicities of palbociclib administered on this schedule.&lt;br/&gt;To characterize the pharmacokinetics of palbociclib in pediatric patients with relapsed      B- or T-lineage ALL/LL.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To preliminarily define the antitumor activity of palbociclib in combination with      chemotherapy for children with relapsed ALL/LL within the confines of a phase I study.&lt;br/&gt;To assess the biologic activity of palbociclib in this patient population.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients will be included because the patient population will be rare and these patients will be most commonly treated with ALL regimens. The proposed starting dose for this study will be 50 mg/m(2)/day for 21 days.&lt;br/&gt;Patients will receive palbociclib 50 mg/m(2) (starting dose with maximum dose of 100 mg) po (or via NG- tube) once daily on Days 1 to 21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, doxorubicin 60 mg/m(2) iv push or infusion over 1 to 15 min on Day 4; prednisone or prednisolone 40 mg/m(2) po divided bid or tid on days 4 to 31; vincristine 1.5 mg/m(2) (maximum dose 2 mg) iv push or mini-bag per institutional policy on days 4, 11, 18, and 25; and &lt;ulink linkType="Drug" linkID="2573"&gt;pegaspargase&lt;/ulink&gt; 2500 IU/m(2) iv over 1 to 2 h on Days 5, and 18. If CNS3 leukemia  present, patients will receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. If CNS1 and 2 leukemia present, patient receive methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Children's Healthcare of Atlanta - Egleston</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30322</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>William T. Cash</Name><Phone>888-785-1112</Phone></Contact><Contact type="Facility investigator"><Name>William T. Cash</Name></Contact></Contacts></Site><Site><Name>Children's National Medical Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20010</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Jeffrey S. Dome</Name><Phone>202-884-2549</Phone></Contact><Contact type="Facility investigator"><Name>Jeffrey S. Dome</Name></Contact></Contacts></Site><Site><Name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>prmc.coordinator@nyumc.org</Email><Name>Elizabeth A. Raetz</Name><Phone>212-263-4434</Phone></Contact><Contact type="Facility investigator"><Name>Elizabeth A. Raetz</Name></Contact></Contacts></Site><Site><Name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>prmc.coordinator@nyumc.org</Email><Name>Sharon L. Gardner</Name><Phone>212-263-4434</Phone></Contact><Contact type="Facility investigator"><Name>Sharon L. Gardner</Name></Contact></Contacts></Site><Site><Name>University of Minnesota/Masonic Cancer Center</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55455</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Joseph P. Neglia</Name><Phone>612-624-2620</Phone></Contact><Contact type="Facility investigator"><Name>Joseph P. Neglia</Name></Contact></Contacts></Site><Site><Name>University of Oklahoma Health Sciences Center</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73104</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ou-clinical-trials@ouhsc.edu</Email><Name>Rene Y. McNall-Knapp</Name><Phone>405-271-8777</Phone></Contact><Contact type="Facility investigator"><Name>Rene Y. McNall-Knapp</Name></Contact></Contacts></Site><Site><Name>University of Oklahoma Health Sciences Center</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73104</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>julie-traylor@ouhsc.edu</Email><Name>Rene Y. McNall-Knapp</Name><Phone>405-271-4272</Phone></Contact><Contact type="Facility investigator"><Name>Rene Y. McNall-Knapp</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3530">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19048">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3979">Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3981">Subjects with B-Cell Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3982">Subjects with T-Cell Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3986">Pediatric Leukemia Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3999">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19052">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03792256</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7651"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="28749">Assessment by Common Terminology Criteria for Adverse Events (CTCAE)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7701">Assessment of toxicity rate</SubEndpoint><SubEndpoint disease="Lymphoma" id="7704">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7680"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7778">Area under concentration curve (AUC)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7779">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7780">Time to maximum concentration (Tmax)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7781">Assessment of t½ (terminal phase and/or effective half-life)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7785">Assessment of clearance (Cl)</SubEndpoint><SubEndpoint disease="Lymphoma" id="9133">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7819"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7845"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7987">Assessment of maximum tolerated dose (MTD)</SubEndpoint><SubEndpoint disease="Leukemia" id="43187">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Leukemia" id="43188">Area under concentration curve (AUC)</SubEndpoint><SubEndpoint disease="Leukemia" id="47606">Time to maximum concentration (Tmax)</SubEndpoint><SubEndpoint disease="Leukemia" id="47608">Assessment of clearance(CL/f)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8090">Assessment of dose limiting toxicity</SubEndpoint><SubEndpoint disease="Leukemia" id="8091">Toxicity measured by NCI common toxicity criteria for adverse events, v 3.0</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7586"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7588">Response assessment by computed tomography (CT) scan</SubEndpoint><SubEndpoint disease="Lymphoma" id="7590">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7569">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7576">Assessment of biological response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7625"><Endpoint>Assessment of Clinical Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7651"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7720"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7727">Assessment of cyclins D1</SubEndpoint><SubEndpoint disease="Lymphoma" id="7729">Assessment of cyclins D3</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7739"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7730">Assessment of apoptosis markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7768"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7811"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7819"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7845"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7848"><Endpoint>Assessment of Tumor Related Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7909">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Leukemia" id="46415">Assessment of biologic response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7952"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7988"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8015"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8016"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8031"><Endpoint>Assessment of Tumor Suppressor Genes/Proteins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8036"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8041">Assessment of markers of apoptosis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8049"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8137">Assessment of Antileukemia Activity/Anti-Tumor Activity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="45153"><Endpoint>Assessment of Clinical Response</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Leukemia" id="7935"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="9415"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3497"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3542">Subjects with Karnofsky score of 50 or higher</SubCriterion><SubCriterion disease="Lymphoma" id="3546">Subjects with Lansky performance status of 40 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3610">Subjects with first relapse of lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3633">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3657"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="5256">Subjects recovered from prior therapy/therapies</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="4981"><Criterion>Subjects with Acute Myeloid Leukemia (AML)</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="4995">Subjects with myeloblastic leukemia (M2)</SubCriterion><SubCriterion disease="Leukemia" id="4996">Subjects with promyelocytic leukemia (M3)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="4984"><Criterion>Subjects with Specific Sub-type of Lymphoid Leukemia</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="4987">Subjects with B-cell leukemia</SubCriterion><SubCriterion disease="Leukemia" id="4988">Subjects with T-cell leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="4985"><Criterion>Subjects with Acute Lymphocytic Leukemia (ALL)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5075">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5093">Subjects with Karnofsky score of 50 or higher</SubCriterion><SubCriterion disease="Leukemia" id="35316">Subjects with Lansky performance score &gt; 50%</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5164"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5174">Subjects with first relapse</SubCriterion><SubCriterion disease="Leukemia" id="5182">Subjects with morphologic relapse</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5413">Subjects with study specific protocol requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5195"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Lymphoma" id="7083"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3561">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="3578">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="3580">Subject with history of stem cell therapy for lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5102">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Leukemia" id="5125">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Leukemia" id="5139">Subjects with history of stem cell therapy for leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="22405"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion></Inclusion><Inclusion disease="Lymphoma" id="34439"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3659">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34442"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5190">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="35109"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4717"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4729"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4825"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4831">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Lymphoma" id="4838">Subjects failing to meet protocol specified criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6546"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="25410">Subjects co-morbid with CNS/neuropsychiatric disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="6685"><Criterion>Subjects with Relapsed/Recurrent Leukemia</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6930">Subjects with extramedullary relapse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6700"><Criterion>Subjects with Specific Grade of Toxicity</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6701">Subjects with grade 1 toxicity (mild)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6714">Males with partners of child bearing potential who are not willing to use condoms or abstinence</SubCriterion><SubCriterion disease="Leukemia" id="6723">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Leukemia" id="6725">Subjects not suitable to take part in study according to investigator's opinion</SubCriterion><SubCriterion disease="Leukemia" id="6726">Subjects not fulfilling eligibility criteria</SubCriterion><SubCriterion disease="Leukemia" id="25405">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Lymphoma" id="25574"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4839">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="25755"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="25404">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26917"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Lymphoma" id="26938"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Lymphoma" id="26955"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4830">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="27392"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Lymphoma" id="27397"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Leukemia" id="27727"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Leukemia" id="27879"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6718">Subjects unwilling or unable to comply with the protocol/study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="27884"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4828">Subjects with inability to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-04-29T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="368826"><TitleDisplay>From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1</TitleDisplay><TitleOfficial>Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03826940</Identifier><Identifier type="Organisational Study">CRU2C-ICNAS-001</Identifier><Identifier type="Secondary Organisational">FLAD LIFE SCIENCE 2020</Identifier><Identifier type="Trial Acronym">ASD/NF1inhib</Identifier></Identifiers><Indications><Indication id="3521">Neurofibromatosis type I</Indication><Indication id="423">Autism</Indication></Indications><BiomarkerNames><BiomarkerName id="6540" role="Therapeutic effect marker" type="Biochemical">Glutamic acid</BiomarkerName><BiomarkerName id="7643" role="Therapeutic effect marker" type="Biochemical">gamma-Aminobutyric acid</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lovastatin</Name><Drug id="44300">lovastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44300">lovastatin</Drug><IndicationsPioneer><Indication id="423">Autism</Indication></IndicationsPioneer><Companies><Company><Company id="1004242">University of Coimbra</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44300" type="Drug"><TargetEntity id="90077" type="siDrug">Lovastatin</TargetEntity></SourceEntity><SourceEntity id="1004242" type="Company"><TargetEntity id="5035555116" type="organizationId">Universidade de Coimbra</TargetEntity></SourceEntity><SourceEntity id="3521" type="ciIndication"><TargetEntity id="Q85.01" type="ICD10"></TargetEntity><TargetEntity id="D009456" type="MeSH"></TargetEntity><TargetEntity id="636" type="ORPHANET"></TargetEntity><TargetEntity id="-1668622175" type="omicsDisease"></TargetEntity><TargetEntity id="2661" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="423" type="ciIndication"><TargetEntity id="F84.0" type="ICD10"></TargetEntity><TargetEntity id="10003805" type="MEDDRA"></TargetEntity><TargetEntity id="D001321" type="MeSH"></TargetEntity><TargetEntity id="-1744075483" type="omicsDisease"></TargetEntity><TargetEntity id="39" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1004242">University of Coimbra</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2667">Antiarteriosclerotic</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2019-02-19T00:00:00Z</DateStart><DateEnd type="estimated">2020-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-17T12:05:33Z</DateChangeLast><DateAdded>2019-02-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>mcbranco@fmed.uc.pt</Email><Extension>518505</Extension><Name>Miguel S Castelo-Branco, MD, PhD</Name><Phone>+351 239488510</Phone></Contact><Contact type="Scientific contact"><Affiliation>ICNAS-Institute of Nuclear Sciences Applied to Health</Affiliation><Name>Miguel S Castelo-Branco, MD, PhD</Name></Contact><Contact type="Public contact"><Email>soniapires@uc.pt</Email><Extension>518517</Extension><Name>Sónia Pires</Name><Phone>+351 239488510</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Positive diagnostic results for ASD in: the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria&lt;/li&gt;&lt;li&gt;Positive diagnostic results for NF1: clinical diagnosis based on the well-established clinical criteria&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Global intelligence quotient&amp;lt; 80&lt;/li&gt;&lt;li&gt;Associated medical condition such as epilepsy, neurologic conditions, genetic syndromes, or other usual comorbidity in ASD and NF1 populations&lt;/li&gt;&lt;li&gt;Medication capable of interfering with the intervention and/or study results&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Drug use and/or alcohol abuse&lt;/li&gt;&lt;li&gt;Contra-indications to MR and TMS&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Neurochemical response changes to GABAergic stimulation: comparing changes in brain excitation-inhibition measures (ie, glutamate and GABA) when the GABAergic system is activated by oral dose of lovastatin 60 mg during 3 days versus the placebo condition</Description><Timeframe>Up to study completion, an average of one year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Brain oscillations changes under sensory stimulation: power (microV[2]) will be recorded during sensory stimulation using high density electroencephalography</Description><Timeframe>Up to study completion, an average of one year</Timeframe></Measure><Measure><Description>Cortical excitability changes under motor cortical stimulation: periods (millis) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</Description><Timeframe>Up to study completion, an average of one year</Timeframe></Measure><Measure><Description>Event-related potentials changes under sensory stimulation: amplitude (microV) will be recorded during sensory stimulation using high density electroencephalography</Description><Timeframe>Up to study completion, an average of one year</Timeframe></Measure><Measure><Description>Motor evoked potentials changes under motor cortical stimulation: amplitudes (microV) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</Description><Timeframe>Up to study completion, an average of one year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of      this study is to investigate synaptic physiology and behavioral inhibition in patients with      neurofibromatosis 1 (NF1) and autism spectrum disorder (ASD) and to answer whether inhibitory deficits at these levels are modulated by      &lt;ulink linkType="Drug" linkID="44300"&gt;lovastatin&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators aim to test whether a mechanistic link can be established between that synaptic inhibitory dysfunction, systems levels changes in oscillatory synchrony and regulation of inhibition and treatment with lovastatin in the two neurodevelopmental disorders (ASD and NF1). This link will be explored through the application of complementary quantitative measures (putative biomarkers), such as magnetic resonance spectroscopy (MRS), transcranial magnetic stimulation (TMS) and electroencephalogram (EEG) applied to the same group of adult patients before and after the lovastatin or placebo intake during three days.&lt;/para&gt;&lt;para&gt;Structure of this study is as follows: visit 1: baseline assessment- patient's characterization, baseline outcome measures and additional evaluations; 3 consecutive days of physiologically probing drug/placebo intake; visit 2: outcome measures and additional evaluations in the day after the last drug/placebo intake; washout period of 4 to 6 weeks; 3 Consecutive days of drug/placebo intake; visit 3: outcome measures and additional evaluations in the day after the last placebo/drug intake.&lt;/para&gt;&lt;para&gt;The intervention comprehends three sessions: the first two visits will occur in the same week and the third visit will take place 4 to 6 weeks later. In the first visit (baseline assessment), patients will perform neuropsychological, EEG, MRS and TMS assessment. In the other two visits, patients will repeat EEG, MRS and TMS assessments to study possible post- intervention effects.&lt;/para&gt;&lt;para&gt;Patients are randomized into four arms:&lt;br/&gt;Arm 1 (NF1 -experimental): patients will receive 60 mg of lovastatin per day for 3 consecutive days  before the second and the third visits.&lt;br/&gt;Arm 2 (NF1 -control): patients will receive 60 mg of placebo per day for 3 consecutive days  before the second and the third visits.&lt;br/&gt;Arm 3 (ASD -experimental): patients will receive 60 mg of lovastatin per day for 3 consecutive days  before the second and the third visits.&lt;br/&gt;Arm 4 (ASD -control): patients will receive 60 mg of placebo per day for 3 consecutive days  before the second and the third visits.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Portugal"><Sites><Site><Name>ICNAS-Institute of Nuclear Sciences Applied to Health</Name><Contacts></Contacts></Site><Site><Name>ICNAS</Name><Address1>Coimbra</Address1><Address3>3000-043</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>mcbranco@fmed.uc.pt</Email><Name>Miguel Castelo-Branco, MD PhD</Name></Contact><Contact type="Facility contact backup"><Email>ines.s.bernardino@gmail.com</Email><Name>Inês Bernardino, PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="19583">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="19253">Subjects with Neurofibromatosis Type 1 (NF1) tumors</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03826940</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Central nervous system tumor" id="13572"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Autism" id="18979"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Autism" id="18980">Assessment of neurotransmitters</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Central nervous system tumor" id="13544"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13572"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Autism" id="18969"><Endpoint>Neurological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Autism" id="18971">Assessment of EEG changes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Autism" id="18970"><Endpoint>Assessment of Brain Structure and Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Central nervous system tumor" id="13577"><Endpoint>Assessment of Neuropsychological Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Autism" id="18930"><Endpoint>Assessment of Neuropsychological Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Autism" id="44029"><Endpoint>Cognitive, Global and Functional Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Central nervous system tumor" id="13072"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Autism" id="16847"><Criterion>Subjects with Autism Spectrum Disorders</Criterion></Inclusion><Inclusion disease="Autism" id="16851"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Autism" id="16923"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="35379"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="35244">Subjects with Neurofibromatosis Type 1 (NF1) tumors</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Central nervous system tumor" id="10641"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10680"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10690">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Autism" id="14344"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Autism" id="14352">Subjects co-morbid with substance abuse disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Autism" id="14355"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Autism" id="14359">Subjects with genetic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Autism" id="14368"><Criterion>Subjects with Abnormal/Unacceptable Neuropsychological Assessment</Criterion><SubCriteria><SubCriterion disease="Autism" id="14369">Subjects with unacceptable IQ levels</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Autism" id="14413"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Autism" id="14416">Contraindication to imaging procedures</SubCriterion><SubCriterion disease="Autism" id="14422">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Autism" id="26018"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Autism" id="26139"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="26971"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="27125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Autism" id="27287"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="27299"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="29247"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10692">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-01-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-02-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-04-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="38185"><TitleDisplay>DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas</TitleDisplay><TitleOfficial>Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ID01-310</Identifier><Identifier type="NCT">NCT00805376</Identifier></Identifiers><Indications><Indication id="1108">Glioma</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="2567">Anaplastic astrocytoma</Indication><Indication id="2727">Gliosarcoma</Indication><Indication id="60">Central nervous system disease</Indication><Indication id="760">Brain tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="174" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-12</BiomarkerName><BiomarkerName id="588" role="Therapeutic effect marker" type="Genomic;Proteomic">V-set domain containing T cell activation inhibitor 1</BiomarkerName><BiomarkerName id="623" role="Therapeutic effect marker" type="Genomic;Proteomic">Indoleamine 2,3-dioxygenase</BiomarkerName><BiomarkerName id="707" role="Therapeutic effect marker" type="Genomic;Proteomic">CD276 antigen</BiomarkerName><BiomarkerName id="816" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor receptor superfamily member 4</BiomarkerName><BiomarkerName id="824" role="Therapeutic effect marker" type="Genomic;Proteomic">Programmed cell death 1 ligand 1</BiomarkerName><BiomarkerName id="1289" role="Therapeutic effect marker" type="Structural (imaging)">Tumor mass</BiomarkerName><BiomarkerName id="1645" role="Therapeutic effect marker" type="Genomic;Proteomic">Macrosialin</BiomarkerName><BiomarkerName id="1731" role="Therapeutic effect marker" type="Genomic;Proteomic">B-lymphocyte antigen CD20</BiomarkerName><BiomarkerName id="1855" role="Therapeutic effect marker" type="Proteomic">CD3 Antigens</BiomarkerName><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="1880" role="Therapeutic effect marker" type="Cellular">T-Helper Lymphocytes</BiomarkerName><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1942" role="Therapeutic effect marker" type="Genomic;Proteomic">Leukocyte common antigen</BiomarkerName><BiomarkerName id="1977" role="Therapeutic effect marker" type="Genomic;Proteomic">Forkhead box protein P3</BiomarkerName><BiomarkerName id="2130" role="Therapeutic effect marker" type="Genomic;Proteomic">Programmed cell death 1 ligand 2</BiomarkerName><BiomarkerName id="2509" role="Therapeutic effect marker" type="Genomic;Proteomic">Hepatitis A virus cellular receptor 2</BiomarkerName><BiomarkerName id="2586" role="Toxic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="3447" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD8 alpha chain</BiomarkerName><BiomarkerName id="3916" role="Therapeutic effect marker" type="Genomic;Proteomic">Programmed cell death protein 1</BiomarkerName><BiomarkerName id="5565" role="Therapeutic effect marker" type="Genomic;Proteomic">Centromere protein J</BiomarkerName><BiomarkerName id="5992" role="Therapeutic effect marker" type="Genomic;Proteomic">Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName><BiomarkerName id="10766" role="Therapeutic effect marker" type="Proteomic">Anti-cancer/testis antigen 1 antibodies</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="23432" role="Therapeutic effect marker" type="Genomic;Proteomic">V-type immunoglobulin domain-containing suppressor of T-cell activation</BiomarkerName><BiomarkerName id="26206" role="Disease marker" type="Genomic;Proteomic">Melanoma-associated antigen E1</BiomarkerName><BiomarkerName id="46505" role="Therapeutic effect marker" type="Cellular">Cytotoxic T-Lymphocytes</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName><BiomarkerName id="46507" role="Therapeutic effect marker" type="Cellular">Macrophages</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>craniotomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tasadenoturev</Name><Drug id="60630">tasadenoturev</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="60630">tasadenoturev</Drug><IndicationsPioneer><Indication id="1108">Glioma</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="2567">Anaplastic astrocytoma</Indication><Indication id="2727">Gliosarcoma</Indication><Indication id="60">Central nervous system disease</Indication><Indication id="760">Brain tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1063679">DNAtrix Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1063679" type="Company"><TargetEntity id="4297538582" type="organizationId">DNAtrix Inc</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"></TargetEntity><TargetEntity id="D005909" type="MeSH"></TargetEntity><TargetEntity id="360" type="ORPHANET"></TargetEntity><TargetEntity id="-1357419475" type="omicsDisease"></TargetEntity><TargetEntity id="678" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2567" type="ciIndication"><TargetEntity id="10002224" type="MEDDRA"></TargetEntity><TargetEntity id="251589" type="ORPHANET"></TargetEntity><TargetEntity id="583" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2727" type="ciIndication"><TargetEntity id="10018340" type="MEDDRA"></TargetEntity><TargetEntity id="D018316" type="MeSH"></TargetEntity><TargetEntity id="251576" type="ORPHANET"></TargetEntity><TargetEntity id="-797787304" type="omicsDisease"></TargetEntity><TargetEntity id="2740" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="760" type="ciIndication"><TargetEntity id="C71" type="ICD10"></TargetEntity><TargetEntity id="10061019" type="MEDDRA"></TargetEntity><TargetEntity id="D001932" type="MeSH"></TargetEntity><TargetEntity id="-927909969" type="omicsDisease"></TargetEntity><TargetEntity id="581" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1063679">DNAtrix Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5860">Integrin alpha-5/beta-3 modulator</Action><Action id="5866">Integrin alpha-5/beta-5 modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="393">Immunostimulant</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="649">Intraperitoneal formulation</Technology><Technology id="347">Intratumoral formulation</Technology><Technology id="62">Virus recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>37</PatientCountEnrollment><PatientCountEvaluable>37</PatientCountEvaluable><DateStart>2009-02-28T00:00:00Z</DateStart><DateEnd type="actual">2015-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T00:25:55Z</DateChangeLast><DateAdded>2009-02-13T13:10:53Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with histologically proven recurrent malignant primary glioma will be
             eligible. Glioma type will be restricted to: GBM, gliosarcoma (GS), anaplastic gliomas
             [anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic
             infiltrating glioma (AIG), mixed anaplastic glioma (MAG), anaplastic ependymoma]&lt;/li&gt;&lt;li&gt;Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan within 15 days prior to day 0/baseline procedure after failing prior surgical resection, biopsy, chemotherapy or radiation&lt;/li&gt;&lt;li&gt;For patients entered in group A (see Treatment Plan) tumors must be accessible for
             stereotactic injection. Tumors must be between 1.0 to 5.0 cm in diameter&lt;/li&gt;&lt;li&gt;For patients entered in Group B (see Treatment Plan) tumors must be surgically
             resectable, and surgical resection must be indicated at the time of baseline
             evaluation. Tumors must be &amp;gt; 1.0 cm in diameter&lt;/li&gt;&lt;li&gt;Patients will consent to have a biopsy taken at the time of the stereotactic injection
             to confirm the presence of malignant glioma (based on frozen section) before injection
             of &lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;For each patient there must be a consensus between the physician investigators in this
             study that injection will not delivery&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; into the ventricular system.
             Patients must have a stable steroid regimen for at least 1 week prior to&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt;  administration&lt;/li&gt;&lt;li&gt;Patients may or may not have had prior chemotherapy&lt;/li&gt;&lt;li&gt;Patients must be willing and able to give informed consent&lt;/li&gt;&lt;li&gt;Age&amp;gt; /= 18 years&lt;/li&gt;&lt;li&gt;Patients must have a Karnofsky performance status&amp;gt;/= 70&lt;/li&gt;&lt;li&gt;Patients must have recovered from the toxic effects of prior therapy (ie, CTC grade
             1 or less). For example, they must be at least two weeks after vincristine, 6 weeks
             after nitrosoureas, and 3 weeks after procarbazine or temozolomide administration&lt;/li&gt;&lt;li&gt;Patients must have adequate bone marrow function (absolute granulocyte count&amp;gt; 1,500
             and platelet count of &amp;gt; 100,000), adequate liver function (SGPT and alkaline
             phosphatase &amp;lt; 2 x institutional normals and bilirubin &amp;lt; 1.5 mg%), and adequate
             renal function (BUN or creatinine &amp;lt; 1.5 x institutional normal) prior to starting
             therapy&lt;/li&gt;&lt;li&gt;This study was designed to include women and minorities, but was not designed to
             measure differences of intervention effects. Males and females will be recruited with
             no preference to gender&lt;/li&gt;&lt;li&gt;No exclusion to this study will be based on race. Minorities will actively be
             recruited to participate. The malignant glioma patient population treated at MDACC
             over the past year is as follows: American Indian or Alaskan Native - 0, Asian or
             Pacific Islander - &amp;lt;2%, Black, not of Hispanic Origin - 3%, Hispanic - 6%, White, not
             of Hispanic Origin - 88%, Other or Unknown - 2%, Total - 100%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any radiotherapy within 4 weeks prior to date of&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; administration &lt;/li&gt;&lt;li&gt;Active uncontrolled infection or severe intercurrent medical conditions. All patients must be afebrile at baseline (ie,&amp;lt; 38.0degC) &lt;/li&gt;&lt;li&gt;Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery. If the medication can be discontinued , based on the clinical judgment of the surgeon, prior to&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; injection then patient may be eligible &lt;/li&gt;&lt;li&gt;History or current diagnosis of any medical or psychological condition that in the Investigator's opinion, might interfere with the subject's ability to participate or inability to obtain informed consent because of psychiatric or complicating medical problems&lt;/li&gt;&lt;li&gt;Female who is pregnant and/or nursing. Because of the potential risk of a recombinant virus containing a gene involved in cellular growth regulation and differentiation which could potentially affect a developing fetus or growing infant, females who are pregnant, at risk of pregnancy, or breast feeding a baby during the study period are excluded&lt;/li&gt;&lt;li&gt;Tumor position that, in the Investigator's opinion, would pose the risk of penetration of the cerebral ventricular system during injection with study drug. If, during the&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; injection procedure, penetration of the ventricular system is suspected or confirmed, &lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; administration will be aborted &lt;/li&gt;&lt;li&gt;Immunocompromised subjects, subjects with autoimmune conditions, active hepatitis (B or C) or HIV seropositivity&lt;/li&gt;&lt;li&gt;Patients with Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways&lt;/li&gt;&lt;li&gt;Age &gt; /= 18 years&lt;/li&gt;&lt;li&gt;Multiple intracranial malignant glioma lesions at the time of recurrence. Multiple enhancing areas within a single tumor will not be considered multiple glioma lesions&lt;/li&gt;&lt;li&gt;Tumor involvement which would require ventricular, brainstem or posterior fossa injection or access through a ventricle in order to deliver the virus&lt;/li&gt;&lt;li&gt;Tumor involving the subependyma or suspected cerebrospinal fluid (CSF) dissemination&lt;/li&gt;&lt;li&gt;Documented extracranial metastasis&lt;/li&gt;&lt;li&gt;Biological/immunotherapy (eg, IL-2, IL-12, interferon) within 4 weeks of&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; administration&lt;/li&gt;&lt;li&gt;Concurrent chemotherapy, radiation or biological therapy&lt;/li&gt;&lt;li&gt;Any contraindication for undergoing MRI such as: individuals with pacemakers, epicardial pacer wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prosthesis, implants with potential magnetic properties, metallic bodies in the eyes, etc&lt;/li&gt;&lt;li&gt;White blood cell (WBC)&amp;lt; 2.5 x 10(3)/mm3, absolute neutrophil count (ANC) &amp;lt; 1.5 x 10(3)/mm3, platelet &amp;lt; 100,000/mm3, hemoglobin (Hgb) &amp;lt; 10.0 g/dl, prothrombin time/international normalized ratio (PT/INR) or partial thromboplastin time (PTT) &gt; 1.8 x control&lt;/li&gt;&lt;li&gt;Grade 4 hematological toxicity&lt;/li&gt;&lt;li&gt;Serum creatinine &gt; 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) or total bilirubin &gt; 2 x the upper limits of normal&lt;/li&gt;&lt;li&gt;Vaccinations of any kind within 30 days prior to&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt; administration&lt;/li&gt;&lt;li&gt;Current diagnosis of other cancer except curative cervical cancer in situ, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer, but who are cancer free for a minimum of three years remain eligible&lt;/li&gt;&lt;li&gt;History of encephalitis, multiple sclerosis, other CNS infection or primary CNS disease that would interfere with subject evaluation&lt;/li&gt;&lt;li&gt;Patients with history of prior gene transfer therapy or prior therapy with cytolytic virus of any type, especially&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with&lt;ulink linkType="Drug" linkID="60630"&gt;delta24-RGD-4C&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum Tolerated Dose (MTD) DELTA-24-RGD-4C: each cohort of three subjects each sequentially assigned to escalating doses of DNX-2401, with acceptable grade of neurotoxicity Common Toxicity Criteria (CTC) &lt; grade 3, related to the study drug, and according to standard Gehan phase I dose-escalating criteria for toxicity</Description><Timeframe>Assessed during 14-day waiting period between doses (every 28 days)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>To examine to which extent Delta-24-RGD infects, replicates and kills glioma cells</Description></Measure><Measure><Description>To ascertain whether the adenovirus infection of tumors ignites an anti-tumor immuneresponse with therapeutic benefit</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were presented in June 2013.     &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD&lt;/ulink&gt;  was found to be well tolerated in 37 patients with no dose-limiting toxicity  [&lt;ulink linkType="Reference" linkID="1440131"&gt;1440131&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, results were published. No toxicity was observed and the MTD was 3x10(10) virus particles [&lt;ulink linkType="Reference" linkID="1619323"&gt;1619323&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this clinical research study was to find the highest tolerable dose of  &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;  (DNX-2401) that could be injected directly into brain tumors and into the surrounding brain tissue where tumor cells could multiply. A second goal was to study how the new drug  &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;  affects brain tumor cells and the body in general [&lt;ulink linkType="Reference" linkID="1212562"&gt;1212562&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, this study was initiated [&lt;ulink linkType="Reference" linkID="1212562"&gt;1212562&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2012, results were presented. Radiographic responses were seen in 50% of patients. In a subset of these, there was decrease of tumor volume within weeks after Delta-24-RGD injection. In another subset there was an initial phase of pseudo-progression that lasted several weeks and was eventually followed by marked shrinkage of the tumor. One of these patients showed a complete radiographic response by 14 months after the treatment. IHC showed active adenovirus replication that lasted at least for 15 days; a subset of tumors were positive for MAGE E1. Antibodies against CTAs were detected that were present before the treatment or developed afterwards. Median survivals for patients with recurrent gliomas is 6 months, however, all four patients with high titers of anti-NY-ESO-1 antibodies survived after treatment: 301days (still alive), 281days (deceased), 273 days (still alive), and 126 days (still alive). Histological analyses of the post-treatment tumor from a patient with high titers of anti-NY-ESO 1, showed 80%-necrosis, striking inflammatory reaction, and predominant CD8+ lymphocytic infiltration [&lt;ulink linkType="Reference" linkID="1276797"&gt;1276797&lt;/ulink&gt;]. Similar results were presented in June 2012 [&lt;ulink linkType="Reference" linkID="1306390"&gt;1306390&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results were presented. In a subset of patients, there was a radiographic response observed in 50% of patients and 40% survived for more than one year. One patient showed a complete radiographic response by 17 months post-treatment. In these patients, tumors showed adenovirus replication and treatment-related tumor necrosis. The investigators detected antibodies against cancer testis antigens (CTAs) before the treatment and some patients developed them after &lt;ulink linkType="Drug" linkID="60630"&gt;Delta-24-RGD&lt;/ulink&gt; injection. IHC analyses showed that a subset of these tumors were positive for the CTA MAGE E1. Histological analyses  of the post-treatment tumor from one patient with high titers of anti-NY-ESO1 demonstrated vast areas of necrosis, massive inflammatory reaction, and CD3+/CD8+ lymphocytic infiltration [&lt;ulink linkType="Reference" linkID="1306390"&gt;1306390&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were presented in June 2013. Highly impressive activity and efficacy was observed with      &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD&lt;/ulink&gt;   [&lt;ulink linkType="Reference" linkID="1440131"&gt;1440131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, results were published. There was a median survival of 11 months and complete response was observed in three patients (12%). There was no evidence of disease at 3.2, 2 and 1.75 years post treatment. The three patients with complete response showed 10- to 1000-fold increases in IL-12p70. The responses were inflammatory mediated and histological analysis revealed macrophages and CD8 T-cells with only rare tumor cells in resected tumors [&lt;ulink linkType="Reference" linkID="1619323"&gt;1619323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, results were presented. In gliomas, targeted proteins were expressed in different patterns and tumor regions. There was no significant treatment-related changes observed in the expression of programmed death (PD)-1 in lymphocytes and PD-ligand-1 in glioma cells; however, TIM3 (a marker for T cell exhaustion) was downregulated after Delta-24-RGD treatment. Furthermore, expression of B7-H3 (a marker of poor prognosis in other tumors) was found to correlate with poorer survival   [&lt;ulink linkType="Reference" linkID="1914149"&gt;1914149&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, results were published. The IHC scores were expressed for CD3, CD4, CD8, CD45Ro, FOXP3, TIM3, LAG-3, VISTA, CD20, CD57, CD68, and OX40   as cell density in the inflammatory cell population (number of positive cells per mm square of tumor area), except PD-L1, PD-L2, B7-H3, B7-H4, IDO-1, which were expressed using percentage of positive tumor cells, and also as H-score of the tumor cells. Correlations between immunostaining marker values and survival and dose level using Spearman rank correlation analysis and differences in immunostaining marker values before and after treatment were assessed which demonstrated that all the target proteins are expressed in gliomas in different patterns and tumor regions. Although,  significant treatment-related changes were not observed in the expression of PD-1 in lymphocytes and PD-L1 in glioma cells, TIM3, a marker for T cell exhaustion, was downregulated after DNX-2401 treatment. In addition, expression of B7-H3, a marker of poor prognosis in other tumors, correlated with poorer survival [&lt;ulink linkType="Reference" linkID="1985295"&gt;1985295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in May 2018. It was observed that a total of 20% patients survived &amp;gt; 3 years from treatment, and 3 patients had a &gt;/= 95% reduction in the enhancing tumor (12%), with all 3 of these dramatic responses resulting in &amp;gt; 3 years of progression-free survival from the time of treatment in group A. It was reported that Delta-24-RGD replicated and was spread within the tumor, documenting direct virus-induced oncolysis in patients, as evaluated by analyses of post-treatment surgical specimens (group B, n = 12). Histopathological examination in addition to radiographic signs of inflammation showed tumor infiltration by CD8-positive and T-bet-positive cells, and transmembrane immunoglobulin mucin-3 downregulation after treatment. After Delta-24-RGD administration, analyses of patient-derived cell lines for damage-associated molecular patterns revealed induction of immunogenic cell death in tumor cells [&lt;ulink linkType="Reference" linkID="2049751"&gt;2049751&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study groups:  patients  would eventually be divided into two groups (Groups A and B).  At first, all patients would only be enrolled into Group A. &lt;br/&gt;Patients in Group A would receive the study drug but would not have the recurrent malignant glioma tumor removed by surgery.  Enrollment into Group B would not start until the FDA has reviewed initial results on how the treatment for patients in Group A effected brain tumor cells and the body in general. Once approval for enrollment was given, all eligible patients would be assigned to Group B and would receive the study drug and have their tumors removed by surgery. If patients were to receive surgery, they would be asked to sign a separate surgical consent form to help further explain the operation.  If patients were found to be eligible to take part in this study, they would be assigned to a dose level of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; based on when patients joined this study.  Up eight dose levels of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; would be tested. A total of three  patients would be enrolled at each dose level. The first group of patients would receive the lowest dose level. Each new group would receive a higher dose than the group before it, if no intolerable side effects were seen. This would continue until the highest tolerable dose of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; was found. Patients would be informed of which dose they would receive. &lt;/para&gt;&lt;para&gt;Study drug administration:  &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; was given by a surgical procedure where a neurosurgeon precisely injects &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; through a catheter (small tube) that was inserted into patients brain tumor. Patients would stay in the hospital and be watched closely afterward for at least 3 days, but it might be longer if patients doctors feel that patients were not ready to go home.  After receiving &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;, all patients must wear a mask. Patients must also stay away from pregnant women, babies, children under three years of age, elderly people and large groups of people who might have weaker defenses to disease or those who can spread a disease. Patients must also stay away from other patients who might have immune system problems, such as people with AIDS, or people who are getting chemotherapy or radiation therapy. The study doctors would decide how long patients would need to follow these precautions. Patients should not donate blood or sperm for at least 6 months after receiving &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;Group A:  before receiving &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;, patients in Group A would have a sample (biopsy) of brain tumor tissue collected to confirm that recurrent malignant glioma was present. On the morning of the biopsy, patients would have an MRI (with dye). Before the MRI, a dye would be injected to help give the doctors a better picture of patients brain. The head frame allows the surgeon to use MRI to identify the precise location of the tumor within the brain. The frame would stay in place for several hour while the procedure was being performed.  A portion of patients head would be shaved for the biopsy. Patients would have a small incision (cut) in their head (about 2 to 3 inches). The protective covering of the brain (dura) would be opened and a piece of brain tumor would be removed. If, under a microscope, the biopsy shows that the tumor was still malignant glioma, patients would then have an injection of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;. The anesthesiologists (doctor who gives the anesthesia) might give patients medication to make them sedated (anesthesia). They would place a needle into patients vein (intravenous line or 'iv') to give patients this medicine. The anesthesia was given so that patients do not feel any pain or discomfort and do not move during the MRI or the surgery.  A small catheter would be placed into the tumor and the metal frame would help guide the proper placement. Some anti-inflammatory medication (a steroid called dexamethasone) would be given in patients vein. Then &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; would be slowly injected into the tumor over about 10 min. After the injection, the incision would be closed in a standard and cosmetically acceptable manner.&lt;/para&gt;&lt;para&gt;Group B:  before receiving &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt;, patients in Group B would have a biopsy to confirm that the tumor was recurrent glioma. The procedure would be exactly the same as described for those in Group A. However, at the end of the biopsy and study drug injection procedure, the catheter would be clipped off next to patients skull and a portion of the tube would remain inside the tumor and in place for the next 2 weeks. The scalp would be closed over the clipped catheter to prevent any possibility of infection. The next day, patients would have a CT scan to check the tumor and placement of the catheter. &lt;/para&gt;&lt;para&gt;Group A follow-up visits:  patients would come back to the study center for check-ups at 4, 7,14 and 28 days, then 2, 3, and 4 months after the injections, and then every 2 months for two years. After that  patients would be asked to return to the clinic every 4 months for the rest of their life. At each visit, the following tests and procedures would be performed:  &lt;br/&gt;Patients would be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that they might be taking.  &lt;br/&gt;Patients would be asked to describe any changes in their health or how they feel.  &lt;br/&gt;Patients would have a neurological exam.  &lt;br/&gt;Patients weight would be measured on day 28 and at 2, 3 and 4 months.  &lt;br/&gt;Patients vital signs would be measured.  &lt;br/&gt;Patients would be asked to provide a blood sample, a urine sample and a swab of their nose and throat would be taken.  &lt;br/&gt;Patients would have a blood tests to evaluate patients clinical status on days 4, 7, 28, and at 2, 3 and 4 months.  &lt;br/&gt;Blood  would be collected to look for the presence of anti-AD5 and virus.  &lt;br/&gt;Women who were able to become pregnant must have a blood pregnancy test on 1 and 4-month visit and all follow-up visits after that.  &lt;br/&gt;Patients would have an MRI at each visit except for day 4.  &lt;br/&gt;After the 4-month visit, patients would have an evaluation to see how they have responded to treatment for the first two years and every 4 months after that.&lt;/para&gt;&lt;para&gt;Group B Follow-up Visits:  patients would be seen in the study center for check-ups on days 4, 7, and 13 after the injection but before patients craniotomy. At each visit the following tests and procedures would be performed:  &lt;br/&gt;Patients would be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that they  might be taking.  Patients would be asked to describe any changes in their health or how they feel.  &lt;br/&gt;Patients would have a neurological exam.  &lt;br/&gt;Patients vital signs would be measured.  &lt;br/&gt;Patients would be asked to provide a blood sample, a urine sample and a swab of patients nose and throat would be taken.  &lt;br/&gt;Patients would have a blood test  to evaluate their clinical status.   &lt;br/&gt;Blood  would be collected to look for the presence of anti-AD5 and virus.  &lt;br/&gt;Women who were able to become pregnant must have a blood pregnancy test on day 13, 1 and 4-month visits and all follow-up visits after that.  &lt;br/&gt;Patients would have an MRI on days 7 and 13 only.  &lt;/para&gt;&lt;para&gt;If patients were feeling well 14 days after the first injection of study drug, patients would be brought back to the operating room for a second procedure to remove the tumor. Patients would undergo a craniotomy, in which the skull over the tumor was removed to get to the brain and tumor. The neurosurgeon would try to remove the tumor as completely as possible with the catheter tip from the first procedure in place. After the tumor has been removed, patients would receive another dose of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta24-RGD-4C&lt;/ulink&gt; that would be injected into the brain tissue that surrounded the tumor to try to kill any remaining tumor cells. The skull would then be replaced and the skin closed. Within 6 h of the craniotomy on day 14, patients would have a neurological exam and their vital signs would be measured. &lt;/para&gt;&lt;para&gt;Group B Follow-up Visits after Craniotomy:  After the surgery, patients would be seen in the hospital or come back to the center on days 15, 18, 21, and 28, at 2, 3 and 4 months, and then every 2 months for two years. After that, patients would be asked to come back every 4 months for the rest of their life. At each visit, the following tests and procedures would be performed:  &lt;br/&gt;Patients would be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that they might be taking.  Patients would be asked to describe any changes in their health or how they feel.  &lt;br/&gt;Patients would have a neurological exam.  &lt;br/&gt;Patients weight would be measured on day 28 and at 2, 3 and 4 months only.  &lt;br/&gt;Patients vital signs would be measured.  &lt;br/&gt;Patients would be asked to provide a blood sample, a urine sample and a swab of their nose and throat would be taken.  &lt;br/&gt;Patients would have a blood test (about four teaspoons) to evaluate their clinical status.  &lt;br/&gt;Blood  would be collected to look for the presence of anti-AD5 and virus.  &lt;br/&gt;Women who were able to have children must have a blood  pregnancy test at all visits except day 15 and 18.  &lt;br/&gt;Patients would have an MRI.&lt;/para&gt;&lt;para&gt;This was an investigational study. Up to 96 patients would take part in this study (up to 48 in Group A and 48 in Group B). All would be enrolled at &lt;ulink linkType="Company" linkID="23382"&gt;M. D. Anderson&lt;/ulink&gt;.&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;In group A, patients with unresectable gliomas were administered with an intratumoral injection of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta-24-RGD&lt;/ulink&gt; and were followed for toxicity. In group B, patients underwent a two-phase approach. In group B, at first, patients received a single dose of &lt;ulink linkType="Drug" linkID="60630"&gt;Delta-24-RGD&lt;/ulink&gt; intratumorally, and 2 weeks later the tumor mass was resected. Surgical specimens were assessed for viral replication. Immunohistochemistry (IHC) and Flow cytometry (FACS) were used to identify lymphocyte populations and expression of cancer antigens in resected tumors. Antibodies against cancer testis antigens (CTAs) in the sera of 20 patients were detected before and after the injection of the adenovirus using a modified solid-phase ELISA [&lt;ulink linkType="Reference" linkID="1306390"&gt;1306390&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1914149"&gt;1914149&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1276797"&gt;1276797&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients with recurrent glioblastoma received Delta-24-RGD (1  x 10(7) to 3 x 10(10) virus particles) as a single intratumoral injection (n = 25) or intratumoral injection via catheter followed by en bloc tumor/catheter resection after 14 days and subsequent injection into post-resection cavity [&lt;ulink linkType="Reference" linkID="1619323"&gt;1619323&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1985295"&gt;1985295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In group A (n = 25), patients received a single intratumoral injection of Delta-24-RGD into biopsy-confirmed recurrent tumor to evaluate safety and response across eight dose levels and patients in group B (n = 12) underwent intratumoral injection through a permanently implanted catheter, followed 14 days later by en bloc resection to acquire post-treatment specimens [&lt;ulink linkType="Reference" linkID="2049751"&gt;2049751&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>UT MD Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Glioblastoma</Disease><PatientSegments><PatientSegment><PatientSegment id="7988">Subjects with Relapse/Recurrent Glioblastoma Multiforme</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8001">Subjects with high grade gliomas</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8003">Anaplastic/grade III astrocytoma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9624">Subjects with Brain Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9632">Subjects with Gliomas</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9633">Subjects with Astrocytomas</PatientSegment><SubSegments><SubSegment id="9637">Subjects with anaplastic astrocytoma (WHO Grade III)</SubSegment><SubSegment id="9638">Subjects with glioblastoma (WHO Grade IV)</SubSegment><SubSegment id="9639">Subjects with gliosarcoma (WHO Grade IV)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9642">Subjects with Oligodendroglioma</PatientSegment><SubSegments><SubSegment id="9643">Subjects with anaplastic oligodendroglioma (WHO Grade III)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9644">Subjects with Mixed Gliomas</PatientSegment><SubSegments><SubSegment id="9646">Subjects with anaplastic oligoastrocytoma (WHO Grade III)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9647">Subjects with Ependymomas</PatientSegment><SubSegments><SubSegment id="9648">Subjects with anaplastic ependymoma (WHO Grade III)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9670">Subjects with High Grade CNS Tumors</PatientSegment><SubSegments><SubSegment id="9671">Subjects with WHO grade III CNS tumors</SubSegment><SubSegment id="9672">Subjects with WHO grade IV CNS tumors</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9674">Subjects with Recurrent/Relapsed CNS Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9675">Subjects with Resectable CNS Tumor</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00805376</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Glioblastoma" id="13223"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13573"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Glioblastoma" id="13208"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Glioblastoma" id="7984"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Glioblastoma" id="8001"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8008">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8012"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8013">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8021"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8022">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Glioblastoma" id="8023">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8028"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="14497">Subjects with high grade gliomas</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="12981"><Criterion>Subjects with Brain Tumors</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="12989"><Criterion>Subjects with Gliomas</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="12990"><Criterion>Subjects with Astrocytomas</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="12994">Subjects with anaplastic astrocytoma (WHO Grade III)</SubCriterion><SubCriterion disease="Central nervous system tumor" id="12995">Subjects with glioblastoma (WHO Grade IV)</SubCriterion><SubCriterion disease="Central nervous system tumor" id="12996">Subjects with gliosarcoma (WHO Grade IV)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="12999"><Criterion>Subjects with Oligodendroglioma</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13000">Subjects with anaplastic oligodendroglioma (WHO Grade III)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13001"><Criterion>Subjects with Mixed Gliomas</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13003">Subjects with Anaplastic oligoastrocytoma (WHO Grade III)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13004"><Criterion>Subjects with Ependymomas</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13005">Subjects with anaplastic ependymoma (WHO Grade III)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13030"><Criterion>Subjects with High Grade CNS Tumors</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13031">Subjects with WHO Grade III CNS Tumors</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13032">Subjects with WHO Grade IV CNS Tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13052">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13054"><Criterion>Subjects with Resectable CNS Tumors</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13056"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13057">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13060">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13061">Subjects with history of surgery/procedure for CNS Tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13062"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13063"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13065"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13066">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13067">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="14498"><Criterion>Anaplastic/grade III astrocytoma</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="34035"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13068">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="34040"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8024">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Glioblastoma" id="9554"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9555"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9565"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9570">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="9574"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9581">Subjects with contraindications to surgical procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="9582"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9583">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Glioblastoma" id="9586">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="9589"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9590"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10641"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10651"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10656">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10668"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10669">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10673">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="26348"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10652">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10653">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="26357"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9566">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Glioblastoma" id="9567">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="26807"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10671">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="26837"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9585">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-02-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>50.13 Months</EnrollmentPeriod><EnrollmentRate>0.74 Patients/Month</EnrollmentRate><DateFirstReceived>2008-12-08T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-13T13:10:53Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="383011"><TitleDisplay>Effect of isometric training on blood pressure</TitleDisplay><TitleOfficial>Efficacy of acute bout of isometric handgrip training on heart rate</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2019/05/019466</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>isometric handgrip training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1145937" type="Company"><TargetEntity id="5055456740" type="organizationId">Guru Jambheshwar University of Science and Technology</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1145937">Guru Jambheshwar University of Science and Technology</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2019-06-04T00:00:00Z</DateStart><DateChangeLast>2019-06-05T06:30:45Z</DateChangeLast><DateAdded>2019-06-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Guru Jambheshwar University</Affiliation><Email>malik_manoj@yahoo.com</Email><Name>Dr Manoj Malik</Name><Phone>9896221262</Phone></Contact><Contact type="Public contact"><Affiliation>Guru Jambheshwar University</Affiliation><Email>sonu.punianeuropt@gmail.com</Email><Name>Dr Sonu Punia</Name><Phone>9466373990</Phone></Contact><Contact type="Scientific contact"><Affiliation>Guru Jambheshwar University of Science and Technology</Affiliation><Email>sudeshk484@gmail.com</Email><Name>Sudesh Kumar</Name><Phone>9467637471</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosed hypertensive patients &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Persons suffering from pulmonary disease like Asthma, Bed ridden patients, arthritis&amp;amp; carpal tunnel which may be aggravated with handgrip exercise , Musculoskeletal conditions, neurological condition &lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Heart rate</Description><Timeframe>Single time</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Calculate rate pulse pressure</Description><Timeframe>Single time</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to assess the effect of acute bout of isometric handgrip training on heart rate. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Participants will receive acute bout of isometric handgrip training.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Guru Jambheshwar University of Science and Technology</Name><Address1>Hisar</Address1><Address2>HARYANA</Address2><Address3>125001</Address3><CountrySubDivision>HARYANA</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2019/05/019466</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="91"><Endpoint>Assessment of Heart/Pulse Rate</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="99"><Endpoint>Assessment of Pulse Pressure</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></OtherEndpoint><OtherEndpoint disease="Hypertension" id="46164"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="114"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="160"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Hypertension" id="231"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="235">Subjects co-morbid with asthma</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="256"><Criterion>Subjects co-morbid with musculoskeletal diseases/disorders</Criterion></Exclusion><Exclusion disease="Hypertension" id="271"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Hypertension" id="26001"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-06-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="383980"><TitleDisplay>Study for a New Eradication Therapy of Penicillin-allergic Patients with Helicobacter Pylori Infection</TitleDisplay><TitleOfficial>Study for a New Eradication Therapy of Penicillin-allergic Patients with Helicobacter Pylori Infection</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900023702</Identifier></Identifiers><Indications><Indication id="149">Helicobacter pylori infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cefuroxime</Name></Intervention><Intervention type="InterventionPrimary"><Name>esomeprazole</Name><Drug id="16026">esomeprazole</Drug></Intervention><Intervention type="InterventionPrimary"><Name>metronidazole</Name></Intervention><Intervention type="InterventionPrimary"><Name>minocycline</Name><Drug id="46889">minocycline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16026">esomeprazole</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1061546">Peking University Third Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="46889">minocycline</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1061546">Peking University Third Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16026" type="Drug"><TargetEntity id="272598" type="siDrug">Esomeprazole magnesium</TargetEntity><TargetEntity id="628353" type="siDrug">Esomeprazole sodium</TargetEntity></SourceEntity><SourceEntity id="46889" type="Drug"><TargetEntity id="70094" type="siDrug">Minocycline hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1061546" type="Company"><TargetEntity id="5035553249" type="organizationId">Peking University Third Hospital</TargetEntity></SourceEntity><SourceEntity id="149" type="ciIndication"><TargetEntity id="1350" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="208" type="Action"><TargetEntity id="434" type="Mechanism">H+/K+-ATPase Inhibitors</TargetEntity><TargetEntity id="2955" type="Mechanism">Reversible H+/K+-ATPase Inhibitors </TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1061546">Peking University Third Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="208">H+ K+ ATPase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1332">Gastrointestinal system agent</Class><Class id="1539">Tetracycline</Class><Class id="1545">Anticancer</Class><Class id="1593">Antimicrobial</Class><Class id="1594">Antibacterial</Class><Class id="2953">Anti-inflammatory</Class><Class id="2970">Anti-emetic</Class><Class id="38200">Acid pump inhibitor antiulcerant product</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="743">Granule</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="559">Oral controlled release formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="742">Pellet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="630">Stereochemistry</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>426</PatientCountEnrollment><DateStart>2019-06-17T00:00:00Z</DateStart><DateEnd type="estimated">2021-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-21T06:25:56Z</DateChangeLast><Contacts><Contact type="Public contact"><Affiliation>Peking University Third Hospital</Affiliation><Email>tiantian1188_163@163.com</Email><Name>Xueli Tian</Name><Phone>+86 18614012400</Phone></Contact><Contact type="Scientific contact"><Affiliation>Peking University Third Hospital</Affiliation><Email>zhoumed@126.com</Email><Name>Liya Zhou</Name><Phone>+86 15611908239</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Consecutive patients with dyspepsia who are referred to the Peking University Third Hospital&lt;/li&gt;&lt;li&gt;Urea breath test positive or gastroscopic mucosal biopsy revealed double positive staining of Hp RUT and Warthin-Starry&lt;/li&gt;&lt;li&gt;Aged 18 years and elder man or woman&lt;/li&gt;&lt;li&gt;Penicillin allergy&lt;/li&gt;&lt;li&gt;Willing and available for participation this study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Received treatment for Hp infection; taking any drug which could influence the study results such as PPI, H2-receptor blockers, bismuth salts and antibiotics in the previous 4 weeks&lt;/li&gt;&lt;li&gt;Gastrointestinal malignancy&lt;/li&gt;&lt;li&gt;Zollinger-Ellison syndrome&lt;/li&gt;&lt;li&gt;Previous gastric and esophageal surgeries&lt;/li&gt;&lt;li&gt;Severe concomitant cardiovascular, respiratory, renal, hepatic, hematological, neurological, endocrine or psychiatric diseases&lt;/li&gt;&lt;li&gt;History of allergy to any of the drugs used in the study&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Any other clinically significant medical condition that could increase risk of side effects&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Eradication rate</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Compliance</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study is to compare the eradication rates of Chinese naive patients with helicobacter pylori infection treated with the three quadruple regimens.&lt;br/&gt;The secondary objective of this study is to compare the compliance and safety of treated patients with helicobacter pylori infection among the three quadruple regimens.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized into three groups:&lt;br/&gt;Group 1 (n=142): patients will receive quadruple therapy containing cefuroxime and &lt;ulink linkType="Drug" linkID="46889"&gt;minocycline&lt;/ulink&gt;.&lt;br/&gt;Group 2 (n=142): patients will receive quadruple therapy containing cefuroxime and metronidazole.&lt;br/&gt;Group 3 (n=142): patients will receive quadruple therapy containing minocycline and metronidazole.&lt;/para&gt;&lt;para&gt;Scheme A: a 14-day therapy comprising cefuroxime 500 mg, minocycline 100 mg, &lt;ulink linkType="Drug" linkID="16026"&gt;esomeprazole&lt;/ulink&gt; 20 mg bismuth potassium citrate 220 mg, all given bid.&lt;br/&gt;Scheme B: a 14-day therapy comprising cefuroxime 500 mg, esomeprazole 20 mg, bismuth potassium citrate 220 mg, all given bid; metronidazole 400 mg, given qid.&lt;br/&gt;Scheme C: a 14-day therapy comprising minocycline 100 mg, esomeprazole 20 mg, bismuth potassium citrate 220 mg, all given bid; metronidazole 400 mg, given qid.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Peking University Third Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peptic ulcer</Disease><PatientSegments><PatientSegment><PatientSegment id="10922">Subjects with Active H.Pylori Infection</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19144">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900023702</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peptic ulcer" id="21694"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Peptic ulcer" id="21717">Assessment of H. Pylori eradication</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peptic ulcer" id="21681"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peptic ulcer" id="21709"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peptic ulcer" id="19044"><Criterion>Subjects with Active H.Pylori Infection</Criterion></Inclusion><Inclusion disease="Peptic ulcer" id="19054"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="19055">Subjects with dyspepsia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peptic ulcer" id="19070"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="19075">Subjects with normal/acceptable urea breath test</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peptic ulcer" id="19076"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="19077">Subjects with normal/acceptable biopsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peptic ulcer" id="19101"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Peptic ulcer" id="19104"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Peptic ulcer" id="34383"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peptic ulcer" id="17046"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17047">Subjects with abnormal/unacceptable cardiac function</SubCriterion><SubCriterion disease="Peptic ulcer" id="17048">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Peptic ulcer" id="17050">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Peptic ulcer" id="17051">Subjects with abnormal/unacceptable hematological functions</SubCriterion><SubCriterion disease="Peptic ulcer" id="17052">Subjects with abnormal endocrine function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="17049"><Criterion>Subjects with Abnormal Lung Function</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17058"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="17066"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17071">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="17072"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17074">Subjects with history of proton pump inhibitors (PPI) therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="17085"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17091">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="25908"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17059">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="26288"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Peptic ulcer" id="17075">Subjects with history of antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peptic ulcer" id="26951"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="27647"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Peptic ulcer" id="29311"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType></Trial><Trial id="384747"><TitleDisplay>To study the therapeutic effect of oral vinorelbine soft capsule combined with capecitabine on HER2 negative advanced breast cancer</TitleDisplay><TitleOfficial>To study the therapeutic effect of oral vinorelbine soft capsule combined with capecitabine on HER2 negative advanced breast cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900023851</Identifier></Identifiers><Indications><Indication id="3657">Metastatic breast cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="3" role="Disease marker" type="Genomic;Proteomic">HER2</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>vinorelbine</Name><Drug id="6408">vinorelbine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1059122">Hubei Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6408">vinorelbine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1059122">Hubei Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6408" type="Drug"><TargetEntity id="101739" type="siDrug">Vinorelbine</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="1059122" type="Company"><TargetEntity id="5035552307" type="organizationId">Hubei Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1059122">Hubei Cancer Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2575">Microtubule inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2019-07-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-07-01T00:00:00Z</DateEnd><DateChangeLast>2019-06-20T06:25:03Z</DateChangeLast><DateAdded>2019-06-19T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hubei Cancer Hospital</Affiliation><Email>18627135966@163.com</Email><Name>Zhong Wei</Name><Phone>+86 18971449155</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged &gt;/= 18 years and&amp;lt;/= 70 years&lt;/li&gt;&lt;li&gt;Breast cancer patients confirmed by pathology and conforming to the clinical diagnostic criteria for advanced breast cancer; at least one measurable target lesion (according to RECIST V1.1 standard)&lt;/li&gt;&lt;li&gt;HER expression was negative&lt;/li&gt;&lt;li&gt;There are no contraindications to chemotherapy, patients who have received anthracyclines and paclitaxel adjuvant therapy before and have not used capecitabine and/or vinorelbine&lt;/li&gt;&lt;li&gt;Physical condition (KPS) score &gt;/= 70 points&lt;/li&gt;&lt;li&gt;The expected survival time is &gt; 3 months&lt;/li&gt;&lt;li&gt;The patient (legal representative) can understand the purpose of treatment, voluntarily accept the treatment plan and agree to follow-up at the later stage, have good compliance and can sign the informed consent form for chemotherapy (including clinical observation tips)&lt;/li&gt;&lt;li&gt;The treatment plan should at least include vinorelbine soft capsules&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients generally have poor condition and cannot tolerate chemotherapy&lt;/li&gt;&lt;li&gt;The toxicity of previous anti-tumor therapy has not yet recovered to CT CAE (version 4.03) grade 0 to 1&lt;/li&gt;&lt;li&gt;Positive patients have systemic diseases without stable control, including severe diabetes, hypertension, lung diseases and liver diseases, etc&lt;/li&gt;&lt;li&gt;Is suffering from active infection requiring systematic treatment&lt;/li&gt;&lt;li&gt;Active tuberculosis history, active hepatitis B or hepatitis C patients (HBsAg positive and HBV DNA copy number positive; HBcAb positive) and HIV positive&lt;/li&gt;&lt;li&gt;Patients who are transferred to hospital or give up treatment during treatment&lt;/li&gt;&lt;li&gt;Patients taking other drugs that may affect the effect of chemotherapy during treatment&lt;/li&gt;&lt;li&gt;Pregnant or lactating women patients; Women of childbearing age refuse to accept contraceptive measures&lt;/li&gt;&lt;li&gt;Researchers think that it is not suitable for the group&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free survival (PFS)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease control rate (DCR)</Description></Measure><Measure><Description>Overall survival rate (OS)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to assess the therapeutic effect of oral &lt;ulink linkType="Drug" linkID="6408"&gt;vinorelbine&lt;/ulink&gt; soft capsule combined with capecitabine on HER2 negative advanced breast cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to two study groups.&lt;br/&gt;Group 1: patients (n = 50)  will receive vinorelbine soft capsule combined with capecitabine.&lt;br/&gt;Group 2:  patients (n = 50)  will receive capecitabine.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Hubei Cancer Hospital</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><Address3>430072</Address3><CountrySubDivision>Hubei</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3937">Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3954">Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900023851</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8713"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8712"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="53327">Assessment of clinical benefit/disease control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4814"><Criterion>Subjects with HER-2 Negative Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4840"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4856"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4857">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4877"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4885">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4893"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4894">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4924"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="33170">Subjects with a cytological diagnostic and/or pathology of breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="34443"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4955">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="34920"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4928">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6261">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6308">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6415"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6440">Subjects unfit as per principal investigator (PI)</SubCriterion><SubCriterion disease="Breast tumor" id="6474">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="17557"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26151"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26604"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26752"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6418">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26805"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26916"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Breast tumor" id="27116"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="27297"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Breast tumor" id="28045"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Breast tumor" id="28255"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6259">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-06-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="41116"><TitleDisplay>A phase I/II, multicentric, open-label study to evaluate the safety, the immune effects and the potential clinical activity of TG-1042 in patients with cutaneous lymphomas</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="203">Lymphoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ASN-002, Ascend</Name><Drug id="3366">ASN-002, Ascend</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3366">ASN-002, Ascend</Drug><IndicationsPioneer><Indication id="203">Lymphoma</Indication></IndicationsPioneer><Companies><Company><Company id="25713">University of Zurich</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3366" type="Drug"><TargetEntity id="277639" type="siDrug">ASN-002</TargetEntity></SourceEntity><SourceEntity id="25713" type="Company"><TargetEntity id="4298324199" type="organizationId">University of Zurich</TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25713">University of Zurich</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="21689">IFNG gene stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="12379">Therapeutic vaccine</Class><Class id="1545">Anticancer</Class><Class id="4780">Adenovirus based gene therapy</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="347">Intratumoral formulation</Technology><Technology id="62">Virus recombinant</Technology></Technologies><TrialCategories><Category>Vaccine</Category><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>39</PatientCountEnrollment><PatientCountEvaluable>39</PatientCountEvaluable><DateStart>2002-01-08T00:00:00Z</DateStart><DateChangeLast>2017-08-04T22:06:52Z</DateChangeLast><DateAdded>2009-01-15T17:14:38Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with cutaneous lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure><Measure><Description>Adverse events</Description></Measure><Measure><Description>Immune response</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Preliminary results from 13 patients showed  &lt;ulink linkType="Drug" linkID="3366"&gt;TG-1042&lt;/ulink&gt; to be well-tolerated up to the highest dose. The only two serious adverse events to occur were diarrhea and nausea/vomiting which were transient. Other adverse events were mild to moderate and included  injection site reactions, transient fever and headache [&lt;ulink linkType="Reference" linkID="493172"&gt;493172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, similar results were published. Adverse events in the study included injection site reactions, chills, lymphopenia, and fever [&lt;ulink linkType="Reference" linkID="1110669"&gt;1110669&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This  phase I/II, multicentric, open-label study was designed to evaluate the safety, the immune effects and the potential clinical activity of &lt;ulink linkType="Drug" linkID="3366"&gt;TG-1042&lt;/ulink&gt; in patients with cutaneous lymphomas [&lt;ulink linkType="Reference" linkID="493172"&gt;493172&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="517508"&gt;517508&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="520003"&gt;520003&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="543006"&gt;543006&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="638738"&gt;638738&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="671209"&gt;671209&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="435161"&gt;435161&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1110669"&gt;1110669&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;By February 2003, the phase I part of the trial had been completed. Clinical responses and stabilizations had been observed in most patients and confirmed by histological analyses. &lt;ulink linkType="Drug" linkID="3366"&gt;TG-1042&lt;/ulink&gt; had been well tolerated. In June 2003, preliminary data from  13 patients who had been analyzed at that time, showed that  clinical responses were observed both locally (five complete and two partial responses of 11 evaluable patients) and at distant sites (three complete responses out of nine evaluable patients), leading to an overall response rate of 60% (four complete and two partial responses of 10 evaluable patients). In June 2004, further data were presented from 16 patients, who had been treated for up to four cycles in which &lt;ulink linkType="Drug" linkID="3366"&gt;TG-1042&lt;/ulink&gt; (3 x 10(9) to 3 x 10(11) vp) was delivered on days 1, 8 and 15 with no injection in the fourth week. There were six complete and three partial lesional responses [&lt;ulink linkType="Reference" linkID="478346"&gt;	&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="493172"&gt;493172&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="517508"&gt;517508&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="520003"&gt;520003&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="543006"&gt;543006&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005  data  showed that of  27 evaluable patients, 13 (including 7 complete responses) showed local clinical response. Disappearance of non-injected lesions was also observed and led to 12 overall responses (including six complete responses) of the 26 patients who completed the trial [&lt;ulink linkType="Reference" linkID="638738"&gt;638738&lt;/ulink&gt;]. In January 2012, similar data were presented [&lt;ulink linkType="Reference" linkID="1253753"&gt;1253753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006,  final results from 39 patients showed that seven achieved a complete response, eight showed a partial response, while 15 had stable disease, in an evaluation of all lesions. In an analysis of locally-injected drug into lesions, the number of patients were 10, 8 and 15, respectively [&lt;ulink linkType="Reference" linkID="671209"&gt;671209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, results were published from phase II study (n = 21). Repeated treatment with &lt;ulink linkType="Drug" linkID="3366"&gt;TG-1042&lt;/ulink&gt; consistently showed local tumor regressions in about half of treated patients and one-third of patients also in regressions in noninjected distant lesions, likely reflecting the systemic immune activation after intralesional therapy. Systemic immune activation was seen in peripheral blood and there was induction of antibodies against tumor antigens in some patients without clear association with clinical responses  [&lt;ulink linkType="Reference" linkID="1110669"&gt;1110669&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The trial began as a dose-escalation, phase I study which was to enroll at least nine patients with advanced cutaneous T-cell or multilesional B-cell lymphomas but progressed to a phase I/II trial targeting a larger patient population in different cutaneous lymphomas subtypes [&lt;ulink linkType="Reference" linkID="493172"&gt;493172&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="435161"&gt;435161&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1110669"&gt;1110669&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>ASN-002, Ascend</Name><Drug id="3366">ASN-002, Ascend</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication></AdverseEvent><AdverseEvent><Indication id="1833">Fever</Indication></AdverseEvent><AdverseEvent><Indication id="1992">Lymphocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="3050">Chill</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Switzerland"><Sites><Site><Address1>Zurich</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-01-15T17:14:38Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="41913"><TitleDisplay>A placebo-controlled, phase I/II trial to evaluate the tolerability and efficacy of PapViRx vacccine, a potential treatment for precancerous cervical dysplasia</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="396">Papillomavirus infection</Indication><Indication id="427">Uterine cervix tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PapViRx</Name><Drug id="13441">PapViRx</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13441">PapViRx</Drug><IndicationsPioneer><Indication id="396">Papillomavirus infection</Indication><Indication id="427">Uterine cervix tumor</Indication></IndicationsPioneer><Companies><Company><Company id="19687">Bayer Schering Pharma AG</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="24224">MediGene AG</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="13441" type="Drug"><TargetEntity id="307877" type="siDrug">HPV16L1E7CVLP</TargetEntity></SourceEntity><SourceEntity id="19687" type="Company"><TargetEntity id="4295869029" type="organizationId">Bayer Pharma AG</TargetEntity></SourceEntity><SourceEntity id="24224" type="Company"><TargetEntity id="4295869325" type="organizationId">Medigene AG</TargetEntity></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"></TargetEntity><TargetEntity id="-774172916" type="omicsDisease"></TargetEntity><TargetEntity id="865" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"></TargetEntity><TargetEntity id="10008342" type="MEDDRA"></TargetEntity><TargetEntity id="D002583" type="MeSH"></TargetEntity><TargetEntity id="-837567682" type="omicsDisease"></TargetEntity><TargetEntity id="590" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="19687">Bayer Schering Pharma AG</Company><Company id="24224">MediGene AG</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="12367">Inactivated viral vaccine</Class><Class id="12378">Prophylactic vaccine</Class><Class id="12379">Therapeutic vaccine</Class><Class id="1545">Anticancer</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="83">Protein chimeric</Technology><Technology id="84">Protein fusion</Technology><Technology id="62">Virus recombinant</Technology></Technologies><TermsPatientSelection><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><PatientCountEvaluable>36</PatientCountEvaluable><DateStart>2000-10-31T00:00:00Z</DateStart><DateChangeLast>2017-08-04T22:07:03Z</DateChangeLast><DateAdded>2009-01-22T18:31:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Females with pre-cancerous lesions of the cervix  caused by human papilloma viruses&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Tolerability</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This placebo-controlled, phase I/II  trial was to evaluate the tolerability and efficacy of &lt;ulink linkType="Drug" linkID="13441"&gt;PapViRx &lt;/ulink&gt;vaccine compared to placebo in women with precancerous cervical dysplasia [&lt;ulink linkType="Reference" linkID="483432"&gt;483432&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;The treatment was very well tolerated. Evaluation of the immunological data revealed preliminary efficacy trends with higher T-cell response and antibody reaction when treated with the vaccine. However, the morphological data did not show increased efficacy in comparison to the placebo group.  These results led to discontinuation of the development program as the predefined criteria, efficacy in 90% of patients, was not met [&lt;ulink linkType="Reference" linkID="483432"&gt;483432&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 36 patients received two different dosages of the vaccine or placebo and were monitored for 24 weeks [&lt;ulink linkType="Reference" linkID="483432"&gt;483432&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;A total of 36 patients received two different dosages of the vaccine or placebo and were monitored for 24 weeks [&lt;ulink linkType="Reference" linkID="483432"&gt;483432&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-01-22T18:31:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="46017"><TitleDisplay>A study to evaluate the efficacy of citicoline in patients with ischemic stroke using DWI, a modification of regular MRI technique</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="65">Stroke</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>citicoline</Name><Drug id="11554">citicoline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11554">citicoline</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="16118">Ferrer Internacional SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17247">Endo Pharmaceuticals Solutions Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="11554" type="Drug"><TargetEntity id="91366" type="siDrug">Citicoline sodium</TargetEntity></SourceEntity><SourceEntity id="16118" type="Company"><TargetEntity id="4296610720" type="organizationId">Grupo Ferrer Internacional SA</TargetEntity></SourceEntity><SourceEntity id="17247" type="Company"><TargetEntity id="4295906851" type="organizationId">Endo Pharmaceuticals Solutions Inc</TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="17247">Endo Pharmaceuticals Solutions Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="16118">Ferrer Internacional SA</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1389">Lipid metabolism modulator</Class><Class id="1615">Neuroprotectant</Class><Class id="457">Neurotransmitter release stimulator</Class><Class id="633">Acetylcholine release stimulator</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>81</PatientCountEnrollment><PatientCountEvaluable>81</PatientCountEvaluable><DateStart>1999-02-04T00:00:00Z</DateStart><DateChangeLast>2009-02-18T07:08:16Z</DateChangeLast><DateAdded>2009-02-18T07:08:16Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with cerebrovascular ischemia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Difference in the lesion volumes</Description><Timeframe>Between baseline and week 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was designed to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="11554"&gt;citicoline&lt;/ulink&gt; using DWI (diffusion-weighted imaging), in patients with ischemic stroke [&lt;ulink linkType="Reference" linkID="316044"&gt;316044&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results demonstated that there was no significant difference in the lesion volumes between week 12 and baseline but lesion volumes were significantly smaller in the citicoline group at week 12 compared to week 1 [&lt;ulink linkType="Reference" linkID="316044"&gt;316044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-18T07:08:16Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="48170"><TitleDisplay>A safety and efficacy study of Beriplex in patients with prothrombin complex deficiency and liver damage</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="201">Liver disease</Indication><Indication id="553">Blood clotting factor deficiency</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Beriplex P/N</Name><Drug id="21500">Beriplex P/N</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="21500">Beriplex P/N</Drug><IndicationsPioneer><Indication id="201">Liver disease</Indication><Indication id="553">Blood clotting factor deficiency</Indication></IndicationsPioneer><Companies><Company><Company id="1007640">CSL Behring LLC</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="21500" type="Drug"><TargetEntity id="660015" type="siDrug">BE-1116</TargetEntity></SourceEntity><SourceEntity id="1007640" type="Company"><TargetEntity id="5000042200" type="organizationId">CSL Behring LLC</TargetEntity></SourceEntity><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"></TargetEntity><TargetEntity id="D008107" type="MeSH"></TargetEntity><TargetEntity id="-35813413" type="omicsDisease"></TargetEntity><TargetEntity id="415" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="553" type="ciIndication"><TargetEntity id="D020147" type="MeSH"></TargetEntity><TargetEntity id="-1428253094" type="omicsDisease"></TargetEntity><TargetEntity id="1257" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1007640">CSL Behring LLC</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1725">Factor X modulator</Action><Action id="1749">Factor VII modulator</Action><Action id="1771">Factor IIa modulator</Action><Action id="1773">Factor IX modulator</Action><Action id="446">Vitamin K dependent protein C modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1546">Blood system agent</Class><Class id="7243">Antidote</Class><Class id="968">Coagulation stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1651">Blood constituents</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>22</PatientCountEnrollment><PatientCountEvaluable>22</PatientCountEvaluable><DateStart>1998-12-31T00:00:00Z</DateStart><DateChangeLast>2015-01-22T13:43:38Z</DateChangeLast><DateAdded>2009-03-10T08:45:14Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with prothrombin complex deficiency and liver damage&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A safety and efficacy study of &lt;ulink linkType="Drug" linkID="21500"&gt;Beriplex&lt;/ulink&gt; in patients with prothrombin complex deficiency and liver damage [&lt;ulink linkType="Reference" linkID="311108"&gt;311108&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results showed that an infusion of &lt;ulink linkType="Drug" linkID="21500"&gt;Beriplex&lt;/ulink&gt; was a safe and effective treatment [&lt;ulink linkType="Reference" linkID="311108"&gt;311108&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-03-10T08:45:14Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="56018"><TitleDisplay>A phase I study to evaluate the safety and efficacy of Y-90-DOTA-peptide-m170 in combination with indium-111-m170 and paclitaxel in patients with metastatic breast and prostate cancers</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="276">Prostate tumor</Indication><Indication id="557">Breast disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>indium-111-m170</Name></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>radioimmunotherapy, University of California</Name><Drug id="39970">radioimmunotherapy, University of California</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer><Indication id="557">Breast disease</Indication></IndicationsPioneer><Companies><Company><Company id="1006257">University of Alabama</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20547">University of California</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="39970">radioimmunotherapy, University of California</Drug><IndicationsPioneer><Indication id="276">Prostate tumor</Indication><Indication id="557">Breast disease</Indication></IndicationsPioneer><Companies><Company><Company id="1006257">University of Alabama</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="20547">University of California</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="1006257" type="Company"><TargetEntity id="4298338024" type="organizationId">University of Alabama</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="557" type="ciIndication"><TargetEntity id="10061021" type="MEDDRA"></TargetEntity><TargetEntity id="D001941" type="MeSH"></TargetEntity><TargetEntity id="-1349138" type="omicsDisease"></TargetEntity><TargetEntity id="1270" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20547">University of California</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1006257">University of Alabama</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="1552">Radioimmunotherapeutic</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="51">Monoclonal antibody</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2002-05-31T00:00:00Z</DateStart><DateChangeLast>2017-02-07T10:28:04Z</DateChangeLast><DateAdded>2009-06-08T09:37:11Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with metastatic breast and prostate cancers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficcay</Description></Measure><Measure><Description>Toxicity</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;There was no dose-limiting toxicity with the addition of &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, allowing further dose escalation of &lt;ulink linkType="Drug" linkID="39970"&gt;Y-90-DOTA-peptide-m170&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="452465"&gt;452465&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase I study was to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="39970"&gt;Y-90-DOTA-peptide-m170&lt;/ulink&gt; in combination with indium-111-m170  and &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; in patients with metastatic breast and prostate cancers  [&lt;ulink linkType="Reference" linkID="452465"&gt;452465&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;The linker did not affect the radiation dose to tumors, however, hepatic radiation dose was higher with the DOTA-2IT linker   [&lt;ulink linkType="Reference" linkID="452465"&gt;452465&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with metastatic breast and prostate cancers received imaging (Indium-111) and treatment (Y-90) doses of m170 conjugated by either DOTA-2IT or by DOTA peptide. A radiosensitizing dose of &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; (75 mg/m2) was added 48 h after radioimmunotherapy  [&lt;ulink linkType="Reference" linkID="452465"&gt;452465&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients with metastatic breast and prostate cancers received imaging (Indium-111) and treatment (Y-90) doses of m170 conjugated by either DOTA-2IT or by DOTA peptide. A radiosensitizing dose of &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; (75 mg/m2) was added 48 h after radioimmunotherapy  [&lt;ulink linkType="Reference" linkID="452465"&gt;452465&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="133274">paclitaxel</Intervention><Treatments><Treatment><Dose>75 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-06-08T09:37:11Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="62678"><TitleDisplay>Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)</TitleDisplay><TitleOfficial>Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">WRAMC07-17022</Identifier><Identifier type="NCT">NCT00612157</Identifier><Identifier type="Trial Acronym">CPAPASAP</Identifier></Identifiers><Indications><Indication id="1490">Sleep apnea</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>eszopiclone</Name><Drug id="18873">eszopiclone</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="18873">eszopiclone</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1040909">Walter Reed Army Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="19858">Sunovion Pharmaceuticals Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="18873" type="Drug"><TargetEntity id="283666" type="siDrug">Eszopiclone</TargetEntity></SourceEntity><SourceEntity id="1040909" type="Company"><TargetEntity id="5035525430" type="organizationId">Walter Reed Army Medical Center</TargetEntity></SourceEntity><SourceEntity id="19858" type="Company"><TargetEntity id="4295907900" type="organizationId">Sunovion Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1490" type="ciIndication"><TargetEntity id="G47.3" type="ICD10"></TargetEntity><TargetEntity id="327.2" type="ICD9"></TargetEntity><TargetEntity id="10040979" type="MEDDRA"></TargetEntity><TargetEntity id="D012891" type="MeSH"></TargetEntity><TargetEntity id="-1599540692" type="omicsDisease"></TargetEntity><TargetEntity id="79" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="175" type="Action"><TargetEntity id="186" type="Mechanism">GABA(A) Receptor Agonists</TargetEntity><TargetEntity id="1180" type="Mechanism">GABA(A) GABA Site Agonists</TargetEntity><TargetEntity id="2848" type="Mechanism">GABA(A) BZ Site 1 (Omega-1) Receptor Agonists</TargetEntity><TargetEntity id="5198" type="Mechanism">GABA(A) Receptor Subunits alpha1beta2gamma2L Positive Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1040909">Walter Reed Army Medical Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19858">Sunovion Pharmaceuticals Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="175">GABA A receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2941">Antidepressant</Class><Class id="2944">Hypnotic</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="630">Stereochemistry</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>154</PatientCountEnrollment><PatientCountEvaluable>154</PatientCountEvaluable><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="actual">2009-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-12-19T06:57:26Z</DateChangeLast><DateAdded>2009-12-20T05:52:09Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Walter Reed Army Medical Center</Affiliation><Name>Christopher J Lettieri</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult patients&lt;/li&gt;&lt;li&gt;Newly diagnosed with OSA who are prescribed CPAP therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients&amp;lt; 18 years old&lt;/li&gt;&lt;li&gt;Patients over 65 years&lt;/li&gt;&lt;li&gt;Pregnant women&lt;/li&gt;&lt;li&gt;Patients with chronic liver disease&lt;/li&gt;&lt;li&gt;Patients who abuse alcohol&lt;/li&gt;&lt;li&gt;Patients taking narcotics or using sedative-hypnotic agents such as Ambien, Klonopin
             or Benadryl&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Short term CPAP compliance</Description><Timeframe>3 months</Timeframe></Measure><Measure><Description>Intermediate CPAP compliance</Description><Timeframe>1 year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Quality of life issue - prostate symptoms for men</Description><Timeframe>1, 3, 6, 9, 12 months</Timeframe></Measure><Measure><Description>Quality of life issue - erectile dysfunction for men</Description><Timeframe>1, 3, 6, 9, 12 months</Timeframe></Measure><Measure><Description>Quality of life issue - sleepiness</Description><Timeframe>1, 3, 6, 9, 12 months</Timeframe></Measure><Measure><Description>Quality of life issue - fatigue</Description><Timeframe>1, 3, 6, 9, 12 months</Timeframe></Measure><Measure><Description>Quality of life issue - subjective sleep quality</Description><Timeframe>1, 3, 6, 9, 12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess the efficacy of &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; in improving short and
      intermediate-term compliance with continuous positive airway pressure (CPAP) in patients
      newly diagnosed with obstructive sleep apnea (OSA).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results in November 2009 showed that   a total of 150, 136, and 120 completed follow-up at 1, 3, and 6 months, respectively. There were improvements observed in the patients treated with &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt;  in CPAP adherence. Patients in the &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; group used CPAP for 20.8% more nights (p = 0.003), 1.3 more hours per night for all nights (p = 0.005), and 1.1 more hours per night of CPAP use (p = 0.019). Time to stopping regular use of CPAP  was shorter with placebo than with &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt;. The mean duration of regular use of CPAP was 13.3 and   17.6 weeks  for the placebo  and &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; groups, respectively (p = 0.005). The mean time to discontinuation of CPAP for the placebo and &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; groups was 17.2 weeks and 19.7 weeks, respectively (p = 0.033). In the &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt;  versus  the placebo group compared to baseline, the ESS score decreased by 22.7  versus 7.6%  (p = 0.046), fatigue decreased by 17.7 versus 10.2% (p = 0.31), and the Functional Outcomes of Sleep Questionnaire total score increased by 12.6 versus 9.4% (p = 0.47), respectively [&lt;ulink linkType="Reference" linkID="1063603"&gt;1063603&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; 3 mg po  (n = 76) or a placebo (n = 78) at bedtime for first 14 nights of CPAP and were followed for 24 weeks. After the first 4 weeks of treatment open-label use of sedative-hypnotic agents was allowed 	[&lt;ulink linkType="Reference" linkID="1063603"&gt;1063603&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="18873"&gt;eszopiclone&lt;/ulink&gt; 3 mg po  (n = 76) or a placebo (n = 78) at bedtime for first 14 nights of CPAP and were followed for 24 weeks. After the first 4 weeks of treatment open-label use of sedative-hypnotic agents was allowed 	[&lt;ulink linkType="Reference" linkID="1063603"&gt;1063603&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="149804">eszopiclone</Intervention><Treatments><Treatment><Dose>3 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Walter Reed Army Medical Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20307</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Sleep apnea</Disease><PatientSegments><PatientSegment><PatientSegment id="11198">Subjects with Obstructive Sleep Apnea</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11211">Subjects with De-novo Diagnosis of Sleep Apnea</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00612157</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Sleep apnea" id="25186"><Endpoint>Assessment of compliance/adherence</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Sleep apnea" id="25070"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="25076">Assessment of daytime fatigue</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Sleep apnea" id="25086"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="25075">Assessment of day-time sleepiness</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25087">Assessment of sleep quality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Sleep apnea" id="25110"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="33362">Assessment of quality of Life (Unspecified)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Sleep apnea" id="20794"><Criterion>Subjects with De Novo Disease Diagnosis</Criterion></Inclusion><Inclusion disease="Sleep apnea" id="20798"><Criterion>Subjects Included Based on Type of Sleep Apnea</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="20799">Subjects with obstructive sleep apnea</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Sleep apnea" id="20841"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="20842">Subjects with history of/scheduled to receive continuous positive airway pressure device(CPAP)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Sleep apnea" id="18919"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="18924">Subjects co-morbid with substance abuse disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Sleep apnea" id="18966"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="18969">Subjects with history of/scheduled to receive agents to curtail substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Sleep apnea" id="18977"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Sleep apnea" id="26043"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="18932">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2008-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>25.54 Patients/Month</EnrollmentRate><DateFirstReceived>2008-01-29T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-12-20T05:52:09Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="72287"><TitleDisplay>Propofol in Obese Children</TitleDisplay><TitleOfficial>Propofol in Obese Children</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">H-22091</Identifier><Identifier type="NCT">NCT01242241</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>propofol, AstraZeneca/Fresenius</Name><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20534">Baylor College of Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44308" type="Drug"><TargetEntity id="90057" type="siDrug">Propofol</TargetEntity></SourceEntity><SourceEntity id="20534" type="Company"><TargetEntity id="5035456284" type="organizationId">Baylor College of Medicine</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"></TargetEntity><TargetEntity id="D000758" type="MeSH"></TargetEntity><TargetEntity id="-564538434" type="omicsDisease"></TargetEntity><TargetEntity id="23" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20534">Baylor College of Medicine</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2944">Hypnotic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="597">Injectable emulsion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Dose Comparison</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2008-04-30T00:00:00Z</DateStart><DateEnd type="estimated">2010-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-10-16T13:20:00Z</DateChangeLast><DateAdded>2010-11-18T11:04:25Z</DateAdded><Contacts><Contact type="Public contact"><Email>oao@bcm.edu</Email><Name>Olutoyin A Olutoye, M.D</Name><Phone>832-824-5800</Phone></Contact><Contact type="Public contact"><Email>dleast@texaschildrenshospital.org</Email><Name>Deborah East, RN,BS,BA,CCRC</Name><Phone>832-824-5913</Phone></Contact><Contact type="Scientific contact"><Affiliation>Baylor College of Medicine</Affiliation><Name>Olutoyin A Olutoye, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children between the ages of 3 and 17 years who fall into the categories of
             non-obese (BMI  between 25 to 84th%) or obese(&amp;gt; 95th%)
&lt;/li&gt;&lt;li&gt;American Society of Anesthesiology (ASA) classification 1 or 2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients classified as ASA (American Society of Anesthesiology) class 3 or greater&lt;/li&gt;&lt;li&gt;Patients with documented kidney or liver disease or those presenting for open surgery
             on the liver or kidney&lt;/li&gt;&lt;li&gt;Patients who will not be receiving&lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; for induction as part of their anesthetic
             regimen&lt;/li&gt;&lt;li&gt;Patients who are currently on anti-convulsant medication or receiving drugs with
             sedative effects&lt;/li&gt;&lt;li&gt;Patients currently being treated for attention deficit disorder&lt;/li&gt;&lt;li&gt;Patients who are diagnosed with failure to thrive or those with a BMI&amp;lt; 25th%&lt;/li&gt;&lt;li&gt;Patients who are hemodynamically unstable&lt;/li&gt;&lt;li&gt;Patients with egg allergy&lt;/li&gt;&lt;li&gt;Patients with low levels of albumin&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Loss of consciousness: propofol is administered over 10 s. A 20 s after adminstration, loss of consciousness is assessed by the presence or absence of a lash reflex</Description><Timeframe>20 s</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Depth of sedation: 2-min after propofol adminstration, the patient is assessed for depth of sedation using the University of Michigan sedation scale and the Ramsey sedation scale</Description><Timeframe>2 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study
      is to determine the effective dose in 95% (ED95) of patients (children). The hypothesis is the ED95
      of &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; in obese children will be higher than that of non-obese children.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Arm A  (non-obese with BMI  between 25 to 84th%): this arm of patients will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; from a range of 1.0 to 4.25 mg/kg depending on the response of the previous patient to their assigned dose.&lt;br/&gt;Arm B (obese children with BMI &amp;gt; 95th%): each obese child/subject in this group will receive a predetermined dose of &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; ranging from 1.0  to 4.25 mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Texas Children's Hospital, Baylor College of Medicine</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>oao@bcm.edu</Email><Name>Olutoyin A Olutoye, MD</Name><Phone>832-824-5800</Phone></Contact><Contact type="Facility contact backup"><Email>dleast@texaschildrenshospital.org</Email><Name>Deborah East, RN</Name><Phone>832-824-5913</Phone></Contact><Contact type="Facility investigator"><Name>Olutoyin A Olutoye, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7740">Pediatric Obese Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01242241</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19691"><Criterion>Subjects with Protocol Specified American Society of Anesthesiologists (ASA) Physical Status</Criterion></Inclusion><Inclusion disease="Obesity" id="22432"><Criterion>Pediatric Obese Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15292"><Criterion>Subjects with BMI not Meeting Inclusion Criteria</Criterion></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15350">Subjects with history of/scheduled to receive hormone therapy / steroid / corticosteroid</SubCriterion><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2010-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-11-15T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-11-18T11:04:25Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="8273"><TitleDisplay>A randomized, double-blind, parallel-group study comparing lamotrigine to phenytoin in patients with newly diagnosed, untreated epilepsy</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">H34-074-C87</Identifier></Identifiers><Indications><Indication id="119">Epilepsy</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lamotrigine</Name><Drug id="6189">lamotrigine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>phenytoin</Name><Drug id="44376">phenytoin</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6189">lamotrigine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6189" type="Drug"><TargetEntity id="100324" type="siDrug">Lamotrigine</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2941">Antidepressant</Class><Class id="70">Anticonvulsant agent</Class><Class id="746">Glutamate release inhibitor</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>181</PatientCountEnrollment><PatientCountEvaluable>181</PatientCountEvaluable><DateStart>1999-05-31T00:00:00Z</DateStart><DateChangeLast>2014-02-21T13:03:38Z</DateChangeLast><DateAdded>2008-03-06T14:38:52Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with newly diagnosed, untreated partial seizures, or secondarily or primary generalized tonic-clonic seizures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage of patients remaining on treatment</Description><Timeframe>During the last 24 and 40 weeks of the study</Timeframe></Measure><Measure><Description>Percentage of patients remaining seizure-free</Description><Timeframe>During the last 24 and 40 weeks of the study</Timeframe></Measure><Measure><Description>Time to first seizure</Description><Timeframe>After the first 6 weeks of treatment</Timeframe></Measure><Measure><Description>Time to discontinuation</Description></Measure><Measure><Description>Safety</Description></Measure><Measure><Description>Side effect and life satisfaction (SEALS)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Adverse events led to discontinuation of 13 (15%) patients from &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; and 18 (19%) from &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt;. The adverse event profile for &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; was dominated by skin rash (discontinuation of ten [11.6%] patients compared with five [5.3%] from &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt;) rather than central nervous system side effects; asthenia, somnolence, and ataxia were each significantly more frequent in the &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt; group. The high rate of rash with &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; was probably due to the high starting dose and may be avoidable [&lt;ulink linkType="Reference" linkID="438105"&gt;438105&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a randomized, double-blind, parallel-group study comparing &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; to &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt; in patients with newly diagnosed, untreated partial seizures, or secondarily or primary generalized tonic-clonic seizures [&lt;ulink linkType="Reference" linkID="438105"&gt;438105&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 1999, results were published. The percentages of patients remaining on each treatment and seizure free during the last 24 and 40 weeks of the study, and times to first seizure after the first 6 weeks of treatment (dose-titration period), did not differ significantly between the treatment groups. Time to discontinuation did not distinguish between treatments. A quality-of-life instrument, the side effect and life satisfaction (SEALS) inventory, favoured &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt;. Patients receiving &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt; showed the biochemical changes expected of an enzyme-inducing drug, whereas those taking &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; did not [&lt;ulink linkType="Reference" linkID="438105"&gt;438105&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;One group (n = 86) received &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; titrated over 6 weeks from a starting dose of 100 mg/day. The other group (n = 95) received &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt; titrated from 200 mg/day. Treatment continued for &amp;lt;/= 48 weeks [&lt;ulink linkType="Reference" linkID="438105"&gt;438105&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>lamotrigine</Name><Drug id="6189">lamotrigine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>11.6</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>phenytoin</Name><Drug id="44376">phenytoin</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>5.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication></AdverseEvent><AdverseEvent><Indication id="813">Ataxia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="7954">lamotrigine</Intervention><Treatments><Treatment><Dose>100 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="7955">phenytoin</Intervention><Treatments><Treatment><Dose>200 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Contacts></Contacts></Site><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Epilepsy</Disease><PatientSegments><PatientSegment><PatientSegment id="10305">Subjects with De Novo Diagnosis of Epilepsy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10306">Subjects with Partial Seizures</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10310">Subjects with Primarily Generalized Seizures</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Epilepsy" id="17070"><Endpoint>Assessment of Seizure Freedom</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Epilepsy" id="17057"><Endpoint>Assessment of Seizure Activity</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17061">Assessment of time to first seizure</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Epilepsy" id="15255"><Criterion>Subjects with De Novo Disease Diagnosis</Criterion></Inclusion><Inclusion disease="Epilepsy" id="15256"><Criterion>Subjects with Diagnosis of Epilepsy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15257">Subjects with partial onset epilepsy</SubCriterion><SubCriterion disease="Epilepsy" id="15258">Subjects with generalized epilepsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15318"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-03-06T14:38:52Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-02-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="90604"><TitleDisplay>Bioequivalence Study of Montelukast Sodium Chewable Tablets 4 mg and 5 mg Under Fed Condition</TitleDisplay><TitleOfficial>An Open-Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">742/09</Identifier><Identifier type="NCT">NCT01674517</Identifier></Identifiers><Indications><Indication id="1107">Allergic rhinitis</Indication><Indication id="2976">Bronchiolitis</Indication><Indication id="31">Asthma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>montelukast sodium (Dr Reddy's Laboratories Limited)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>montelukast sodium</Name><Drug id="5326">montelukast sodium</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29387" type="Company"><TargetEntity id="4295872868" type="organizationId">Dr.Reddy's Laboratories Ltd</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2976" type="ciIndication"><TargetEntity id="10006448" type="MEDDRA"></TargetEntity><TargetEntity id="D001988" type="MeSH"></TargetEntity><TargetEntity id="-414497616" type="omicsDisease"></TargetEntity><TargetEntity id="276" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29387">Dr Reddy's Laboratories Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term></TermsEndpoint><PatientCountEnrollment>35</PatientCountEnrollment><DateStart>2010-02-28T00:00:00Z</DateStart><DateEnd type="actual">2010-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-02-05T22:02:17Z</DateChangeLast><DateAdded>2012-09-03T12:35:58Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bioserve Clinical Research Private Limited,</Affiliation><Name>Dwarakanath A, Dr.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provide written informed consent&lt;/li&gt;&lt;li&gt;Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)
             weighing at least 50 kg&lt;/li&gt;&lt;li&gt;Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight
             in kg/height in m2&lt;/li&gt;&lt;li&gt;Must be of normal health as determined by medical history, physical examination and
             laboratory investigation performed within 28 days prior to the commencement of the
             study. (Laboratory values must be within normal limits or considered by the physician
             I investigator to be of no clinical significance)&lt;/li&gt;&lt;li&gt;Female Subjects&lt;/li&gt;&lt;li&gt;Of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence
&lt;/li&gt;&lt;li&gt;Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Incapable of understanding the informed consent&lt;/li&gt;&lt;li&gt;Systolic blood pressure&amp;lt; 90 mmHg or &gt; 140 mmHg&lt;/li&gt;&lt;li&gt;Diastolic blood pressure&amp;lt;  60 mmHg or &gt;  90 mmHg&lt;/li&gt;&lt;li&gt;Oral temperature is below 95.0degF or above 98.6degF&lt;/li&gt;&lt;li&gt;Pulse rate below 50/min or above 100/min&lt;/li&gt;&lt;li&gt;History of hypersensitivity or idiosyncratic reaction to investigational drug product
             or any other related drugs&lt;/li&gt;&lt;li&gt;Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function&lt;/li&gt;&lt;li&gt;Consumption of grapefruit for the past ten days prior to the check-in, in each
             period&lt;/li&gt;&lt;li&gt;Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking during sample collection period&lt;/li&gt;&lt;li&gt;Habit of alcoholism and difficulty in abstaining from alcohol during the sample
             collection period&lt;/li&gt;&lt;li&gt;Difficulty in abstaining from xanthene containing food or beverages (like tea,
             coffee, chocolates and cola drinks) during the sample collection period&lt;/li&gt;&lt;li&gt;Intake of over the counter (OTC) or prescribed medications and enzyme modifying
             medication or systemic medication for the last 30 days before dosing&lt;/li&gt;&lt;li&gt;Clinically significant abnormalities and / or with significant diseases&lt;/li&gt;&lt;li&gt;Prevalence of oral candidiasis, aphthous ulcer or other oral lesions&lt;/li&gt;&lt;li&gt;Difficulty in swallowing tablets/capsules&lt;/li&gt;&lt;li&gt;Confirmed positive in alcohol screening&lt;/li&gt;&lt;li&gt;Confirmed positive in selected drug of abuse&lt;/li&gt;&lt;li&gt;Participated in any other clinical investigation using experimental drug/donated
             blood in past 90 days before the date of start of study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Area under curve(AUC)</Description><Timeframe>Blood samples were withdrawn at predose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, hours post-dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an open-label, randomized, balanced, two-treatment, two-period, two-sequence, single
      dose, crossover, oral bioequivalence study of montelukast sodium (manufacture by  &lt;ulink linkType="Company" linkID="29387"&gt;Dr Reddy's Laboratories Limited&lt;/ulink&gt;) comparing with that of &lt;ulink linkType="Drug" linkID="5326"&gt;Singulair&lt;/ulink&gt;   in healthy, adult, human subjects under fed conditions.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects in the experimental arm would receive  montelukast sodium    chewable tablets 4 and 5 mg of &lt;ulink linkType="Company" linkID="29387"&gt;Dr Reddy's Laboratories Limited&lt;/ulink&gt; and those in the active control arm would receive  &lt;ulink linkType="Drug" linkID="5326"&gt;Singulair&lt;/ulink&gt; chewable tablets 4 and 5mg of &lt;ulink linkType="Company" linkID="18077"&gt;Merck Sharp &amp;amp; Dohme Ltd&lt;/ulink&gt;. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Bioserve Clinical Research Private Limited</Name><Address1>Balanagar</Address1><Address2>Hyderabad</Address2><Address3>500 037</Address3><CountrySubDivision>Hyderabad</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01674517</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2010-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-08-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-09-03T12:35:58Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="93878"><TitleDisplay>Double-blind, parallel-group, controlled Phase III study of MRA in rheumatoid arthritis (RA)</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">JapicCTI-050018</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tocilizumab (intravenous), Roche/Chugai</Name><Drug id="6259">tocilizumab (intravenous), Roche/Chugai</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>methotrexate</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6259">tocilizumab (intravenous), Roche/Chugai</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6259" type="Drug"><TargetEntity id="276293" type="siDrug">Tocilizumab</TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3058" type="Action"><TargetEntity id="1949" type="Mechanism">IL-6 Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3058">IL-6 receptor modulator</Action><Action id="471">IL-6 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2005-09-02T00:00:00Z</DateStart><DateChangeLast>2012-11-03T01:48:32Z</DateChangeLast><DateAdded>2012-10-09T04:24:51Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Clinical Trials Information</Affiliation><Email>clinical-trials@chugai-pharm.co.jp</Email><Name>Chugai Pharmaceutical Co., Ltd.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR)&lt;/li&gt;&lt;li&gt;Between 20 and 75 years old&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Efficacy: Frequency of ACR improvement</Description></Measure><Measure><Description>Safety: Frequency and severity of adverse events and adverse drug reactions</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This trial was conducted to investigate the clinical efficacy and safety of iv &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; (MRA) in a double-blind, parallel-group, controlled study using &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; or methotrexate (MTX) in rheumatoid arthritis (RA) patients with MTX administered [&lt;ulink linkType="Reference" linkID="1329433"&gt;1329433&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier type="Other">JapicCTI-050018</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-09T04:24:51Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="96154"><TitleDisplay>Cranberry Consumption Improves Gamma Delta T Cell Function</TitleDisplay><TitleOfficial>Cranberry Consumption Improves Gamma Delta T Cell Function</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CB-472-2012</Identifier><Identifier type="NCT">NCT01713829</Identifier></Identifiers><Indications><Indication id="504">Immune deficiency</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="2706" role="Therapeutic effect marker" type="Cellular">Natural killer cells</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Cranberry Beverage</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1074662" type="Company"><TargetEntity id="5037940747" type="organizationId">Cranberry Institute</TargetEntity></SourceEntity><SourceEntity id="20575" type="Company"><TargetEntity id="4296863617" type="organizationId">University of Florida</TargetEntity></SourceEntity><SourceEntity id="504" type="ciIndication"><TargetEntity id="10021460" type="MEDDRA"></TargetEntity><TargetEntity id="D007153" type="MeSH"></TargetEntity><TargetEntity id="-886084388" type="omicsDisease"></TargetEntity><TargetEntity id="1130" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20575">University of Florida</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1074662">The Cranberry Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>52</PatientCountEnrollment><DateStart>2012-10-31T00:00:00Z</DateStart><DateEnd type="actual">2013-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-05-19T07:54:35Z</DateChangeLast><DateAdded>2012-11-01T07:42:48Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Florida</Affiliation><Name>Susan S Percival, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Between 21 and 35 years of age and in good health&lt;/li&gt;&lt;li&gt;Have a BMI between 18.5 and 29.9&lt;/li&gt;&lt;li&gt;Willing to consume the study beverage for 12 weeks&lt;/li&gt;&lt;li&gt;Willing to have a small amount of blood drawn two times&lt;/li&gt;&lt;li&gt;Willing to stop consuming tea and immune-enhancing dietary supplements (eg,
             antioxidant-, probiotic-, or flavonoid-containing supplements, fish oil, and
             Echinacea) before and during the 12 weeks of the study
&lt;/li&gt;&lt;li&gt;Willing to consume no more than seven servings of fruits and vegetables a day&lt;/li&gt;&lt;li&gt;Willing to limit your alcohol consumption to no more than 14 glasses a week&lt;/li&gt;&lt;li&gt;Willing to limit your yogurt consumption to no more than one 8 oz serving per day&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have food allergies&lt;/li&gt;&lt;li&gt;Have hypertension&lt;/li&gt;&lt;li&gt;Taking non-steroidal anti-inflammatory drugs on a chronic basis, antibiotics, or
             immunosuppressive drugs&lt;/li&gt;&lt;li&gt;Sensitive to Aspirin or prone to kidney stones&lt;/li&gt;&lt;li&gt;Current smoker&lt;/li&gt;&lt;li&gt;Pregnant, lactating, or on hormone therapy, except for birth control pills&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in immune cell function: change in leukocyte phenotype, change in the ability of the natural killer and/or gamma delta T cells to proliferate when cultured ex vivo, change in peripheral blood mononuclear cell cytokine and chemokine production in response to mitogens</Description><Timeframe>Measured at baseline and 6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cold and flu symptoms: incidence and severity of cold and flu symptoms, total and individual. Other signs of severity, for eg, visits to doctor or health clinic, reduction in daily activities, prescribed or over-the-counter medications taken</Description><Timeframe>12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine the extent to which consuming a cranberry beverage
      modifies immune function, specifically related to gamma delta T cells and other innate immune cells.
      It is hypothesized that cranberry components will interact with immune cells to activate
      signaling pathways that enhance cell function.  Enhanced immune cell function should result
      in reduced number, duration, and severity of cold and flu symptoms.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists of two arms.&lt;br/&gt;Arm 1: subjects recieve 8 oz  cranberry beverage consumed qd for 12 weeks.&lt;br/&gt;Arm 2: subjects recieve 8 oz placebo beverage consumed qd for 12 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>449 Food Science and Human Nutrition Department, University of Florida</Name><Address1>Gainesville</Address1><Address2>Florida</Address2><Address3>32611</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01713829</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>1.03 Months</EnrollmentPeriod><EnrollmentRate>50.49 Patients/Month</EnrollmentRate><DateFirstReceived>2012-09-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-01T07:42:48Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-15T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>